



BCRI

, Value creation through innovation

PATRICIA KEEN, B.Sc. Project Scientist Environmental Sciences and Engineering E-Mail: keen@bcr.bc.ca

BC Research Inc. 3650 Wesbrook Mall Vancouver, BC Canada V6S 2L2 Canada Tel: (604) 224-4331 Fax: (604) 224-0540 USA Tel: (206) 738-0958 Fax: (206) 733-3590

Dr i Mrs. Bader, Thursdays lecture was the third time go listened to you have in my acade correr. It gives me you express 70 our My Udies m DWED 4)17 remic invironmenta 20 5 OL years partitime studi hotory. nom you u ove hint hors NAIDU ALON De en Dassi man students More B.Sc. Chemistry U.B.C



Edgar Degas, French, 1834-1917 Oil on canvas Musée d'Orsay, Paris © Musées Nationaux

WB 10613C

H. GEORGE CASPARI. INC. NEW YORK/ZÜRICH Printed in Switzerland



SAVE THIS RECEIPT FOR REGISTERED MAIL CLAIMS & INQUIRIES

DECLARATION OF VALUE - <u>Mailers are Required to declare the Full value</u> at the time of mailing on all registered mail articles, whether insurance is desired or not.

WITH POSTAL INSURANCE – Domestic postal insurance against loss or damage may be purchased by paying the appropriate fee. Domestic insurance on registered mail is limited to the lessor of (1) the value of the article at the time of mailing if lost or totally damaged, or (2) the cost of repairs. Consult your postmaster for additional details of insurance limits and coverage for domestic and international registered mail. See sections 149 and 911, Domestic Mail Manual for limitations of coverage.

WITHOUT POSTAL INSURANCE – An article may also be sent by registered mail without postal insurance by paying the appropriate fee. No indemnity will be paid for articles mailed without postal insurance coverage.

TO FILE INSURANCE CLAIM – Claim must be filed within 1 year from the date of mailing. Present this receipt. Claims for complete or partial loss of contents, damage or alleged rifling must be filed immediately. The article, container, and packaging must be presented when filing a complete or partial loss of contents or damage claim. Submit evidence of value or repair costs to substantiate your claim. Inquiries on registered mail claims should not be filed for at least 3 months after the date the original claim was filed.

INTERNATIONAL REGISTERED MAIL – Indemnity coverage for International Registered Mail is limited to the maximum set by the Convention of the Universal Postal Union. Consult postmaster and the International Mail Manual for limitations of coverage and individual country prohibitions and restrictions.

PS Form 3806, April 1991 (Reverse)

Dr. Alfred Bader 2961 North Shepard Avenue Milwaukee, Wisconsin 53211

January 19, 1995

Mr. J. J. Elkin Chairman and Chief Executive Officer Emtech Technology Corporation 2486 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada

Dear JJ,

Enclosed is copy of letter dated September 30th and statement showing Isabel's loss in mortgage capital. Canadian mails can be so bad that, perchance, this letter did not reach you, or it may just have escaped attention in your office.

I hate to think of the alternative, namely, that you want to stonewall Isabel. I discussed your not replying with Stephen Lipper, who thought it inconceivable that you would not keep your promise, and I find it equally so, you, the grandson of Martin Wolff.

Of course I can hear you say to yourself that a couple that can give millions of dollars to Queen's University can give a few hundred thousand dollars to Brahm Elkin. However, keep in mind that you promised to return just the capital to Isabel, who thus forgoes substantial interest and loss through the Canadian dollar devaluation and will thus share the loss with you, Brahm's brother.

I am sending this by registered mail and look forward to hearing from you.

Sincerely,

Enclosure



FAX FROM

DR. ALFRED R. BADER Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin 53202 Telephone 414-277-0730 Fax No. 414-277-0709

January 19, 1995

To: Emtech Technology Corporation

905 820 3030

Gentlemen:

I would like to write to Mr. J. J. Elkin. Could you please confirm by return fax that your address is:

2486 Dunwin Drive Mississauga, Ontario L5L 1J9 Canada

Thank you.

M.a Bad



Box 1011 Station """ Fant fal, Suébec. H70 205 - Static.

Jonuary 20th. 1995

Alfred Bode Tine Arts Acto: Hotel J2' Test Juneau Avenue suite 622 Milwoulise - Winconsin 57202 - Wilted States

Den Dr. Bade.,

by deMC.PER showing the figure waving his a de as being nude, clothing was added something along the way.

This seems to correspond with rest of the groun which all seem to be equally uplo.

Yours since ely,

F. Thomson

file

(51/) 35. 13. 75 - F.K: (51/) 9/4. 05. 71









ALFRED BADER FINE ARTS

DR. ALFRED BADER

January 23, 1995

ESTABLISHED 1961

Ms. Lois E. Lieff Assistant to Executive Director Jewish Education Council of Montreal Edifice Cummings House 5151 Cote Ste-Catherine Montreal, Quebec H3W 1M6 Canada

Dear Ms. Lieff:

In response to your kind letter of January 10th, please find enclosed my check for U.S.\$3,600.00 to the United Israel Appeal.

All good wishes.

Sincerely,

c: Mr. Ralph Lipper

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709









ALFRED BADER FINE ARTS

DR. ALFRED BADER

e

December 30, 1994

ESTABLISHED 1961

Mr. Shlomo Shimon Jewish Educational Council 5151 Cote Ste Catherine Road Montreal, Quebec H3W 1M6 Canada

Dear Mr. Shimon:

My friend, Mr. Ralph Lipper, has told me of your excellent work, and I would like to make a contribution to help that work.


Do you work with a U.S. organization to which I could make the contribution which--if that organization is registered with the IRS--would be tax deductible for me. I hope you do not mind this question, but if I can make a tax-deductible contribution, I can make one which is larger.

I look forward to hearing from you, and all good wishes.

Sincerely,

c: Mr. Ralph Lipper

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709





Glen Fast, Music Director Jane Former, General Manager

Honorary Directors Peter Milliken, M.P. Gary Wilson, M.P.P. Mayor Ken W. Matthews Reeve Barry Gordon Reeve Ian Wilson Reeve Isabel Turner Principal David C. Smith

Board of Directors

Marion D. Westenberg, President Hilary Richards, Vice-President Betty Clark, Secretary Kenneth D. Wollin, Treasurer Grace Bastianutti Marilyn Bennett Robert Bruce Beverley Coles James Coles Dorothy Cotton Carolyn Crowson Robert H. Crowson Donald J. Duff Walter Fenloa Les D. Foreman Alan Grant Ameena Jaffer William Kamphuis Douglas Morren Barbara Parrott Laura Seiffert Daniel Soberman Robert Van Winckle Malcolm Williams

Consultative Directors Moira Cartwright Myrtle Dalziel David Dawes Michael Davies Peggy Geracimo Donald J. Neil Diane Provan Harriet Scott

Women's Committee Carolyn Crowson, President

Kingston Choral Society Glen Fast, Director Robert Bruce, President

Kingston String Centre Kingston Youth Orchestra James Coles, Director Dr and Mrs Alfred Bader, 2961 N.Sheppard Avenue, Milwaukee, Wisconsin, 53211 U.S.A.

l February, 1995

Dear Dr and Mrs Bader,


Because you had a correspondence with my husband Hans Westenberg about the Agnes Etherington Art Centre (and the possibility of locating it on the vacant waterfront lot called Block D), I feel I know you a little bit, and from that I take courage to write you this letter.

The Art Centre and the Kingston Symphony are generally considered to be the two most important cultural manifestations in the City of Kingston, proof of which can be seen in the fact that together they command approx. 75% of the annual grant budget the City allocates for non-profit organizations. The last few years we all, bundling our forces into K.R.A.C., the Kingston Regional Arts Council, have really had to do battle with the powers that be to keep the City's budget for the Arts to no more than a few percentage points below that of the year before! And so from time to time Anndale McTavish, myself, our Conductor Glen Fast, and many other people find ourselves in Council Chambers, prepared to plead for that which we all so deeply believe in: the power of the Arts to make life more beautiful; and more specifically, the duty of City Council to use part of our tax money to keep all our large and small Arts Organizations flowering, and to nurture that very special quality that makes life so wonderful here.

Our Kingston Symphony Association consists of an Orchestra with 65 musicians, (our 12 principal players on contract, with an annual salary; the other 53 on a fee for service basis), the 120 voice Choral Society (amateur), the Kingston Youth Orchestra, the Kingston String Centre, and the Community Strings, as well as the 200 member Women's Committee, whose sole raison d'etre is to raise money; and a large volunteer group for day to day jobs in assisting the 2 full time office managers. Our annual budget is \$450.000, and as you can see from this year's brochure, we have a wonderful and creatively presented programme.

But... we are in some trouble. For years we have worked with a "line of credit", set up to be an annual, temporary loan with the Bank, to be dipped into and slipped out of during the summer, when the musicians' monthly salaries, and that of our maestro and office

P.O. Box 1616, Kingston, Ontario K7L 5C8 • Telephone: (613) 546-9729 • Fax: (613) 546-8580



monthly salaries, and that of our maestro and office staff, need to be paid, while there are no concerts, and the next season's subscription money is not coming in yet. In other words, temporary cash flow.

After having been in the black for over 40 years, 2 1/2 years ago, through the careless actions of the then President and Manager, and the timidity and lack of vigilance of an otherwise honorable and hardworking Board, our \$50,000 "line of credit" with the Bank, and more, had all of a sudden been used up for day to day affairs, which had been allowed to run up far too high; this brought us to the edge of the abyss, from which we are in the steady process of retreating, thanks to the hard work, generosity, and devotion of many people, including the musicians themselves.

The Bank of Montreal, our Bank since 1954, has demanded that we now guarantee our line of credit. This was easily done with 25 guarantors, who all signed for \$1000 (never to be used, I hope!), which Michael Davies generously matched from the Davies Foundation. Over and above this we have a debt of \$25,000 to the bank (brought back from \$40,000 through a series of Board-originated fundraisers), for all of which we pay a great deal of interest, plus there are always bills to pay to our suppliers.

Now our Treasurer has come up with an interesting plan: we are looking for 15 Kingstonians or old-Kingstonians, who each will lend us \$5,000, for which the interest will be paid in kind, namely in 2 subscriptions to all our concerts, in the B section, or a \$400 reduction on the same in the A section. In this way we will not be beholden for this loan to the Bank, and pay the interest charges that are crippling us. Paying off would go via a lottery system, so that one lender at a time is released from his/her commitment. Since you don't live in Kingston, this proposal may not suit you, although we could give your tickets, each time you can <u>not</u> attend, to friends of yours in the community, according to your directions.

But, dear Dr and Mrs Bader, I have another proposal/request for you. Do you think that you could find it in your hearts to <u>give</u> us, rather than <u>lend</u> us, an amount of money, which will ensure the continued health of our Symphony? I am first of all thinking of the above \$5000, but even more so of another possibility. If you were to give us the incredible donation of \$25.000, the K.S.A. would dedicate the entire Friday Night Live Series, (which next year will include Bach's St. Matthew Passion) to Alfred and Isabelle Bader, our generous sponsors, mentioned everywhere in our publicity, and you



give away to friends and relations. (Naturally we have a charitable number!)


It is a lot of money, and you would not have a beautiful painting to show for it, but the happy faces of Kingston music lovers, who would be grateful to you with every note played, would be a painting in itself.

I must add that of course we do not work in isolation. Our principals all teach music at Queen's Music Department, and privately, as do many of our other musicians. We have an intensive school programme, partly funded by the generosity of the Whig Standard, and our musicians play independently from us in many other smaller ensembles. This May we are reaching out into the greater community with a huge V-E Day concert in the Kingston Memorial Centre, toghether with numerous other bands.

I hope to have good news from you soon. With many thanks, and kind regards, also from Hans, I remain,

Sincerely, 1Wistal

Marion D. Westenberg, President





THE CHEMICAL INSTITUTE OF CANADA L'INSTITUT DE CHIMIE DU CANADA

130 SLATER STREET, SUITE 550, OTTAWA, ONTARIO, K1P 6E2 TELEPHONE (613) 232-6252 FAX: (613) 232-5862

15 Feb 1995

From: Jacqueline Estabrooks, CIC Accountant

To: A. Bader

Please find enclosed 1994 Audited Financial Statements as follows:

A. Bader Award fund

Comments:

for your records

Constituent Societies of The Institute • Les sociétés constituantes de l'Institut



Canadian Society for Chemistry Société canadienne de chimie



Canadian Society for Chemical Engineering Société canadienne du génie chimique



Canadian Society for Chemical Technology Société canadienne de technologie chimique



THE CANADIAN SOCIETY FOR CHEMISTRY

6

ALFRED BADER AWARD FUND

BALANCE SHEET

AS AT DECEMBER 31, 1994

ASSETS	1994	1993
Accrued interest receivable Deposit certificates Due from The Chemical Institute of Canada	\$ 389 - <u>1,099</u>	\$ 689 19,344
	1,488	20,033
Bond (market value \$41,017) (note 2)	<u>48,176</u> \$ <u>49,664</u>	<u>48,375</u> \$ <u>68,408</u>
LIABILITY		
Due to The Chemical Institute of Canada	\$ -	\$19,905
EQUITY		
BALANCE - BEGINNING OF YEAR Interest on investments Donation	48,503 4,584 	42,783 1,622 8,000
	53,087	52,405
Expenses - administration - award - framed scroll - travel	268 3,000 155	250 3,000 152 500
	3,423	3,902
BALANCE - END OF YEAR	49,664	48,503
	\$49,664	\$68,408

NOTES TO FINANCIAL STATEMENT

DECEMBER 31, 1994

1. SIGNIFICANT ACCOUNTING POLICY

Accrual Basis of Accounting

Revenue and expenses are recorded on the accrual basis, whereby they are reflected in the accounts in the period in which they have been earned and incurred respectively, whether or not such transactions have been finally settled by the receipt or payment of money.

2. BOND

The bond is stated at cost plus a premium which is amortized over the term of the bond.

Approved by:

Treasurer

MCCAY, DUFF & COMPANY, CHARTERED ACCOUNTANTS





ALFRED BADER FINE ARTS

DR. ALFRED BADER

March 21, 1995

ESTABLISHED 1961

Dean Alan Shaver Department of Chemistry McGill University 801 Sherbrooke St. West Montreal, Quebec H3A 2K6 Canada

Dear Alan:

I was just delighted to note your happy picture as new Dean on the March issue of the Maass Spectrum. It couldn't happen to a greater guy.

In the same mail, I received notice that McGill has been forced to reject applications for medical school from Canadian students outside Quebec. What next?

Obviously, it can't be easy being Dean at McGill, but if anybody can succeed, it will be you.

I very much hope that you will like your picture in my autobiography, which will be available from Little, Brown in May.

Best wishes, as always,

AB/cw

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 532 2 Fri 212 277 Tot I (N 212 277 7 2



Beatrice M. B. Corbett

The Shipyards 319-33 Ontario Street Kingston, Ontario K7L 4N4 613 - 544 - 7165

30 March 1995

Dr. Alfred Bader Astor Hotel Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin USA 53202

Dear Dr. Bader,

Thank you for sending me a copy of the letter which you wrote to Michael Den Tandt in response to his editorial in The Kingston Whig-Standard. Than you also for reading the letter which I wrote to the Whig.

Your letter was informative, and provocative--in the best sense of the word. The reports of your giving, and the giving of the Helen Bader Foundation were enlightening, and I look forward to the establishment of the Chair in Northern Art History.

Regarding your "off-hand" remark about your art collection going to Harvard, may I say that I am glad this was a "throwaway" remark and I am pleased to stand corrected.

I was particularly moved by another letter to the Whig, the one from the mature student who had received an award established by you. This letter was a significant expression of the difference such a gift can make in the life of an individual, and other gifts, no matter how generous, cannot surpass in worth one such as this.

Kingston has always had a cultural climate that is strongly receptive to the arts, and the Agnes Etherington Gallery is a dominant and influential presence in this context. In her book on André Bieler, Frances K. Smith describes the celebrated "Kingston Conference" of 1941, which led ultimately, over many steppingstones, to the foundation of the Canada Council in 1957. Unfortunately, this local appreciation of the arts has not always been evident to people who have never lived here, either as students or permanent residents.

Dr. Bader, I respect your gifts for their obvious aspects, but also because they exemplify how it is possible to bridge the perceived chasm between the sciences, and the arts and humanities. I believe that it is essential that we all try to bridge that chasm.

Sincerely yours,

Bud rice M. B. Conbell Beatrice M.B. Corbett BA, Hon., English 1944 MA, English 1995



The Edmonton Journal, Monday, April 10, 1995 B7*

avish donations put art lover Bader on map

Millionaire philanthropist, in town for two lectures, has never forgotten his wartime benefactors



Tefugee, Bader became the founder of the Aldrich chemical Company, a multi-millionaire, and an art collector.

A net current can puttanturopist is in Edmonton to deliver a talk on art restoration tonight we the Edmonton Art Gallery, and a lecture Tuesday night on art history at King's University College. Most recently, Bader gained notoriety for his lavish donations to his alma mater, Queen's University in Kingston

the money to purchase an English castle. England, has the distinction of being the Most recently, Bader gained notoriety Dutario. Bader gave the school some 120 former Royal Greenwich Observatory. It 140 rooms. Bader says all but one of the refurbish it. The university uses it as an In 1992, Bader provided Queen's with mater, Queen's University in Kingston, couple of million English pounds" to 🕬 observatory's telescopes are still there. the funds for the castle, negotiated the Outch old master paintings, as well as Herstmonceux Castle, near London, sits on 530 acres of land and has about sale on their behalf, and gave them "a for his lavish donations to his alma Bader spoke to the Journal from international study centre.

Vancouver, where he was lecturing and touring in support of his new autobiography, *The Adventures of a Chemist Collector*. The book will be published in Canada by Little Brown. The 70-year-old casually mentioned that he bought a "beautiful Italian stilllife painting at 3 a.m. Saturday morning. Three in the morning happened to be noon in London, England, and there was a sale." Bader added that selling or buying old master paintings in Milwaukee, Wis,

master paintings in Milwaukee, Wis, where he måkes his home is "pretty … impossible." Life wasn't always so grand for Baden

Life wasn't always so grand for Bader. As a young boy the Vienna-born Bader fied Austria in 1938 following Kristallnacht, the night of Nazi violence and a prelude to the horrors to come. He lived as a refugee in England, supported by a woman who paid his rent of one pound, one shilling. In 1940, English authorities rounded

In 1940, English authorities rounded up Bader as part of a crackdown on German and Austrian refugees during the Second World War. Canada agreed to hold the "prisonersof-war," so Bader was shipped to Fort Lennox near Sherbrooke, Quebee... He remained there until 1941, at which



point a benefactor in Montreal took him in and sponsored him for school. Bader's first choice was McGill University, however, at that time they had a quota system for Jews and Bader's application was turned down. The University of Toronto also refused Bader

entrance. But Queen's University accepted him. "For the first time in wy life I was treated as an equal," says Bader. He graduated from Queen's in 1945 with a Bachelor of Science degree in engineering chemistry. For the next couple of summers, Bader worked for Montreal's Murphy Paint Company. He helped the company's sales

to the point where the president gave

research, something his job at Pittsburgh on weekends and started a company with When Bader graduated from Harvard research chemical processes on his own and named the company after his flance, Bader's devotion to his old school caused Bader wanted to concentrate on pure "The first year we sold \$1,705 worth of had a profit of \$20," recalls Bader. Today anniversary of his arrival at Queen's with a major gift to the school. In 1991, he sold individual shareholder, but is no longer University two years later, the Murphy Pittsburgh Plate Glass Company. They Unable to decide on a name, the two the company is worth over \$800 million. chemicals. We paid no salaries and we Betty Aldrich. Bader says they formed men held a coin toss. Eisendrath won involved with its operation. Ironically, Plate Glass didn't allow. He began to * Paint Company had been sold to the Bader is still the company's largest the rift with the company he formed. him the tuition to pursue his Ph.D. Milwaukee, where Bader settled. based all their paint research in Bader wanted to mark the 50th the company in 1951 with \$500. his friend Jack Eisendrath.

"The first year we sold \$1,705 worth of chemicals. We paid no salaries ... had a profit of \$20." — philanthropist Alfred Bader million he owned of Aldrich stock. In a

two-month period, the stock rose in value from \$41 to \$47 a share. 4 for a share. 1 for Cori, the son of two Nobel prize laureates and Sigma-Aldrich's CEO (the merger with the Sigma Chemical

Company took place in 1975), said the sale amounted to betting against the company. He called on Bader to resign as the company's chairman emeritus. Bader retired in 1992. Since then Bader has devoted himself

to art and to philanthropy. He opened Alfred Bader Fine Arts in Milwaukee, bought himself paintings by Rembrandt and Rubens, and purchased his old school a castle. Bader's talks are part of the Canadian Society for Chemistry 75th Conference

Bader's talks are part of the Canadian Society for Chemistry 75th Conference Lecture Series. Bader's lecture tonight at the Edmonton Art Gallery (2 Sir Winston Churchill Square) starts at 8 pm. His lecture Tuesday night at King's University College (9125-50 St.) begins at 7:30 pm.

a major gift to the school. In 1991, he sold Univers an option of 10,000 shares of the 3.6 7:30 p.m.



CBC Radio P.O. Box 4600 Vancouver, B.C. Canada V6B 4A2

April 12, 1995

Dr. Alfred Bader Alfred Bader Fine Arts Astor Hotel, Suite 622 924 East Juneau Ave. Milwaukee, Wisc. 53202

Dear Dr. Bader,

Here is a cassette copy of your interview as broadcast across Canada on Monday April 10.

GABEREAU

Thank you so much for coming into the studio. Vicki and I both enjoyed meeting you, and I am sure our listeners found your eloquently told story fascinating.

All the best in all your many endeavours.

Sincerely,

nek Duo Doug Tack







DR. ALFRED BADER

ESTABLISHED 1961

April 20, 1995

Ms. Beatrice M.B. Corbett Shipyard Apartments 319-33 Ontario Street Kingston, Ontario K7L 5E3 Canada

Dear Ms. Corbett:

I appreciate your thoughtful letter of March 30th more than I can tell you.

The Chair in Northern Art History has now been established, and you will enjoy meeting the professor, Volker Manuth, who is a member of the Rembrandt Research Project and one of the most eminent Rembrandt scholars in the world.

I note that we must at least have seen each other in campus in the 1940's; unfortunately, the 1944 and 1945 reunions are always in succeeding years, which is a great pity because I have so many friends in Sc. '44 and stayed at the Sc. '44 co-op.

Of course, Isabel and I look forward to attending my 50th reunion this coming October, and it would then give me great pleasure if I could meet you and thank you personally then.

With all good wishes, I remain,

Yours sincerely,

AB/cw

bc: Florence Campbell Professor David McTavish





DR. ALFRED BADER

ESTABLISHED 1961

April 20, 1995

Ms. Patricia Keen BC Research, Inc. 3650 Westbrook Mall Vancouver, BC V6S 2L2 Canada

Dear Ms. Keen:

Please accept my sincere thanks for your thoughtful note, which Isabel and I appreciated very much.

With all good wishes, I remain,

Yours sincerely,

AB/cw

bc: FLorence Campbell

8





DR. ALFRED BADER

ESTABLISHED 1961

April 20, 1995

Professor J.S. Ellis Civil Engineering Department Royal Military College of Canada Kingston, Ontario K7K 5L0 Canada

Dear Professor Ellis:

Thank you so much for your thoughtful and most interesting letter of March 22.

Your court dress given by Maria Theresia to Countess von Lockhart sounds most interesting. Undoubtedly you know how highly the Scots were regarded in Vienna, and there was even a Scots Gate in the old walls around the city.

That dress would be one of the most important in the Queen's collection, and Isabel and I sincerely hope that Queen's will be able to accept it.

We will be at the Queen's reunion next October because that will be the 50th reunion of Sc. '45, my year.


Incidentally, are you perchance related to Dean Ellis, who was Dean of Engineering at Queen's when I was a student?

With best personal regards, I remain,

Yours sincerely,

AB/cw

bc: Professor David McTavish Florence Campbell



Royal Military College of Canada • Collège militaire royal du Canada

22 March 1995

Dr. Alfred Bader c/o Queen's Alumni Review Queen's University

Dear Dr. Bader:

I am writing you because of your letter of the 18 March 1995 to the Whig Standard. Your mention of a "priceless collection of costumes" reminds me of my ongoing attempt to place on permanent loan with the Agnes a court dress that allegedly was given by the Empress Maria Theresa to the then Countess of Lockhart (the Count held an Austrian title, although he was a Scot). My brother and I own this, it has come down in the family, and Dorothy Farr is aware of this. When she saw it, she exclaimed "that colour is Maria Theresa gold!" I'd never before heard of such a colour.

Recently I've asked Miss Farr to see if it might be mounted in the French Centre at Queen's because the family story has it that the dress was worn by the Empress for a ceremony to celebrate her daughter's wedding to the Dauphin of France. I haven't heard from Miss Farr but I'm sure she's pursuing this. I saw long dresses very attractively mounted in the art gallery of Vence, Provence. These dresses were hung on mannequins of wicker.


If you'd like, I'll be glad to show you and Mrs Bader this dress, sometime when you are in Kingston.

As a Queen's graduate with ties to Queen's over four generations, I greatly admire what you've done for the University and I hope that you and Mrs. Bader have not been offended by things in the Kingston newspaper, which I've considered insensitive to say the least.

Sincerely,

John S. Elles.

J.S. Ellis, Ph.D. (Cantab) Emeritus Professor Civil Engineering Department





Canadian Chemistry & Physics Olympiad 306 Lawrence Ave. E., Toronto, Ontario, Canada M4N 1T7 Tel: (416) 484-6533 Fax: (416) 481-6529

April 20, 1995

Dr. Alfred Bader c/o Alfred Bader Fine Arts Astor Hotel Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin USA 53202

Dear Dr. Bader,

Gordon Bates of the Chemistry Department at the University of British Columbia has initiated a discussion with you concerning the International Chemistry Olympiad. Canada takes part in this event each year and has done so since 1986. The whole thing is very similar to the sporting Olympics but of an academic (chemistry) nature. Canadian high school students train and compete for a position on the National Chemistry Olympiad Team. Next year, for instance, the Team will travel to Beijing, China for the International competition. I am enclosing a report on our activities in 1994 for your interest. The annual budget for our operation is on the order of \$100,000 (we organize the Canadian Physics Olympiad as well) of which \$60,000 comes from private and corporate sources.

Canada has been selected to act as the host nation for the 1997 International Chemistry Olympiad and we have chosen Montreal for our host site. I have enclosed a prospectus for this project. The projected budget is about \$400,000 towards which we have a pledge for \$160,000 from Merck Frosst Canada. We are also hosting the International Physics Olympiad in 1997 (in Sudbury Canada) with a \$400,000 budget of its own. Inco Limited had pledged \$160,000 towards this separate project.

Clearly, the fund raising challenges we face in mounting these worthy projects are formidable. We are confident, however, that the importance of encouraging our brightest young students to pursue chemistry and physics will prevail. We are a charitable corporation and can issue tax receipt for any donation.

Sponsored by: Merck Frosst Canada Inc., Inco Limited, The Natural Sciences and Engineering Research Council, The Toronto French School. Supported by: Dow Chemical, Bell Canada, DuPont Canada, Imperial Oil Ltd., John Wiley & Sons Canada, Glaxo Canada Inc., The McLean Foundation, The Boland Foundation, Investors Group Inc., Celanese Canada Inc., Royal Bank of Canada, AECL Research, Xerox Research, Canadian Society for Chemistry, Canadian Association of Physicists, Ordre des chimistes du Québec, Bishop's University, University of British Columbia, University of Toronto, Royal Military College of Canada, Memorial University of Newfoundland, University of Manitoba, Dalhousie University, McGill University, The provinces of British Columbia, Ontario, Quebec.

Founded by The Toronto French School

We are planning to accord supporter status for the 1997 projects for contributions of \$20,000 or more. Full details of the events including budgets and itineraries are contained within the enclosed sponsorship proposal. We hope to generate a great deal of local (Sudbury and Montreal), national and international publicity for the 1997 events. Certainly, a supporter will receive recognition on all of our promotional materials.

I understand from Prof. Bates that you have a long interest and history with Queen's University. I have some very close colleagues at Queen's and should it be necessary to facilitate a donation from your foundation through Queen's University, it will not be a problem. I look forward to discussing this with you further.

Yours truly

John Wylie Director

Encl. c.c. Gordon Bates

•



THE TENTH ANNIVERSARY OF THE CANADIAN CHEMISTRY AND PHYSICS OLYMPIAD Since 1985, Canadian students have brought home the gold. *Continue the tradition!* Compete for Canada in the 1995 Physics and Chemistry Olympiad. Ask your teacher for details or call 416-484-6533. Depuis 1985, nos élèves rapportent des médailles d'or au Canada. *Gardons cette tradition vivante!* Participez aux Olympiades Canadiennes de Physique et de Chimie en 1995. Renseignez-vous auprès de votre professeur ou bien appelez le 416-484-6533. **LE DIXIÈME ANNIVERSAIRE DES OLYMPIADES CANADIENNES DE CHIMIE ET DE PHYSIQUE**

SPONSORS • INCO LIMITED • MERCK FROSST CANADA • COMMANDITAIRES

NATURAL SCIENCES AND ENGINEERING RESEARCH COUNCIL • CONSEIL DE RECHERCHES EN SCIENCES NATURELLES ET EN GÉNIE • THE TORONTO FRENCH SCHOOL • BRITISH COLUMBIA •

QUEBEC • ONTARIO • INVESTORS GROUP INC. • JOHN WILEY & SONS CANADA • THE MCLEAN FOUNDATION • CELANESE CANADA INC. • IMPERIAL OIL LTD. • BELL CANADA •

DOW CHEMICAL • DU PONT CANADA • CANADIAN SOCIETY FOR CHEMISTRY • AECL RESEARCH • THE BOLAND FOUNDATION • CANADIAN ASSOCIATION OF PHYSICISTS • GLAXO CANADA

OLYMPIAD TOLYMPIADE

se de la companya de la







Canadian Chemistry & Physics Olympiad 306 Lawrence Ave. E., Toronto, Ontario, Canada M4N 1T7 Tel: (416) 484-6533 Fax: (416) 481-6529

Intermation + history on our war to for four interest.

OT

1994–95 Information:

The Canadian Chemistry and Physics Olympiads are underway for 1994–95. These exciting programs allow students to become eligible for the Canadian Chemistry and Physics olympiad and to represent Canada in the International Chemistry and Physics Olympiad competitions to be held in the summer of 1995. The Olympiads are the world's most prestigious events for excellent science students. Success at the Canadian or International level can open amazing academic and career doors for Canadian students. This newsletter has a report on our 1994 results and describes the Olympiad programs. Enclosed as well is a poster to help publicize the Canadian Olympiad program.

Contact:

The Canadian Olympiad organization has a number of regional chapters. We ask that an interested student contact the following appropriate address for further information and preparation materials. Note that the Chemistry and Physics Olympiads are separate competitions and while we do not rule out a student attempting both, it is generally advisable for a student to focus their efforts on one. High school students of any age may become involved; senior students will generally be more successful but we encourage junior students to become involved and gain valuable experience for future efforts. Eligible students must be in full time attendance at a Canadian high school or Cegep and must be Canadian citizens, permanent residents or have studied at a Canadian School for at least two years. To be eligible a student may not have reached 20 years of age at the time of an International Olympiad. Participation in the Canadian Association of Physicists (CAP) Prize Exam and the Ordre de Chimistes de Quebec (OCQ) Exam is strongly recommended as both are organized in cooperation with the Olympiad and are used to help select talented students.

In British Columbia, Alberta, the Yukon or the Northwest Territories, contact Physics Olympiad Committee Department of Physics University of British Columbia 6224 Agriculture Road Vancouver, B.C. V6T 2A6

Chemistry Olympiad Committee Department of Chemistry University of British Columbia 2036 Main Mall Vancouver, B.C. V6T 1Z1 In Manitoba and Saskatchewan, interested chemistry students should contact Prof. George Hickling at

Chemistry Olympiad Committee Department of Chemistry University of Manitoba Winnipeg, Manitoba R3T 2N2 In Ontario, contact Prof. Sinervo at Physics Olympiad Program Department of Physics University of Toronto 60 St. George St., Toronto, Ontario M5S 1A7

or Prof. Farrar at Chemistry Olympiad Program Department of Chemistry University of Toronto 80 St. George St., Toronto, Ontario M5S 1A1

In Quebec, physics students must contact Prof. R. Harris at

Physics Olympiad Program Department of Physics McGill University 3600 University St., Montreal, Quebec H3A 2T8 In Quebec, New Brunswick and Prince Edward Island, chemistry students must contact Prof. R. Cook at

> Chemistry Olympiad Program Department of Chemistry Bishop's University C.P. 5000 Lennoxville, Quebec J1M 1Z7

In Newfoundland, students should contact Paris Georghiou at

> Chemistry Olympiad Program Department of Chemistry Memorial University of Newfoundland St. John's, Newfoundland A1B 3X7

or Prof. De Bruyn at Physics Olympiad Program Department of Physics Memorial University of Newfoundland St. John's, Newfoundland A1B 3X7

In Nova Scotia, chemistry students should contact Prof. K. Grundy at Chemistry Olympiad Program

Department of Chemistry Dalhousie University Halifax, Nova Scotia B3H 4J3

and physics students from Nova Scotia, New Brunswick and P.E.I. should contact Prof. Goble at Physics Olympiad Program

> Department of Physics Dalhousie University Halifax, Nova Scotia B3H 4J3

Physics students from Manitoba and Saskatchewan should contact the National Office at the address on this letterhead. Any student or teacher may contact the National Office with their questions or for additional materials (including past exam papers).

Report 1994:

The winners of the 1994 Canadian Physics Olympiad were Laurent Goulet of Merici Cegep (Quebec), Michael Forbes of Strathcona Tweedsmuir School (Alberta), Joanna Karczmarek of Vaughan S.S.(Ontario), Anton Pitts of Dawson College (Quebec), and Étienne Rassart of Cegep Edouard-Montpetit (Quebec). The five students also formed the Canadian Team which represented Canada at the International Olympiad held last July in Beijing, China. Forbes and Karczmarek both won bronze medals at that event. This is a great achievement considering that the Olympiad was considered to be one of the most difficult in years. Joanna was the first Canadian women ever selected to the Canadian Physics Team, an honour she earned, in part, by finishing first in Canada on the 1994 Canadian Association of Physicist (CAP) Prize Exam. This competition is held in cooperation with the Olympiad program.

The Canadian Chemistry Olympiad Team consisted of François Labelle of College Rosemont (Quebec), Marc de Vleeschauwer of College Bois de Boulogne (Quebec), Peter Hwang of Sir Winston Churchill S.S. (Alberta), and Stephanie Beck of Western Canada S.S.(Alberta). These four were also the winners of the 1994 Canadian Chemistry Olympiad. Competing last July in Oslo, Norway, the team brought home silver (Labelle) and bronze (Hwang) medals. Canada traditionally does very well at the International Chemistry Olympiad and this year was no exception. The Quebec students had the additional honour of placing highly on the Ordre de Chimistes de Quebec (OCQ) Exam, a competition held in cooperation with the Canadian Olympiad program.

While overseas competing for Canada, the students write five hour theory exams and perform a very difficult experimental problem. Most of the time at an Olympiad is spent getting to know the other students from nearly 50 other countries. The opening ceremonies of the Chemistry Olympiad were held in the grand Oslo City Hall, home of the Nobel Peace Prize ceremony. Canadian Peter Hwang received a special honour when he was given the opportunity to play the hall's concert grand piano. The chemistry students also toured a 300-year old silver mine, and sailed the Norwegian fjords on a replica viking ship. The physics students competing in Beijing had many great experiences of their own including visits to the Great Wall, the Ming Tombs and the Summer Palace. It was an extraordinary experience to visit China as a special guest of their government.

The Canadian program starts each fall when every high school in the Country is sent a poster and an information newsletter. In addition, many schools receive one or more mailings from their regional university partner outlining special preparation programs and materials. Participating students must work very hard throughout the year, on their own or as part of a provincial preparation program, to prepare for the National Selection Exam held in early May. On the basis of this exam, written by all Olympiad hopefuls across Canada, 40 of the top students are invited to the National Olympiad Finals. Results from the Canadian Association of Physicists (CAP) Exam and the Ordre de Chimistes de Quebec (OCQ) Exam are also used to select the Canadian finalists.

The 1994 Canadian National Olympiad Final was held during the last week in May at Bishop's University of Lennoxville, Quebec. The Finals are an intensive week of advanced training in which students are examined on world class Olympiad problems both theoretical and experimental. During the week, the students spent a day in Quebec City and competed in the annual Olympiad grudge-match-this year it was a chemistry versus physics volleyball game. The students were in the limelight as a film crew was there for the week filming for a soon to be released documentary on the Canadian and American Olympiad programs. At the end of the week, the winners of the Canadian Chemistry and Physics Olympiads are announced. These are very prestigious positions for a Canadian student to hold; the winners are the very best science students in Canada. The winners of the National Finals are also chosen to the Canadian International Olympiad Teams.

The Olympiad is committed to providing opportunity in both of Canada's official languages. Preparation materials, the National Selection Exams and the International Exams are available in French and English. At the National Finals, instruction and examination takes place in both english and in french. Many sessions are fully bilingual and so students, both anglophone and francophone, are exposed to both languages in each other's company. Tutors functional in both languages are available to help the students with their studies.

Before the International Chemistry Olympiad, the Team was hosted, for several days, by Merck-Frosst Canada at their Montreal based research centre. There, Merck staff provided additional laboratory training and lectures to further prepare students for the International competition. One other student was invited to this event. Victoria Beck, Stephanie's twin sister, finished so closely behind Stephanie in the final standings that it was decided to bring her to Montreal for the experience. It was too bad that we could not add an extra team member to the International contingent.

History & Future:

The first Chemistry and Physics Olympiads were held in Eastern Europe in 1967-68 with only three participating Countries. Since then the Olympiads have been held nearly every year and now there are nearly 50 Countries that take part. Canada has sent teams to the International Chemistry Olympiad since 1986 and during these past nine years we have won 18 medals including 2 gold, 4 silver and 12 bronze. Canada first competed in the International Physics Olympiad in 1985 and since then we have won 12 medals including a gold and 11 bronze. Our gold medal came in 1991 in Cuba when Michael Montour from British Columbia came second overall in the world! This coming year, 1995, marks the tenth anniversary of the Canadian Chemistry and Physics Olympiad. We have grown from a small pilot project to become the most prestigious competition and opportunity for a Canadian science student. The next ten years will be even more exciting.

The Canadian Chemistry and Physics Olympiad organization is looking forward to July of 1997 when it will be hosting both the International Physics and Chemistry Olympiads in Canada. This will be the first time that both events will be held in the same Country simultaneously. The 28th International Physics Olympiad will be held at Laurentian University in conjunction with Science North, both of Sudbury, Ontario. Participants from perhaps 50 nations will be treated to the beauty and geology of the Canadian Shield, and a visit to the Sudbury Neutrino Observatory 2km underground. Inco Limited has already signed on as our principle sponsor of this event.

The 1997 International Chemistry Olympiad will be held at McGill University in Quebec in conjunction with Bishop's University. Some 300 students and team leaders from around the world will enjoy Montreal and the Quebec Eastern Townships. Surely a trip to Quebec City will be a highlight of the event. Merck Frosst Canada is the generous principle sponsor of the 1997 International Chemistry Olympiad in Canada.

These projects represent a significant fundraising challenge and the Canadian organization is looking for eager corporate partners willing to share in the funding and planning for 1997. Over the next two years, we must raise over one half of a million dollars. Volunteers from the Montreal and Sudbury area will be needed to help organise such events as the opening and closing ceremonies, social events, banquets, and out4

ings. We will need students fluent in many languages who would like to act as a guide for each of the attending nations. We will need chemists and physicists to help mark the many exam papers that will be written. We will need clerical and computer support staff and most of all, we will need interest and support from the communities involved.

A documentary on the Olympiad will begin airing in Canada in early 1995 on the newly formed Discovery Channel. It will be shown in the United States on Public Broadcasting stations. We are very interested in hearing from Canadians wishing to support our 1997 projects either financially or through volunteering for one of the International Olympiads to be held in Sudbury and Montreal. The Canadian Chemistry and Physics Olympiad is a registered charitable corporation and can issue tax receipts for any donation.

Organization:

Board of Directors

President	Doug Frith	Hill & Knowlton Canada
Vice President	Harry Giles, C.M., Q.C.	Founder, Toronto French School
Sec./Treas.	John Wylie, Ph.D.	Toronto French School
Member	Al MacDonald	Merck Frosst Canada Inc.
CIC Liaison	George Brown, M.C.I.C.	CIC, Toronto Section
CAP Liaison	Napoleon Gauthier, Ph.D.	Royal Military College

Academic Committees

Physics

Dr. J. Wylie, Toronto French School

Prof. J. Sipe, University of Toronto

Prof. P. Sinervo, University of Toronto

Prof. R. Harris, McGill University

Prof. A. Kotlicki, University of British Columbia

Prof. C. Waltham, University of British Columbia

Prof. N. Gauthier, The Royal Military College

Prof. D. Goble, Dalhousie University

Prof. J. De Bruyn, Memorial University of Newfoundland

Chemistry

L. Barton, Toronto French School

Prof. D. Farrar, University of Toronto

Prof. R. Cook, Bishop's University

Prof. G. Bates, University of British Columbia

Prof. G. Hickling, University of Manitoba

Prof. P. Georghiou, Memorial University of Newfoundland

Prof. K. Grundy, Dalhousie University

Team Leaders

Physics

Dr. J. Wylie, Toronto French School

Prof. C. Waltham, University of British Columbia Chemistry

Prof. G. Bates, University of British Columbia

Prof. R. Cook, Bishop's University

General Description

The Canadian Chemistry and Physics Olympiad (CCPO) is a registered charitable corporation founded in 1985 to organize Canada's participation in both the International Physics Olympiad and the International Chemistry Olympiad. Towards this end, a Board of Directors coordinates the efforts of a score of volunteers from universities across Canada. The CCPO oversees a number of provincial training programs, organizes provincial and national selection examinations and organizes a National Olympiad Final which is held each year in Québec during the last week of May. The winners of the Canadian Olympiad competitions represent Canada each summer at the international events. The annual budget for these activities is now in excess of \$100,000. This amount must be raised from federal and provincial governments, and from the private sector. The major sponsors of the Olympiads are Merck Frosst Canada Inc. and The Natural Sciences and Engineering Research Council of Canada.

The CCPO is now further charged with organizing the 1997 International Chemistry and Physics Olympiads. A history of the International Chemistry Olympiad (IChO) as well as information on the 1997 event are given in the following paragraphs.

The first International Chemistry Olympiad was held in Prague, in 1968, with only Czechoslovakia, Hungary and Poland participating. Since then it has been held every year except 1971. The first nation outside eastern Europe to participate was Sweden (1974). The first nation outside this block to host an Olympiad was Austria (1980) while the United States was the first host in the Western Hemisphere (1992). Canada participated for the first time in 1986 in Leiden, The Netherlands. From its humble beginnings with only three countries participating, the Olympiad has developed into a prestigious international competition. The 1994 Olympiad in Oslo was attended by delegations from 40 countries.

The competition is for teams of four pre-university students. Individual competitors can be awarded gold, silver or bronze medals or certificates of merit and approximately 60% of the participants receive an award. There are no formal awards or ranking for the overall performance of countries. Each team of students is accompanied by two chemists who act as team mentors and they are also members of the competition jury.

The competition is hosted each July by a different country and is usually held over a period of 8–11 days during which time, each student sits two five-hour examinations, one on theory and one in the laboratory. Cultural, social and tourist activities are planned to allow the students to meet their peers from around the world and to become acquainted with the host country. Each participating country pays the costs of travelling to and from the International Olympiad. All other costs of an Olympiad are covered by the host country; organization costs, room and board for all participants, internal travel, and even a small amount of pocket money for each student.

Under IChO statues each host country prepares a set of preparatory exercises which in essence defines the academic areas covered in the Olympiad of that year. The level of the questions is that of a typical first and second year university program here in Canada. Most countries, Canada included, devote a great deal of time, energy and money towards finding, encouraging and training the most gifted students. The rewards are obvious as these students move on towards a career in science research; this indeed is the most important benefit of the Olympiad program. In spite of the difficulty of the examinations and the high level of the competition, Canada has made a very respectable showing since 1986 winning two gold medals, five silver medals and 11 bronze medals.

Canada will be the host in 1997 and provision has been made for 50 countries to attend over the period of July 13 to July 23. The competition will be held at McGill University in Montréal.

The International Jury will do the work of the preparation and translation of the two exams at Bishop's University in Lennoxville, Québec. Merck Frosst Canada Inc. has signed on as the principal sponsor of the 1997 IChO. The Olympiad organization is also supported by the Canadian Institute of Chemistry. The firm of Hill & Knowlton Canada is also represented on our board of directors; they will help with fundraising and matters involving publicity and communications.

Canada is also hosting the International Physics Olympiad in 1997. This is a separate project but one which falls under the authority of the Canadian Chemistry and Physics Olympiad organization. It will be held at Laurentian University in Sudbury, Ontario in conjunction with Science North from July 13-21 of that year. Inco Limited will be the principal sponsor of that event and there is involvement as well from the Sudbury Neutrino Observatory. We would be happy to provide you with more details on this parallel project if desired.

The total budget for the 1997 IChO is estimated at \$403,000. Towards this, Merck Frosst Canada Inc. has pledged a donation of \$160,000. We must now raise \$243,000 in order to have a successful Olympiad. The need would have been even greater if it were not for the hospitality of the Department of Chemistry at McGill University and the work of dozens upon dozens of volunteers. We hope that those who have been supporting the CCPO will also support the International Olympiads, and, that many new sponsors will come on-board for this important event, which will bring honour not only to our school system but to Canadian science in general.

Sponsorship Details

The 1997 International Chemistry Olympiad program will attract both national and international media attention. Canada will host teams from 50 countries; in most of these countries the Olympiads have a very high profile. The organizing committee will ensure that all our sponsors will receive public and media recognition for their support. A number of Olympiad publications (such as posters, letters, programmes and press releases) will also offer recognition in proportion to a sponsor's contribution. A number of events will lend themselves particularly well to sponsorship; examples of these sponsorship opportunities are:

- General Operating Expenses.
- Opening and Closing Ceremonies.
- VIP Receptions.
- Final Celebration Banquet.
- Awards Presentation Ceremony.
- Special Sight Seeing, Social or Cultural Events.
- Visits to Chemical and Pharmaceutical Companies.

We are looking for foundations and corporations to contribute in one of three ways:

- (1) Donations of between \$20,000-\$50,000 towards the general operation of the 1997 IChO.
- (2) Sponsorship of an event (reception, ceremony, cultural or tourist visit) at the IChO.
- (3) Contribution or loan of equipment (photocopiers, fax, communications systems, computers, laboratory instruments, etc.) or facilities (rooms for reception, transportation, etc.), to the IChO (in-kind donations).

Contributions in the range of \$20,000 and up will be accorded sponsorship status and recognition will be given on all CCPO and 1997 IChO correspondence, documentation, and publicity. Our Board of Directors will work to build as much recognition as possible for our sponsors' support of the Olympiad. We would encourage potential sponsors to break a large contribution into a number of annual donations, say \$10,000 in each of 1995–97. Charitable tax receipts can be issued for any donation, in-kind, or otherwise.

Contributions of an amount less than \$20,000 are of course very welcome. Donations of an amount of \$1,000 or more will receive recognition as a supporter on our CCPO letterhead and annual poster as well as in any publications or publicity that we generate for our annual programs.

Budgetary Considerations

Accommodation: Housing the 400 participants (200 competitors, 50 guides, 100 mentors and 50 observers) for 10 days is the biggest single expense associated with the Olympiad. The competitors and their guides will be housed for the entire period at the McGill University residences. The academic leaders and observers will be housed at Bishop's University during the examination preparation and later will join the students at McGill.

Special events and receptions: Throughout the Olympiad there are special ceremonies and receptions for the 400 participants. The most important of these are the opening and closing ceremonies and the closing banquet. As well, during the tourist program several meals will have to be catered which are separate from the normal room and board costs.

Organizational Expenses: As the Olympiad draws near, an administrator will have to be hired to handle all the paper work associated with its organization. Although this position may be covered by an in-kind donation from one of the institutions involved, there will be associated costs for all printed matter (schedules, posters, tourist information etc.), mailings, photocopying, rental of a fax, and other communication expenses. Included in this item are the insurance costs for the participants.

Concerts, social and tourist activities: All participants go on a number of scientific and sightseeing excursions during the Olympiad. In addition, there are a series of social and cultural events.

Transportation: All participating countries will be required to transport their delegations to either of Montréal's two airports. A fleet of coaches will be hired for transportation between the airports and the sites as well as for all other organized trips.

Competition Expenses: The preparation of the examinations requires a network of computers with word-processing packages in the languages of the different participating countries as well as translation services and clerical staff. For the competition, identical calculators are provided to each participant. The practical examination will also require an identical set of equipment for each of the 200 participants. The host University contributes extensively to the organization of the laboratories but nevertheless a significant amount of what is needed must be purchased, donated or borrowed. The cost of the medals and other prizes are included in this item.

Honoraria: Virtually all the student and academic help is voluntary, however, a small honorarium is usually given to each volunteer. The duties of these volunteers include:

- Student guides, one for each country, who stay with the different teams throughout the Olympiad. These guides must be able to work in French, English, and the language of the team.
- Academic personnel who set, invigilate and grade the examinations of the competition.


- 4 The International Chemistry Olympiad
 - "Gophers" who run errands, supervise transportation, handle communications, accompany excursions, etc.
 - Members of the organizing committee and its sub-committees who take on the overall responsibility for the different areas of the Olympiad.

Budget

Accommodations	Full Room and Board (less meals eaten elsewhere) Total	\$220,000 (\$25,000) \$195,000
Special meals and Receptions	Reception for Mentors at Bishop's Mentor dinner at "relais et chateaux" Opening Ceremony & Reception Dinner on the River Dinner in Québec City Dinner in Ottawa Dinner at La Ronde Closing Dinner Total	\$1,000 \$7,500 \$12,000 \$16,000 \$16,000 \$16,000 \$3,800 \$20,000 \$92,300
Organizational	Letterhead, Programs, Certificates, Photocopying Stationary, Telephone, Fax, Postage, Insurance, Travel	
	Total	\$67,000
Transportation	Arrival and Departure Mentors to and from Lennoxville Tourism Van and Car Rentals Bus Passes Total	\$8,000 \$4,800 \$24,000 \$2,000 \$4,000 \$42,800
Concerts and Sightseeing		\$30,000
Competition Costs	Theoretical and Practical Exams, Calculators, Flags, Medals, Prizes	
	Total	\$25,000
Honoraria	Stipends for Volunteers	\$18,000
Miscellaneous	T-shirts, Flag Rentals, Refreshments, Snacks, Flowers, etc.	
	Total	\$8,000
Total Less (for observers) ¹		\$478,100 (\$75,000)
Total		\$403,100

1 The amount subtracted from the budget for observers is based on 50 such registrants for whom the organizing committee does not have financial responsibility. The costs for the observers are included in all calculations because they participate in all events but they pay a participation fee of \$1,500 each.

Organizational Structure



.

IChO Schedule, July 1997

Sunday July 13

- Arrival of Teams at Montréal Airports
- Dinner and Reception

Monday July 14

- Opening Ceremony and Reception
- Lunch
- Visit to Laboratories (mentors)
- Travel to Lennoxville (mentors)
- Distribution of Practical Examination (mentors)
- Jury Session and Translation (mentors)
- Sightseeing in Montréal (students)
- Laboratory Safety Tutorial (students)
- Dinner

Tuesday July 15

- Practical Examination (students)
- Distribution of Theoretical Examination (mentors)
- Jury Session (mentors)
- Lunch
- Afternoon and Evening at La Ronde (students)
- Tour of Eastern Townships (mentors)
- Dinner at an "auberge" in the Eastern Townships (mentors)

Wednesday July 16

- Jury Session-Statistical Analysis of the Results of the Practical Examination (mentors)
- Free Day for Students (leisure, sports, study)
- Lunch
- Jury Session (mentors)
- Dinner
- Translation (mentors)

Thursday July 17

- Theoretical Examination (students)
- Leave for Montréal (mentors)
- Lunch
- Pick up of Practical and Theoretical Examinations for Grading (mentors)
- Visits in Montréal; Reception at City Hall
- Dinner on the River

Friday July 18

- Leave for Scientific Visits Including Lunch
- Dinner
- Evening Event

Saturday July 19

• Leave for Québec City; All Day Tour Including Lunch and Dinner

Sunday July 20

• Leave for Ottawa; All Day Tour Including Lunch and Dinner

Monday July 21

- Arbitration of Theoretical and Practical Examinations (mentors)
- Leave for All Day Trip to Provincial Park; Swimming and Boating
- Lunch
- Dinner
- Disco Evening (students)
- Jury Session—Business Meeting (mentors)

Tuesday July 22

- Free Morning in Montréal Including Lunch
- Gather at Site for the Closing Ceremony
- Closing Ceremony
- Gala Dinner

Wednesday July 23

• Departure for Airports

Canadian Participants & Awards

1986 Leiden, The Netherlands

1000 Belden, Luc reconcitat		
Colin Plumb	University of Toronto Schools, ON	Gold
Alexandre Huboux	Toronto French School, ON	Bronze
Michael Gharghouri	Toronto French School, ON	
Emilie Hooft	Toronto French School, ON	
1987 Veszprem, Hungary		
Sean Finucane	Toronto French School, ON	
Mila Oh	St. John's Ravenscourt School, MN	
Jasdip Sachdeva	Toronto French School, ON	
1988 Helsinki, Finland		
Julia Kubanek	John Abbott College, PQ	Bronze
Chris Gunn	Steveston H.S., BC	Bronze
Vince Wong	St. Robert H.S., ON	Bronze
Steven Postma	De La Salle College, ON	
1989 Halle, East Germany		
Denis Deschenes	Cegep de Baie Comeau, PQ	
Marilena Fitzsimons	John Abbott College, PQ	Silver
Stephen Cheng	St. Patrick's S.S., ON	
Christopher Chan	Toronto French School, ON	Bronze
1990 Paris, France		
Julie Filion	Champlain Reg. College, PQ	Bronze
David Thiel	South Huron D.H.S., ON	Bronze
Margaret Shih	Steveston S.S., BC	
Howard Fischer	Marianopolis College, PQ	
1991 Lodz, Poland	1 O V	
Jennifer Bryce	Western Canada S.S., AB	Bronze
Mohammed Rumi Faizer	Marianopolis College, PQ	DIOMEO
Erik Rubin	John Abbott College, PQ	Silver
David Thiel	South Huron S.S., ON	Bronze
1992 Pittsburgh, U.S.A.		
Dileepan Joseph	Grant Park, MN	
Sean Margison	Yale H.S., BC	
James Baughan	Western Canada H.S., AB	
Roman Elinson	University of Toronto Schools, ON	
1993 Perugia, Italy	·····, ····	
Arvind Govindarajan	Woburn C.I., ON	Bronze
Michael Hawkes	Lindsay Thurber Composite School, AB	Gold
Cyrus Master	Western Canada H.S., AB	Silver
Andras Pattantyus-Abraham	John Abbott College, PQ	Silver
Anulds Fattantyus-Abraham	JOHH PROPOSE COHERC' I &	CHACT

1994 Oslo, Norway

Stephanie Beck Peter Hwang Marc De Vleeschauwer Francois Labelle Western Canada High School, AB Sir Winston Churchill Senior H.S., AB College Bois de Boulogne, PQ College Rosemont, PQ

Bronze Silver

Hosts of the International Chemistry Olympiads

Past:

1 0.00.		
I	1968	Prague, Czechoslovakia
II	1969	Katowice, Poland
III	1970	Budapest, Hungary
IV	1972	Moscow, USSR
V	1973	Sofia, Bulgaria
VI	1974	Bucharest, Rumania
VII	1975	Veszprem, Hungary
VIII	1976	Halle, GDR
IX	1977	Bratislava, Czechoslovakia
Х	1978	Torun, Poland
XI	1979	Leningrad, USSR
XII	1980	Linz, Austria
XIII	1981	Burgas, Bulgaria
XIV	1982	Stockholm, Sweden
XV	1983	Timisoara, Rumania
XVI	1984	Frankfurt, Germany
XVII	1985	Bratislava, Czechoslovakia
XVIII	1986	Leiden, Netherlands (First Canadian Participation)
XIX	1987	Veszprem, Hungary
XX	1988	Helsinki, Finland
XXI	1989	Halle, GDR
XXII	1990	Paris, France
XXIII	1991	Lodz, Poland
XXIV	1992	Pittsburgh, USA
XXV	1993	Perugia, Italy
XXVI	1994	Oslo, Norway
Future:		
XXVII	1995	Beijing, China
XXVIII	1996	Moscow, Russia
XXIX	1997	Montréal, Canada
XXX	1998	Australia
XXXI	1999	Thailand
XXXII	2000	Denmark





DR. ALFRED BADER

ESTABLISHED 1961

April 24, 1995

Christopher R. Davy Studio, 165 King Street East, #1 Kingston, Ontario K7L 3A3 Canada

Dear Mr. Davy:

I am sorry that I am so late in responding to your interesting letter of March 23rd, but you sent that to the Aldrich Chemical Company, which dismissed me some three years ago.

Your work looks very interesting, and I am happy to see that you are well-known at the Agnes Etherington Art Centre.

However, please understand that I specialize in 17th Century paintings and know very little about modern art.

With all good wishes, I remain,

8

Yours sincerely,

AB/cw

Enclosure

bc: David McTavish



Christopher R. Davy Studio, 165 King St. E. #1 Kingston, Ontario Canada K7L 3A3 (613) 544-6231

March 23, 1995.

Dr. Alfred Bader Aldrich Chemical Supply P.O. Box 355 Milwaukee, Wisconsin U.S.A. 53201

Dear Dr. Bader:

Enclosed, please find a brochure comprised of a photograph representing my painting, an artist's statement, and a list of exhibitons. I would be very interested in your opinion and naturally would prefer to meet with you in person to discuss it; perhaps we will have the opportunity to meet in the future. It is likely that my future work will be influenced by other great minds and I would consider doing commissioned work on themes I could approach enthusiastically provided I could have artistic freedom. As to the value I place on my work, I paraphrase Somerset Maugham: "...the work of art is a solace...great works of art enrich the soul and their effects are worthy deeds..." I have a vision of the future to share and am looking for others with skills and resources who can help make this vision a reality.

I hope this letter and graphic representation will serve as a good ambassador and I look forward to hearing from you.

Yours very truly,

Christopher R. Davy

Christopher Robb Davy





ALFRED BADER FINE ARTS

DR. ALFRED BADER

ESTABLISHED 1961

April 24, 1995

Mr. Barry Oretsky 223 Coldstream Avenue Toronto, Ontario M5N 1Y4 Canada

Dear Mr. Oretsky:

I recently received a note from the Queen's Alumni Office that you would like to correspond with me.

I specialize in Dutch and Italian 17th Century paintings, but might well be interested in your work if you handle subjects of Jewish interest. If so, I would appreciate your sending me a couple of snapshots.

My wife and I will be in Toronto on May 17th-18th, when Isabel will receive an honorary doctorate. If you do handle Jewish subjects, I could visit with you then and would appreciate directions on how to get from the University of Toronto to your atelier.

Looking forward to hearing from you, I remain,

Yours sincerely, "

AB/cw

bc: Ms. Ivanka Frankovic

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709





ALFRED BADER FINE ARTS

DR. ALFRED BADER

ESTABLISHED 1961

April 24, 1995

Mr. John Miecznikowski RR4 Chatsworth, Ontario N0H 1G0 Canada

Dear Mr. Miecznikowski:

The Office of Queen's Alumni has sent me a note that told me that you are interested in selling a bronze bust of George Grant.

I try very much to concentrate my purchases for Queen's in Dutch and Italian 17th Century paintings and would rather not begin buying modern work for Queen's.

I don't know whether the Agnes Etherington Art Centre has any acquisition funds, but you might like to enquire of the director of the Art Centre, Professor David McTavish.

With all good wishes, I remain,

6.1

Yours sincerely,

AB/cw

cc: Ivanka Frankovich

bc: David McTavish

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709



PARTEQ





JOHN P. MOLLOY, B.Admin., M.B.A. EXECUTIVE DIRECTOR QUEEN'S UNIVERSITY, KINGSTON, ONTARIO K7L 3N6 TELEPHONE: (613) 545-2342 FACSIMILE: (613) 545-6853

28 April 1995

Transmitted to FAX 414 277 0709

Dr. Alfred R. Bader Suite 622, 924 East Juneau Avenue Wilwaukee, Wisconsin 53202

Dear Marvin : What as you Think of Firs ?

Dear Dr. Bader,

Thank you for your fax regarding the financing initiative we have underway. You may certainly share the memorandum with those you feel may have an interest.

The offering is not an easy investment to sell. This approach has not been used by any university before and investment at this stage of technology development is too risky for most investors. The offering is also quite complex and requires an appreciation of what is in the current portfolio and what may result from research at Queen's over the next ten years in order to have any feel for possible return. Therefore, only very sophisticated investors will have an interest and dedicated time needs to be spent with each potential investor.

We are, however, optimistic that we will complete the sale of this offering. We are hopeful that one or more of the Canadian banks will take a lead investment position. I think once we have that lead group, we will be able to close with other interested potential investors such as pension funds, life insurance companies, venture funds, and wealthy individuals/families. I do not anticipate closing before the end of the summer.

I would be pleased to discuss our approach with you, your sons or others who may have an interest. If there is interest I would be happy to visit Milwaukee. Alternatively, I would be pleased to discuss our initiative with you on the phone.

Thank you for your interest.

Kind regards.

Yours very truly, John P. Molloy



Confidential Offering Memorandum dated January 27, 1995

This offering memorandum constitutes an offering of these securities only in those jurisdictions and to those persons where and to whom they may be lawfully offered for sale and only by persons permitted to sell these securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this offering memorandum or the merits of these securities, and any representation to the contrary is an offence. Persons who acquire securities pursuant to this offering memorandum will not have the benefit of the review of this document by any securities commission or similar regulatory authority. This offering memorandum is being furnished on a confidential basis. By their acceptance of this offering memorandum, recipients agree that they will not transmit, reproduce or make available to anyone, other than their professional advisors, this offering memorandum or any information contained in it. No person has been authorized to give any information or to make any representations not contained in this offering memorandum. Any such information or representation which is given or received must not be relied upon.

Private Placement

CATARAQUI TECHNOLOGIES INC.

\$28,000,000

2,800,000 Common Shares

The net proceeds from the issue of the Common Shares offered hereby will be used by Cataraqui Technologies Inc. (the "Company") to purchase a royalty interest in the Net Revenue (as defined) earned by PARTEQ Innovations Inc. ("PARTEQ") from specified intellectual property held by Queen's University at Kingston ("Queen's" or the "University") on the closing of this offering or which may be acquired by Queen's or PARTEQ on or before December 31, 2004 and in respect of which inventors have engaged the services of PARTEQ (the "Portfolio"), to finance and participate in the development and commercial exploitation of the Portfolio as described in this Offering Memorandum and to finance the ongoing operations of the Company. The Portfolio may include intellectual property owned by persons other than Queen's or PARTEQ where the owner has granted rights to and engaged the services of PARTEQ. See "Royalty and Development Agreement". On the closing of this offering, Queen's will grant to PARTEQ, its wholly-owned subsidiary, an exclusive license to exploit all rights to items of intellectual property in the Portfolio owned by Queen's. See "PARTEQ Innovations Inc.".

The Common Shares are being offered for sale under exemptions from the prospectus requirements of applicable securities laws and will be subject to resale restrictions. The minimum subscription is \$150,000. Purchasers of Common Shares will be obliged to establish their qualifications to invest in accordance with the requirements of such securities laws. See "Plan of Distribution".

The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered or sold except in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act and any applicable state securities laws. Accordingly, the Common Shares are being offered and sold in the United States only to qualified institutional buyers within the meaning of and in accordance with Rule 144A under the U.S. Securities Act, and outside the United States in accordance with Regulation S under the U.S. Securities Act. See "Plan of Distribution".

e . . .

The Common Shares have not been approved or disapproved by the United States Securities and Exchange Commission or by any state securities commission or regulatory authority, nor have any of the foregoing authorities passed on the accuracy or adequacy of this Offering Memorandum. Any representation to the contrary is a criminal offence.

Available Information

For so long as any of the Common Shares remain outstanding and are "restricted securities" within the meaning of Rule 144(a)(3) under the U.S. Securities Act, the Company will, during any period in which the Company is neither subject to Section 13 or 15(d) under the *United States Securities Exchange Act of 1934*, as amended (the "U.S. Exchange Act"), nor exempt from reporting under the U.S. Exchange Act pursuant to Rule 12g3-2(b) thereunder, make available to (i) any holder of Common Shares or (ii) any prospective purchaser of Common Shares who is a qualified institutional buyer designated by such holder within the meaning of Rule 144A under the U.S. Securities Act, in connection with any sale thereof, in each case at the holder's written request to the Company, the information specified in, and meeting the requirements of Rule 144A(d)(4) under the U.S. Securities Act.

Enforcement of Civil Liabilities

The enforcement in the United States by investors of civil liabilities under the United States federal securities laws may be affected adversely by the fact that the Company was formed under and is governed by the laws of the Province of Ontario, Canada, that a majority of its directors and officers are not residents of the United States, that the Agents and certain of the experts named in this Offering Memorandum are residents of Canada, and that the assets of the Company and said persons are located outside the United States.

The price of the Common Shares offered hereby was determined by the Agents. An investment in the Common Shares is speculative and involves a significant degree of risk. See "Risk Factors".

There is currently no market through which the Common Shares may be sold.

In the opinion of legal counsel, the Common Shares offered hereby will qualify as eligible investments pursuant to certain statutes as set forth under "Eligibility for Investment".

Price: \$10.00 per Common Share

	Price to	Agents'	Net Proceeds to
	the Public	Fee	the Company ⁽¹⁾
Per Common Share	\$10.00	\$0.60	\$9.40
Total	\$28,000,000	\$1,680,000	\$26,320,000

Notes:

(1) Before deducting expenses of this offering estimated to be \$150,000 which, together with the Agents' fee, are expected to be paid from the proceeds of this offering.

The Agents conditionally offer the Common Shares, subject to prior sale, if as and when issued by the Company and accepted by the Agents in accordance with the conditions contained in the Agency Agreement referred to under "Plan of Distribution" and subject to the approval of certain legal matters by Goodman and Carr on behalf of the Company and the Agents and by Tory DesLauriers & Binnington and Cunningham, Swan, Carty, Little & Bonham on behalf of Queen's and PARTEQ.

Subscriptions will be received subject to rejection or allotment, in whole or in part, and the right is reserved to close the subscription books at any time without notice. It is expected that certificates evidencing the Common Shares will be available for delivery at the closing which is expected to occur on or about March 1, 1995, or such later date as the Company and the Agents may agree, but in any event not later than March 30, 1995.

TABLE OF CONTENTS

P.A	١G	E
1	10	

ELIGIBILITY FOR INVESTMENT	6
SUMMARY	7
THE COMPANY	7
PARTEQ INNOVATIONS INC	7
THE OFFERING	7
THE COMPANY Investment Objective Operating Expenses and Administration Financial Position of Company Directors and Officers of the Company	10
PARTEQ INNOVATIONS INC. Background Reorganization of PARTEQ's Business	
THE OPPORTUNITY	17
ROYALTY AND DEVELOPMENT AGREEMENT Royalty Interest Development Fund PARTEQ Options	
INTELLECTUAL PROPERTY PORTFOLIO Licensed Properties Pharmaceutical/Biotechnology Analytical Instrumentation Chemical/Petrochemical Advanced Materials Medical Devices Other Properties	

USE OF PROCEEDS	46
PARTEQ DIRECTORS AND MANAGEMENT	47
COMPENSATION AND INCENTIVE PROGRAM	48
DESCRIPTION OF SHARE CAPITAL	48
DIVIDEND POLICY	48
PLAN OF DISTRIBUTION	49
RISK FACTORS	50
INTEREST OF MANAGEMENT AND OTHERS	52
MATERIAL CONTRACTS	52
LEGAL MATTERS	53
AUDITORS	53
PURCHASERS' CONTRACTUAL RIGHTS OF ACTION	53
CERTIFICATE OF THE COMPANY	

ELIGIBILITY FOR INVESTMENT

Eligibility of the Common Shares offered hereby for investment by purchasers to whom any of the following statutes apply is, in certain cases, governed by criteria which such purchasers are required to establish as policies or guidelines pursuant to the applicable statute (and, where applicable, the regulations thereunder) and is subject to prudent investment standards and general investment provisions provided therein:

Insurance Companies Act (Canada) Trust and Loan Companies Act (Canada) Loan and Trust Corporations Act (Ontario) Pension Benefits Act (Ontario) Financial Institutions Act (British Columbia) Pension Benefits Standards Act (Canada) Loan and Trust Corporations Act (Alberta) An Act respecting insurance (Quebec) Supplemental Pension Plans Act (Quebec) An Act respecting trust companies and savings companies (Quebec)

The Common Shares will not be qualified investments under the Income Tax Act (Canada) for trusts governed by registered retirement savings plans, registered retirement income funds and deferred profit sharing plans.

SUMMARY

The following is a summary of the principal features of the offering and is qualified by the more detailed information appearing elsewhere in this Offering Memorandum. Certain of the terms used with initial capitals in this summary are defined elsewhere in this Offering Memorandum.

THE COMPANY

The Company has been incorporated to finance and participate in the development and commercial exploitation of scientific research for the purpose of profit. The purpose of this offering is to raise funds to purchase a royalty interest in the Net Revenue (as defined) earned by PARTEQ from the Portfolio, to finance and participate in the development of the Portfolio as described herein and for working capital purposes.

PARTEQ INNOVATIONS INC.

PARTEQ is a wholly-owned subsidiary of Queen's which has been established to facilitate the commercial exploitation of discoveries by researchers at the University. Queen's is a recognized centre for research. For the year ended March 31, 1994 researchers at Queen's conducted over \$68,000,000 of research funded primarily through programs sponsored by the Government of Canada.

THE OFFERING

Issue: 2,800,000 Common Shares

Price: \$10.00 per Common Share

Use of Proceeds: The net proceeds from the sale of the Common Shares offered hereunder are estimated to be \$26,170,000, after deducting the aggregate Agents' Fee of \$1,680,000 and the expenses of the offering which are estimated to be \$150,000.

The Company will use \$25,000,000 of such net proceeds to acquire from Queen's a royalty interest (the "Royalty Interest") entitling the Company to receive 30% of the Net Revenue (as defined) earned by PARTEQ from the Portfolio and to participate in the development of the Portfolio as described herein. The balance of the net proceeds will be retained by the Company for working capital purposes.

PARTEQ will set aside \$10,000,000 of the purchase price paid by the Company to establish a Development Fund for the purpose of financing the development of the Portfolio. The Development Fund will be invested in debt obligations of or guaranteed by the Government of Canada or any province or other high quality instruments (such as bank deposits or bankers acceptances). See "Royalty and Development Agreement - Development Fund".

Risk Factors:

The development of a research-based discovery or innovation into a commercial product involves a high degree of risk. Frequently the same or similar discoveries are made by different researchers within a reasonably close period of time and not disclosed except in secrecy to a patent office. Costly development work may be undertaken only to find another inventor is able to establish priority. Further testing of a discovery may fail to confirm initially favourable results or show side effects which may reduce or eliminate value. Regulatory hurdles may not be achieved after considerable development has occurred. Even when a marketable product is developed, market projections may not be attained. The descriptions in this Offering Memorandum of specific discoveries and innovations should be read with these considerations in mind. In addition, investors should have regard to the following additional risk factors with respect to the Company's participation in the development of the Portfolio:

- Technology Risk The Company's success from this project depends on university research generating discoveries with commercial potential. In addition, the properties included in the Portfolio require significant development and there can be no assurance that any of the properties will be commercialized successfully.
- Researchers' Rights to Discoveries Inventors at Queen's are not required to offer discoveries with commercial potential to PARTEQ. Accordingly, PARTEQ will only obtain rights to new discoveries if researchers choose to offer the discoveries to PARTEQ rather than other private sector companies active in this business. In addition, PARTEQ will only obtain rights to improvements to intellectual property included in the Portfolio if such improvements are assigned to Queen's or PARTEQ. Also, PARTEQ may not obtain rights to an improvement to a property in the Portfolio which is developed by a researcher after moving from Queen's to another employer who advances a competing claim.
- Government Funding Research at Queen's is primarily financed through government funding. Government funding levels have been decreasing and there can be no assurance that current levels of research can be sustained as the level of funding decreases.
- *Patents* There can be no assurance that a patent applied for will be issued or that, once issued, a patent will not be challenged by third parties. There can be no assurance that making, using or

selling the invention claimed in an issued patent will not infringe patents of third parties.

- *Reliance on PARTEQ Management* PARTEQ has limited experience in the commercialization of intellectual property innovations.
- Market Considerations The market in Canada for the development of technology resulting from university research is limited. Development of intellectual properties with parties in foreign countries may require significant effort and expense.
- Lack of Technology Entrepreneurs/Managers There are a limited number of entrepreneurs/managers with experience in commercializing intellectual properties, especially in the biotechnology field. There can be no assurance that PARTEQ will be able to attract or retain qualified entrepreneurs or managers for its commercialization projects.
- Availability of Capital PARTEQ and the Company will require additional financing to complete the commercialization of items in the Portfolio. There can be no assurance that such funding will be obtained.

See "Risk Factors".

THE COMPANY

Cataraqui Technologies Inc. (the "Company") was incorporated on January 25, 1995 under the *Ontario Business Corporations Act*. It has never before carried on business. The head office of the Company is located at Suite 200, 1250 Bay Street, Toronto, Ontario.

Investment Objective

The Company was incorporated to finance and participate in the development and commercial exploitation of scientific research for purposes of profit. The purpose of this offering is to raise funds to acquire the Royalty Interest, to finance and participate in the development of the Portfolio, as described herein, and for working capital purposes. Pursuant to the terms of an agreement to be dated the closing date of this offering (the "Participation Agreement") between the Company and Queen's, the Company will agree to pay to Queen's on the closing of this offering \$25 million and to grant the PARTEQ Options in consideration for Queen's granting to the Company the Royalty Interest which entitles the Company to receive 30% of the Net Revenue earned by PARTEQ from the Portfolio and causing PARTEQ to enter into the Royalty and Development Agreement. See "Royalty and Development Agreement" and "Use of Proceeds".

The Company may acquire other interests similar to the Royalty Interest, however, pursuant to the terms of the Royalty and Development Agreement, the Company has undertaken not to engage in any business other than as described herein without the prior consent of PARTEQ. In considering whether to grant its consent, PARTEQ may have regard only to factors affecting the reputation of the University. The Company may raise additional funds by way of public offering and/or private placement to expand the business of the Company. The Company has agreed not to approach researchers at the University, or invest in any business a primary object of which is to approach researchers at the University, for the purposes of discussing the commercialization or potential commercialization of researchers' innovations or discoveries.

Operating Expenses and Administration

The Company will be responsible for all of its operating expenses. It is anticipated that the operating expenses of the Company for its first full year of operations will be approximately \$300,000 (excluding consulting fees). The Company will be entitled to receive a minimum royalty payment of \$300,000 per year under the Royalty and Development Agreement up to December 31, 1999. The amount by which the annual minimum royalty payment exceeds what would otherwise have been payable in respect of the Royalty Interest will be accumulated and carried forward to be recovered from future royalty entitlements provided that the annual payment for the first five years will not be less than the agreed minimum. See "Royalty and Development Agreement - Royalty Interest - Minimum Royalty". The Company will also retain approximately \$1,170,000 from the net proceeds of this offering for working capital purposes.

The Company has retained Cumberland Management Services Limited (the "Administrator") under an administration agreement (the "Administration Agreement"), to be dated as of the closing date of this offering, to administer all of the ongoing operations of the

Company. Under the Administration Agreement, the Administrator will fund the Company's operating expenses (such as salaries of officers and clerical staff, occupancy costs and the costs associated with evaluating proposals submitted to the Company by PARTEQ) and will invoice the Company monthly in respect of such expenses. Decisions relating to the appointment of officers, utilization of the Development Fund, the Portfolio, expenditures by the Company not contemplated in the Company's annual budget and all other decisions relating to the business of the Company as a whole will remain the responsibility of the board of directors of the Company. The Administration Agreement has an initial term of one year with automatic one year extensions and may be terminated by either party on 60 days written notice.

Financial Position of Company

The Company will include the payments it receives on account of the Royalty Interest in computing its income for financial statement and tax purposes. It is anticipated that the \$25 million paid to Queen's for the Royalty Interest will be characterized as an eligible capital expenditure of the Company for income tax purposes and will be depreciated accordingly.

Directors and Officers of the Company

The following table sets forth the names, municipality of residence, principal occupation and business experience of each of the directors of the Company:

Name/Municipality of Residence

Thomas I. Csathy Ottawa, Ontario

Principal Occupation

Vice-Chairman of Mosaid Technologies Inc. (business consists of designing memory chips and memory chip test systems), June 1992 to present

Chairman of Fulcrum Technologies Inc. (business consists of design and distribution of text retrieval software), 1992 to present

Chairman of The Branham Consulting Group Inc. (consulting firm)

Member of Board of Directors, Andyne Computing Ltd. (business consists of developing, marketing and support of software applications for information access and reporting), September 1994 to present, and several other high technology companies Robert G. Dickie Newmarket, Ontario

Gordon H. Fox, Toronto, Ontario

Thomas O. Gephart San Diego, California Burroughs Canada, a division of Burroughs Memorex Inc. (computer hardware business) and employed for 20 years with IBM Canada Ltd. in its systems engineering, sales and finance departments

President, T.I. Csathy Associates (consulting firm), October 1989 to present

Chairman of Paige Innovations Inc. (product development company specializing in designing and commercializing a variety of innovative high-tech electrical accessories), June 1992 to present

President of Spark Innovations Inc. (business consists of developing and commercializing new technologies), February 1989 to present

Previously, President of Northern Technologies Ltd. (computer hardware development company). Inventor or coinventor of approximately 85 patents

President of Cumberland Capital Ltd. (limited market dealer), July 1994 to present

Partner of Goodman and Carr (barristers and solicitors), specializing in corporate finance, 1980 to June 1994

Founder and Chairman of Ventana Global, Ltd. (a U.S. technology oriented, private investment banking and equity investment firm engaged in growth capital activities. Ventana also manages a group of funds specializing in life sciences, environmental, high technology and special situations sectors), 1974 to present

Member of several boards of directors (public and private) and participant on the Business Development Advisory Board of Alex Juchymenko Toronto, Ontario

Marvin Kates Toronto, Ontario

Hubert R. Marleau Westmount, Quebec

California Commerce Bank

President of Cogeneration Associates Limited (professional engineering services in the field of development, design, project management and commissioning of cogeneration and electrical power stations), 1980 to present

Partner in Northland Power Partnership (developer of power generating stations) May 1987 to present

Previously, Director of Energy Systems Division for the Department of Energy, Mines and Resources (Canada) and positions with several companies including Ontario Hydro, Emerson Electric Canada Ltd., and General Electric Canada Inc.

President of Marvin Kates Consulting Corporation (consulting firm), December 1992 to present

Partner of Arthur Andersen & Co. (chartered accountants), August 1989 to December 1992

Previously, Senior Partner and Chairman of the Executive Committee, Wm. Eisenberg & Co. (chartered accountants)

Founder and Chairman of Marleau, Lemire Inc. (brokerage company), January 1990 to present

The following table sets forth the names, municipality of residence, principal occupation and business experience of each of the officers of the Company:

Name/Municipality of Residence	Office	Principal Occupation
Gordon H. Fox Toronto, Ontario	Chief Executive Officer	See table of directors above
Marvin Kates Toronto, Ontario	Chief Financial Officer	See table of directors above

The chief executive officer of the Company will be responsible for the day to day management of the affairs of the Company and, together with the chief financial officer, liaison with management of PARTEQ. The officers will review the status of the Portfolio on a regular basis and report periodically to the board of directors of the Company. The officers will also review all proposals submitted by management of PARTEQ regarding the development and commercialization of particular properties in the Portfolio. The officers may retain expert advisors to advise the Company regarding the feasibility of any particular proposal. The chief financial officer will be responsible for financial management of the Company including the preparation of the Company's annual and interim financial statements, budgeting and cash management and review of the financial aspects of proposals submitted to the board of directors of the Company.

PARTEQ INNOVATIONS INC.

Background

Queen's is a recognized centre for research. For the year ended March 31, 1994, researchers at Queen's conducted over \$68 million of research funded primarily through programs sponsored by the Government of Canada. The research budget has grown at a compound annual rate of 10.7% for the past 11 years, although the yearly growth rate between 1991 and 1994 has slowed to an average of 5.4%. Substantially all of the research conducted at Queen's through these funding sources would be considered basic research. This research occasionally leads to discoveries with potential commercial value. Often the discovery itself cannot be commercialized immediately but requires further development, testing, marketing and, in many cases, regulatory approval.

In 1987, PARTEQ Research and Development Innovations ("OLD PARTEQ") was established as a not-for-profit non-share capital corporation to facilitate the exploitation of research discoveries at Queen's. Under the University's current intellectual property policy, researchers are not obliged to convey title to their research discoveries to Queen's or to exploit those discoveries in co-operation with Queen's. However, since its inception, OLD PARTEQ has assisted researchers at Queen's who make discoveries with commercial potential and has been requested by researchers to evaluate the commercialization of many such discoveries. OLD PARTEQ does a preliminary review, normally internally, and if sufficient potential is apparent, the researcher is asked to provide OLD PARTEQ with an exclusive period of time (normally 90 days) for evaluation of the invention. OLD PARTEQ's staff evaluate the potential of the

- 14 -

discoveries for further refinement and the commercial viability of the ultimate product, often with the advice of members of the business community. If the discovery is deemed to have commercial potential, the researcher assigns the intellectual property to Queen's in return for a share of the revenues (after cost recoveries) ultimately realized. The intellectual property assigned to Queen's is then licensed to OLD PARTEQ which assumes responsibility for its commercialization.

Researchers are customarily entitled to 40% to 50% of the net proceeds actually received by OLD PARTEQ in connection with any license or sale of the researcher's intellectual property. Net proceeds is calculated by deducting from gross revenues all identifiable patenting and commercialization expenses incurred by OLD PARTEQ relative to a specific intellectual property project. Identifiable costs do not include salaries or other remuneration paid to OLD PARTEQ employees.

Commercialization of a discovery normally takes the form of licensing. A licence may be granted to an established company or a start-up company created by OLD PARTEQ or the researcher.

OLD PARTEQ had gross revenues of \$683,877 and \$490,038 and losses of \$217,670 and \$150,576 for the years ended March 31, 1994 and 1993, respectively, from properties included in the Portfolio. University generated technology requires long lead times for commercialization. Because many of the technologies in the Portfolio have not yet reached market readiness, OLD PARTEQ's revenues to date have to a large extent resulted from issue fees and milestone payments.

Reorganization of PARTEQ's Business

Immediately prior to closing of this offering, the assets currently held by OLD PARTEQ will be reinstated in Queen's. In consideration for the Royalty Interest granted by Queen's to the Company pursuant to the Participation Agreement and for the agreement to cause PARTEQ to enter into the Royalty and Development Agreement, the Company will pay the University \$25 million and grant the PARTEQ Options.


PARTEQ Innovations Inc. ("PARTEQ") was incorporated on January 27, 1995 under the Ontario Business Corporations Act. The head office of PARTEQ is located at Room 316. Fleming Hall, Queen's University, Kingston, Ontario. Queen's has established PARTEQ as a wholly-owned subsidiary to operate as a commercial entity on a for-profit basis. PARTEQ will carry on the commercialization activities previously conducted by OLD PARTEQ.

Contemporaneously with the closing of this offering, Queen's will transfer to PARTEQ: (i) \$15 million of the \$25 million received from the Company; (ii) Queen's rights under existing licenses relating to the Portfolio; (iii) the PARTEQ Options; and (iv) all other assets utilized in the business of OLD PARTEQ owned by Queen's. In addition, Queen's will grant to PARTEQ a licence (the "Queen's License") to exploit all items of intellectual property in the Portfolio owned by Queen's. In return for these assets, PARTEQ will issue a combination of common shares and debt to Queen's and enter into the Royalty and Development Agreement with the Company. The Royalty and Development Agreement will require PARTEQ to set aside \$10 million of the \$15 million received from the University as the Development Fund. PARTEQ will use the remaining \$5 million for working capital purposes.

Pursuant to the Queen's License, PARTEQ will be granted the irrevocable exclusive world-wide rights to exploit all items of intellectual property owned by Queen's in the Portfolio. The Queen's License will provide that the Portfolio is licensed on an "as is" basis and Queen's will make no representations or warranties relating to the patentability of any item of intellectual property, the validity of any patent or whether the use of any intellectual property pursuant to the license will infringe the rights of others. Queen's will represent and warrant to the Company that to the knowledge of the Vice-Principal (Operations and University Relations) of Queen's, there are no infringement actions, either pending or threatened in writing, against Queen's or PARTEQ relating to the Portfolio, except as disclosed to Cataraqui. In addition, Queen's will represent and warrant to the Company that to the knowledge of the Vice-President (Operations and University Relations), it has not received formal written notification of any presently pending challenge to the validity or ownership of any registered intellectual property or pending intellectual property in the Portfolio, except as disclosed to Cataraqui and not including examinations of pending intellectual property in relevant intellectual property offices. Finally, Queen's will also agree with the Company not to set up any other entity offering commercialization services similar to those offered by PARTEQ.

Unless the context otherwise requires, this Offering Memorandum is presented as if the reorganization described above were completed, and the term "PARTEQ" includes "OLD PARTEQ" for periods prior to the completion of this offering.

The following diagram shows the relationship between Queen's, PARTEQ and the Company following the completion of the transactions described above:



THE OPPORTUNITY

Many discoveries with commercial potential result from university based research. However, commercialization of university generated technology is hampered by a lack of seed funding available to further develop technology to the point where commercial value can be realized. This further development may be required, for example, to scale up an engineering process, to develop a device prototype, to determine the economics of a process, to perform animal tests or to perform toxicology or pharmacokinetic studies. This further development normally reduces the level of risk to be taken by the potential commercial partner and therefore enhances the likelihood of attracting a commercial partner and thus the rate of return realized for such a commercial arrangement.

In addition, there is a lack of technology receptor companies in Canada, a lack of venture capital firms and a shortage of qualified individuals willing and able to build technology oriented companies. Universities represent an under-utilized source of economic development mainly because mechanisms and resources are not in place to capitalize on discoveries resulting from basic research conducted at universities. As a consequence, discoveries of potential commercial value may not be exploited or may be exploited only through foreign licensing programs for a low rate of return.

The level of commercialization activity in North American universities has increased dramatically over the past ten years. A recent survey by The Association of University Technology Managers showed that licensing revenue from U.S. universities increased from U.S.\$186 million in 1991 to U.S.\$323 million in 1993, an increase of 74%. The reporting institutions filed 2,476 patents in 1991, compared to 3,835 in 1993. This increase in activity further contributes to competition for the limited commercialization resources available.

PARTEQ has been proactive in attempting to exploit intellectual property through creating new ventures. These initiatives are labour intensive and the lack of seed funding for early stage venture creation in Canada makes the task very difficult. There is a significant opportunity, given PARTEQ's experience in commercializing intellectual property and its access to discoveries generated from Queen's research activities, to apply financial resources to accelerate product development and seed new venture initiatives to exploit promising technologies.

To date, PARTEQ has not had the resources to conduct research and development and pursue regulatory compliance to bring discoveries to their full commercial potential. Therefore, PARTEQ has usually entered into arrangements with private businesses for that purpose. PARTEQ generally licences the discovery to a business which in turn undertakes the research and development, regulatory compliance and marketing and sale of the end product. PARTEQ and the researchers receive a percentage of the revenue or income from the exploitation of the end product. As a result of PARTEQ not having the resources to carry out the product development process itself, the division of revenues or income between PARTEQ and the private business that undertakes that development is often very favourable to that private business. This offering will raise funds to assist in the development of research discoveries at Queen's through PARTEQ for commercial exploitation and reduce the degree of reliance on private businesses who license the discoveries.

ROYALTY AND DEVELOPMENT AGREEMENT

The material terms of the Royalty and Development Agreement are summarized below. Prospective investors should refer to the Royalty and Development Agreement for the full text of terms of the agreement.

Royalty Interest

The Royalty Interest will entitle the Company to receive 30% of the Net Revenue earned by PARTEQ from the Portfolio on the terms set out in the Royalty and Development Agreement. The Portfolio will include all improvements assigned to the University relating to existing intellectual properties in the Portfolio and all interests derived by PARTEQ from the intellectual property in the Portfolio.

Revenue Sharing Formula

"Net Revenue" is defined to mean (a) gross revenue earned by PARTEQ from the exploitation of, or attributable to, the Portfolio less PARTEQ's direct costs relating to the Portfolio and (b) net proceeds realized by PARTEQ on the disposition of any item in the Portfolio. Direct costs mean all costs incurred by PARTEQ in respect of protection and commercialization of intellectual property in the Portfolio including research and development expenses (including cash investments made in joint ventures undertaking the commercialization of an item of intellectual property), royalty payments to inventors, charges incurred in respect of financing obtained by PARTEQ from a third party for a commercialization project, the full capital cost and operating expenses of project specific equipment, cost of professional services

and marketing expenses specifically related to a commercialization project. Direct costs do not include salary or general administrative or overhead charges of PARTEQ. In addition, any direct costs financed from the Development Fund will not be included as direct costs for the purposes of the Net Revenue calculation.

Net Revenue will be calculated on a cumulative aggregate basis for the Portfolio. Deficiencies will be carried forward to future periods of account for recovery against surpluses to arrive at a measure of cumulative Net Revenue, with a deduction of cumulative royalty payments made to date.

Minimum Royalty

The Company will be entitled to receive a minimum royalty payment of \$300,000 per year for the first 5 years of the term of the Royalty and Development Agreement. The amount by which the annual minimum royalty payment exceeds what would otherwise have been payable in respect of the Royalty Interest will be accumulated and carried forward to be recovered from future royalty entitlements provided that the annual payment for the first 5 years will not be less than the agreed minimum. See "Royalty and Development Agreement - Royalty Interest - Minimum Royalty".

Non-Cash Items

In the course of commercialization of the intellectual property in the Portfolio, PARTEQ is likely to receive non-cash amounts. These may, for example, comprise shares or units in a corporation or partnership established as a joint venture (a "Joint Venture") with an organization that can assist in the commercialization. For the purposes of the Royalty and Development Agreement, a Joint Venture does not constitute a disposition of intellectual property but rather steps towards the commercialization of the intellectual property. Alternatively, the intellectual property might effectively be sold for non-cash consideration, for example in exchange for shares of a public corporation (a "Sale"). A Sale constitutes a disposition of the intellectual property.

The distinction between a Joint Venture and a Sale may not always be clear. PARTEQ and the Company will deal with each situation on a case-by-case basis, working out procedures that are appropriate in the circumstances. The following are general guidelines that will be applied in determining whether a Sale has occurred or whether PARTEQ has entered into a Joint Venture with respect to intellectual property in the Portfolio:

- (1) in most circumstances, PARTEQ will deal with the Company in the same manner as it deals with the inventor. For example, if the transaction is a Sale entitling the inventor to receive his or her royalty percentage of the consideration received by PARTEQ, then, ordinarily, the Company will also be entitled to receive its Royalty Interest in such non-cash consideration;
- (2) if the transaction requires PARTEQ to enter into an agreement which restricts PARTEQ's rights to deal with or transfer non-cash consideration, then the transaction will ordinarily be regarded as a Joint Venture;

- (3) in the event that the transaction is deemed to be a Joint Venture, then the Company will not be entitled to receive its Royalty Interest in the non-cash consideration received by PARTEQ in connection with such transaction; however, such non-cash consideration will become part of the Portfolio and will be subject to the provisions of the Royalty and Development Agreement applicable to the Portfolio;
- (4) the Company will be entitled to receive its Royalty Interest in non-cash consideration received in connection with a Sale on the closing of such transaction net of all costs of disposition; and
- (5) if the Company does not agree with PARTEQ's classification of a transaction as being either a Sale or Joint Venture, then the parties will attempt to resolve the dispute in good faith. If within 14 business days of receipt by PARTEQ of a notice of objection the parties have been unable to resolve the dispute, the dispute will be referred for dispute resolution on the terms described below (See "Development Fund — Dispute Resolution").

Right to Negotiate for Increased Royalty Interest

The Company will have the first opportunity to negotiate for the purchase of any additional royalty interest in revenue generated by the Portfolio which PARTEQ may decide to sell on or before December 31, 2004. PARTEQ has agreed to negotiate in good faith with the Company for 30 days after PARTEQ gives notice of its intention to sell an additional royalty interest. PARTEQ will be free to negotiate with third parties if the Company and PARTEQ are unable to agree on terms within the 30 day period.

Development Fund

PARTEQ will set aside \$10 million (the "Development Fund") to be used to finance the development of the Portfolio. The Development Fund will be held in a segregated bank account of PARTEQ pending disbursement. The Development Fund will be invested by PARTEQ in debt obligations of or guaranteed by the Government of Canada or any province thereof or other high quality instruments (such as bank deposits or banker acceptances). The term to maturity of any debt obligation in which the Development Fund is invested will not exceed 90 days unless the Company and PARTEQ otherwise agree. Income earned on the Development Fund will be released to PARTEQ from the segregated account and may be used by PARTEQ for general corporate purposes.

The following is a description of the procedure for developing properties within the Portfolio (except for decisions that are required in light of existing arrangements with third party licensees as described below under "Intellectual Property Portfolio"):

• PARTEQ will consult with the Company on a regular basis regarding developments in the Portfolio including the development of any business plan relating to proposals for the commercialization of any discoveries and innovations in the Portfolio.

- The responsibility for determining the commercial potential of discoveries and innovations in the Portfolio will primarily be PARTEQ's. If PARTEQ determines that commercialization of a particular innovation or discovery is feasible it will make a proposal to the Company regarding the development and financing of the commercialization. PARTEQ shall not be required to make a proposal or seek access to the Development Fund unless and until PARTEQ determines that the project would involve cumulative anticipated expenditures of \$50,000 or more. Although PARTEQ will be primarily responsible for determining the commercial potential of discoveries and innovations in the Portfolio, the Company will also be responsible for identifying to PARTEQ opportunities regarding commercialization of the Portfolio of which the Company or any of its directors or officers become aware.
- The proposal will, among other things, include a business plan in respect of the commercialization of the intellectual property. In the proposal, PARTEQ will make a recommendation to the Company (a "Development Recommendation") as to the source of financing of the project. PARTEQ may recommend that the Development Fund be used and/or the project be developed with a third party instead of accessing the Development Fund based upon advanced discussions with one or more third parties prior to making its Development Recommendation to the Company.
- The Company will have 30 business days to respond to the Development Recommendation. The Company will make its own assessment of the feasibility of the proposals set out in the Development Recommendation and in that regard will draw upon the expertise of its officers and directors and may retain expert advisors.
- If the Development Recommendation is that the project be developed with a third party and the Company objects to the Development Recommendation, the parties will attempt to resolve the dispute in good faith. If within 30 business days of receipt by PARTEQ of a notice of objection, the parties have been unable to resolve the dispute, the dispute will be referred for dispute resolution on the terms described below (see "Development Fund Dispute Resolution").
- If the Development Recommendation is that the project be financed from the Development Fund, the Company will decide whether funds should be appropriated from the Development Fund to finance the project, such decision to be made within the 30 business day period referred to above.
- If the Development Fund is exhausted the Company shall, nevertheless, be given the first opportunity to negotiate financing for any project involving anticipated expenditures in excess of \$50,000. If the Company and PARTEQ cannot agree on terms for such financing within 30 business days of receipt by PARTEQ of notice from the Company that it wishes to engage in negotiations, PARTEQ shall be free to negotiate financing from third parties on terms no more favourable than those proposed to the Company. This right of first negotiation expires on December 31, 2004. This

arrangement may be extended beyond December 31, 2004 if the Company and PARTEQ mutually agree.

- If the Company and PARTEQ agree on terms for the Company to provide project financing after the Development Fund has been exhausted, the Company shall, in addition to its Royalty Interest, be entitled to a return on its project financing on the terms agreed upon between PARTEQ and the Company.
- Whether or not funds are available in, or provided from, the Development Fund, the project will be included in the Portfolio and thus will be subject to the Company's Royalty Interest.
- The Development Fund may only be applied to finance the development of a PARTEQ commercialization project as described above.
- Any monies remaining in the Development Fund on December 31, 2004 shall be released from the Development Fund and may be used by PARTEQ without restriction unless the Company establishes that PARTEQ did not present sufficient opportunities with legitimate prospects for development to fully utilize the Development Fund on or before such date. The monies will remain in the Development Fund until fully expended if the Company establishes that sufficient opportunities were not presented.

Commercialization of properties in the Portfolio may involve licensing arrangements or joint ventures or development with funding provided by the Development Fund, the Company, an alternative lender or a developer. Generally, if a third party developer assumes the expense and risk of commercializing a discovery, the third party will require a significant interest in the revenues resulting from ultimate exploitation of the commercialized property. If the Company elects to permit the Development Fund or other resources of the Company to be used to commercialize the property, greater risk will be borne by the Company. However, the Company and PARTEQ will, collectively, enjoy an enhanced return if the property is successfully commercialized.

Dispute Resolution

Disputes regarding the development of intellectual property in the Portfolio may be referred to a panel of three members, one of whom shall be appointed by each of PARTEQ and the Company. The third member shall be mutually acceptable to both parties. If, in the opinion of the Company, any decision taken by PARTEQ with respect to any intellectual property in the Portfolio could have a material adverse effect on the value of the Company's interest in such intellectual property, it may refer the decision to the panel for review. The decision of such panel will be binding and conclusive on both parties.

Term of Royalty and Development Agreement

The term of the Royalty and Development Agreement shall coincide with the expiry or sale of the last item of property in the Portfolio or know how relating thereto. Accordingly, the Royalty

and Development Agreement will continue indefinitely so long as items of property remain in the Portfolio. The parties may agree to include intellectual property assigned to Queen's after December 31, 2004 in the Portfolio if they can agree on mutually acceptable terms. PARTEQ and Queen's have agreed to negotiate with the Company, in good faith, regarding a possible extension of the current arrangements for a period of 60 days following December 31, 2004 but are not obligated to commit to an extension on any terms.

After December 31, 2004, PARTEQ will have the right to sell the Portfolio in which case the Company may elect either to receive its share of the proceeds or to continue to hold its Royalty Interest in the Portfolio. At any time after December 31, 2014 if the appraised present value (determined by valuation experts in accordance with the provisions of the Royalty and Development Agreement) of the Royalty Interest is less than \$1 million, then PARTEQ shall have the right to terminate the Royalty and Development Agreement upon payment to the Company of the then present value of the Royalty Interest, less any deficiency in the Royalty Account Amount (as defined in the Royalty and Development Agreement).

PARTEQ Options

Pursuant to the Participation Agreement, the Company will grant to Queen's options (the "PARTEQ Options") to purchase common shares of the Company. The PARTEQ Options will be transferred by the University to PARTEQ on the closing of the offering. The PARTEQ Options will entitle PARTEQ to purchase:

- (a) up to 140,000 common shares at \$15.00 per share at any time on or before December 31, 1996;
- (b) up to 140,000 common shares at \$25.00 per share at any time on or before December 31, 1999; and
- (c) up to 140,000 common shares at \$40.00 per share at any time on or before December 31, 1999.

The Board of Directors of the Company will determine how any proceeds received on the exercise of the PARTEQ Options will be applied.

The PARTEQ Options will provide for adjustment in the exercise price and, in certain events, in the number of common shares issuable upon exercise thereof upon the occurrence of certain events to provide anti-dilution protection.

INTELLECTUAL PROPERTY PORTFOLIO

A number of the material properties included in the Portfolio are described below and summarized in tabular form. Some of the information presented below regarding the licensees of the properties and the incidence of certain conditions and diseases has been extracted from information made publicly available by the licensees or by agencies studying these conditions and diseases. The Company has not independently verified the accuracy or completeness of information derived from publicly available sources included in this Offering Memorandum.

When PARTEQ licenses its properties it does so either to a third party licensee or to a joint venture company. One of the more significant of the joint venture companies to which PARTEQ licences its property is Neurochem Inc. ("Neurochem") which was founded by PARTEQ, Quorum Growth Inc. ("Quorum") of Toronto and Atlas Ventures II LP ("Atlas") of Boston. Quorum and Atlas provided the initial funding for Neurochem and together hold 1,000,000 voting preferred shares. PARTEQ holds 800,000 common shares of Neurochem, 60% of which PARTEQ is required to distribute to scientists who contribute to the development of the properties licensed to Neurochem. The remaining 110,000 issued common shares of Neurochem are owned by Neurochem employees and Argil Management Inc. ("Argil"). Options are outstanding to acquire an additional 341,304 common shares of Neurochem.

Each of PARTEQ, on the one hand, and Quorum and Atlas on the other, currently elect two of the five directors of Neurochem, with an independent director being elected jointly. If the size of Neurochem's board is increased to seven, Quorum and Atlas are entitled to elect four of the seven directors. In this circumstance, PARTEQ would be entitled to elect two of the seven, with the final director being elected jointly. Neurochem operates independently of PARTEQ.

Unless otherwise noted, 40% of the gross revenues (less patenting and commercialization expenses) received from the licenses described below is paid by PARTEQ to the inventors of the licensed intellectual property.

Licensed Properties

The Portfolio currently contains over 80 projects and is protected by more than 30 issued United States patents (in addition to international patents) with over 60 patents pending. The following table sets out a brief description of each intellectual property in the Portfolio which is subject to a license or option, its patent status and commercial status. Most licenses granted by PARTEQ require the licensee to pay PARTEQ an issue fee, milestone payments (payments to be made upon the occurrence of certain predefined events) and royalties calculated by reference to sales levels achieved for products developed from the licensed technology. Certain licenses require maintenance payments (usually annual payments that may or may not be creditable toward royalty payments) from the licensee to pay PARTEQ a fee in respect of sublicenses calculated either with reference to sales levels achieved for products developed from products developed from the licensee of or calculated with reference to sublicensing fees charged by the licensee.

TABLE 1

Technology

Description

Hormone secreted by

heart to control salt levels

Method for potentiating

cholesterol efflux from

atherosclerotic lesions

Compound to bypass

coagulation cascade

fragments of DNA

the treatment of psychogenic impotence

for treatment of

Factor VIII in the blood

Method for manipulating

Orally delivered drug for

Use of elemental iodine

fibrocystic breast disease

Patent Status

Australia; pending in

United States; PCT

Applications not yet filed

application filed

Issued in Canada,

Belgium, Switzerland,

Sweden, Australia; pending in Japan and

Issued in United States

Issued in United States,

Canada and Australia; pending in Europe and

Patent applications

United States

pending in Canada and

United States application

Issued in United States

and Canada; Australia,

U.S., Norway, Japan,

Denmark, Brazil, Bulgaria, Europe, Canada and PCT applications filed

and PCT and United States applications filed

Canada

Japan

filed

Germany, France, U.K., Italy, Netherlands,

Commercial Status

Pharmaceutical/Biotechnology

Method of treating various ALA Photodynamic Therapy forms of lesions and cancers Compounds to block Amyloid Inhibitors amyloid deposition

Compounds aimed at Anti-Epileptics providing anti-epileptic effect

Atrial Natriuretic Factor

Cholesterol Control

Control of Bleeding

DNA Indexing

Linkers

Impotence

Iodine Therapy

Exclusive license with DUSA Issued in United States, Pharmaceuticals, Inc. Products now in Phase 1/11 Canada, Europe, Korea, Netherlands and Japan clinical trials Application pending in

Exclusive license with Neurochem Inc.

Exclusive license with Neurochem Inc.

Exclusive license with Scios Nova Inc. Product now in Phase III clinical trials

Exclusive license with Neurochem Inc.

Exclusive license with IMMUNO AG

Exclusive license with ProtoGene Laboratories Inc.

Exclusive option with Pentech Pharmaceuticals Inc.

Exclusive license to Mimetics Inc

TABLE 1

Technology	Description	Patent Status	Commercial Status
Multidrug Resistance Associated Protein	Protein responsible for multidrug resistance in lung and possibly other cancers	United States and PCT applications filed	Licensed by fields of use. Seven licensees thus far
Analytical Instruments			
Differential Oxygen Analyzer	Device to measure difference in oxygen concentration in gas streams	United States patent application filed	Exclusive license with P.K. Morgan Instruments Inc. Functional prototype completed
Nitrogen Fixation	Three separate inventions related to estimating rate of nitrogen fixation in plants	Some United States patents issued. Applications only in Canada and United States	Exclusive license for complete package to P.K. Morgan Instruments Inc.
Rock Movement Instrumentation	Device for measuring three-dimensional rock movement	Applications filed in United States and Canada	Exclusive license with Roctest Ltd.
Chemical/Petrochemical			
Extractive Fermentation	Use of organic solvent for continuous extraction of ethanol	Issued in United States, U.K., Sweden, France, West Germany and Canada; pending in Japan	Exclusive option with Simon- Carves Fenco Inc.
Temperature Scanning Adiabatic Reactor	Reactor and software to provide rapid kinetic rate information for catalyst evaluation	Issued in United States; pending in U.S., Canada, Europe and Japan	Exclusive license to SE Reactors Inc. Beta test prototype unit now being developed
Advanced Materials			
Nanocrystalline Materials	Method for producing various metals and alloys in nanocrystalline form by electrodeposition	United States patent issued. PCT application pending	Licensed to start-up, Nanometals Corporation
Thick Sol Gel	A process for applying relatively thick ceramic coatings	Patent search being conducted	Applications to be tested and developed. Intend to license to start-up

TABLE 1

Technology	Description	Patent Status	Commercial Status
Medical Devices			
Elbow Implant	An anatomically shaped artificial elbow implant	Issued in Canada and United States	Initial clinical trials completed. Terms agreed for exclusive license with Wright Medical Technologies Inc.
Performance Readiness Monitor	Hand held device to monitor sleep behaviour and performance readiness	Issued United States patent	Exclusive license with EPM Systems Ltd.
Prevention of Decubitus Ulcers	Mattress overlay system for treatment and prevention of pressure ulcers	Issued patents in Taiwan and New Zealand in good standing and issued patents in United States, Austria, Belgium, Switzerland, Germany, Spain, France, the United Kingdom, Greece, Liechtenstein, Luxembourg, the Netherlands, Sweden, Italy, Norway, Australia and Mexico require payment of maintenance fees. Patent applications pending in Canada, Japan and South Korea in good standing and patent application in Finland requires payment of maintenance fees	Exclusive license to MICOS Medical Systems Inc.
O'Straint	Wheelchair and occupant	Issued in United States	Exclusive license with Girardin

Wheelchair and occupant restraint system

Exclusive license with Girardin Corporation

and Canada. Canadian

application on enhancement pending

Pharmaceutical/Biotechnology

ALA Photodynamic Therapy

Description

ALA, the chemical name of which is 5-aminolaevulinic acid, is a naturally occurring compound that is a precursor for protoporphyrin IX (PpIX), an effective biological photosensitizer. PpIX is synthesized and accumulates within certain types of cells when these cells are exposed to ALA. When exposed to an adequate dose of photoactivating light, cells containing PpIX produce singlet oxygen resulting in cell death. This treatment may be selective to abnormal cells with minimal damage to normal surrounding tissues. ALA has been used clinically at Queen's to treat a variety of cancers such as actinic keratosis, basal cell carcinomas and other skin cancers. Statistics Canada estimates that there were 50,200 cases of non-melanoma skin cancer in Canada in 1993. Actinic keratosis is a pre-cancerous skin condition and, according to the 1992 National Disease and Therapeutic Index, there are an estimated 3.12 million patient visits in the United States per year for this condition.

Commercialization Status

The ALA intellectual property portfolio is licensed on a world-wide exclusive basis to DUSA Pharmaceuticals, Inc. ("DUSA") of Toronto, Ontario, whose obligations under the license are guaranteed by Draxis Health Inc. DUSA is a publicly traded company that was formed and financed with an initial public offering, specifically to establish ALA photodynamic therapy as a treatment of choice for specific human disorders, initially focusing on diseases of the skin.

DUSA has now entered Phase I/II clinical trials in the United States for the treatment of actinic keratoses and psoriasis and Phase II trials at two sites in the United States for basal cell carcinoma. Psoriasis is a chronic skin disease that, as of 1994, according to the U.S. National Psoriasis Foundation, affects five million people in the United States. The U.S. National Psoriasis Foundation also reported that, in 1992, there were approximately 2.4 million patient visits for psoriasis in the United States. Research and development is being conducted at Queen's on a number of applications for ALA including endometrial ablation, the treatment of leukaemia and use in treatment of certain internal cancers. DUSA announced on March 9, 1994 that it intends to support pilot human clinical trials on ALA as a non-surgical alternative to hysterectomy.

The ALA intellectual property is a joint invention between Queen's and the Royal Military College of Canada. PARTEQ acts as the agent for Queen's and the Department of National Defence ("DND") and provides one-third of the net proceeds to DND. PARTEQ provides 40% of its share of net proceeds to the Queen's inventors. PARTEQ's license with DUSA provides for royalties of 6% in countries where patent rights exist unless DUSA requires a third party licence in order to commercialize the intellectual property. In addition, PARTEQ holds an option, vesting over five years ending in October 1996, to purchase 20,000 shares of DUSA at U.S.\$6.00 per share and a second option of 20,000 shares at Cdn\$4.69 per share. PARTEQ's benefits under the second option are subject to its agreement with DND to transfer one third of net revenues received by

PARTEQ to DND and is subject to the obligation to hold 40% of the remaining benefit for the Oueen's inventors.

Patents have been issued in the United States and Australia and are pending in Canada, Europe, Korea, Netherlands and Japan.

Amyloid Inhibitors

Description

Amyloid is a generic term referring to a group of diverse but specific protein deposits, with common identifying characteristics, that are associated with a variety of different diseases. Amyloid deposits are involved in the development of a number of degenerative diseases, the most common of which is a neurodegenerative disorder, Alzheimer's disease. According to the Canadian Study of Health and Aging conducted in 1992, it is estimated that the prevalence of Alzheimer's in individuals over the age of 65 is 5.1%. Amyloid is also found in tissues and organs other than the brain. For example, a form of amyloid, AA amyloid, may develop as a result of an inflammatory reaction such as rheumatoid arthritis, tuberculosis, and cystic fibrosis and may lead to death. There are at present more than 15 known types of amyloid protein.

A research group at Queen's has discovered a series of compounds that have resulted in *in vivo* inhibition of amyloid deposition. PARTEQ management believes that these compounds, coupled with a knowledge of why and how they function as amyloid inhibitors, may provide a competitive advantage in the search for suitable drugs for the various forms of amyloidosis, including Alzheimer's. PARTEQ management further believes that amyloid inhibitors have the potential to lead to treatments for other forms of amyloidosis including senile cardiac amyloidosis and amyloidosis associated with rheumatoid arthritis, long-term hemodialysis and adult onset diabetes. According to the Canadian Diabetes Association, in excess of one million Canadians have diabetes and more than 80% of people with this condition have Type 2 (adult onset diabetes).

Commercialization Status

This technology has been licensed to Neurochem. Neurochem has been granted world-wide exclusive rights for human and veterinary therapeutic and diagnostic use. Royalties are charged by PARTEQ from 1.5% to 2.5% of net sales based on gross sales levels. The royalty rates will increase by 2% should the common shares of Neurochem, owned or distributed by PARTEQ, be reduced, without PARTEQ's approval, to less than 10% so long as the capitalization of Neurochem is less than \$75 million. The license also requires an issue fee, maintenance fees, milestone payments and minimum royalties.

A U.S. patent application has been filed as has an application for patent protection in Canada, Europe and Japan pursuant to the Patent Cooperation Treaty ("a PCT application").

Anti-Epileptics

Description

A research group at Queen's is pursuing a drug discovery program aimed at rationally designing anti-epileptic compounds. Epilepsy afflicts an estimated 2.5 million people in the United States. Current treatments limit or control epileptic seizures in approximately 80% of all patients suffering from epilepsy but sometimes produce debilitating side-effects. The aim of the Queen's drug discovery program is to rationally design drugs that will have efficacy and minimal side-effects as both anti-convulsants and anti-epileptics. In other words, researchers are attempting to develop drugs that treat the progression of the disease not just the convulsions resulting from the disease. These compounds are being developed using computer assisted design techniques based upon the researchers' understanding of the biochemistry of epilepsy. Various drug discovery tools, including a computational molecular model of the sodium channel protein, are being used to identify drug candidates that may work at either the voltage-gated channels, the receptor-gated channels or synaptic sites.

Commercialization Status

The intellectual property has been licensed exclusively to Neurochem. Royalty rates are calculated in the manner described above for the Amyloid Inhibitor license. The license also requires an issue fee, maintenance fees, milestone payments and minimum royalties.

No patent protection has yet been sought on this technology.

Atrial Natriuretic Factor

Description

In the early 1980's, a Queen's researcher discovered that the heart serves not only as a pump but also as a gland, secreting a hormone called atrial natriuretic factor ("ANF") that may play an important role in the regulation of blood pressure and volume as well as water and salt levels in the body. This discovery and the ensuing work to determine the precise chemical structure resulted in a number of patents in the field of atrial natriuretic peptides ("ANP").

Commercialization Status

The ANF intellectual property is licensed exclusively on a world-wide basis to Scios Nova Inc. ("Scios Nova") of Mountain View, California. Scios Nova is a publicly traded biopharmaceutical company now conducting Phase III clinical trials of AURICULIN[®] ANP for the treatment of acute renal (kidney) failure. Acute kidney failure is a life threatening form of kidney disorder that occurs after periods of low blood flow to the kidneys and normally results in the requirement for dialysis. Clinical trials have shown that ANP, when administered parenterally, may reduce the incidence of the need for dialysis in patients suffering from acute kidney failure in a statistically significant manner. This license requires milestone payments and provides for a royalty on net sales of products covered by the ANF patents, ranging between 1/4% to 1% depending on sales volume and sales territory.

Patents have issued in Canada, Australia, the United Kingdom, France, Germany, Italy, Netherlands, Switzerland, Belgium and Sweden and are pending in Japan and Canada.

The ANF development work was initially funded by the IDEA Corporation with a loan of approximately \$800,000. IDEA Corporation is entitled to receive 75% of the net revenue received by PARTEQ until such time as this loan is fully repaid and 50% of net revenues received by PARTEQ thereafter. To date, PARTEQ has repaid approximately \$225,000 of the loan from its ANF license revenue.

Scios Nova has recently announced that it has entered into an agreement with Genentech Inc., a California company, to jointly promote AURICULIN® ANP. The announcement indicates that Genentech Inc. will invest \$20 million in Scios Nova and provide Scios Nova with a \$30 million term loan payable in 2002 and \$50 million in potential milestone payments.

Cholesterol Control

Description

Serum amyloid A ("SAA"), an apolipoprotein produced primarily by the liver, is present in large quantities on high density lipoprotein ("HDL") only during inflammatory states. HDL has a well-established role in reverse cholesterol transport and 90% or more of SAA is associated with HDL. A research group at Queen's has shown that SAA serves as a signal to HDL, redirecting HDL to inflammatory cells such as macrophages at sites of inflammation and tissue destruction for the purpose of cholesterol removal. Preliminary work also suggests that SAA has a role in stimulating macrophage cholesterol efflux. Individuals with long-standing inflammatory diseases have a lesser incidence of atherosclerosis in comparison with patients of a comparable age who do not have these diseases.

Heart attack is the single largest killer of American males and females. Cardiologists currently use angioplasty and coronary bypass surgery when a patient's artery narrows because of atherosclerosis. The number of patients in the United States who underwent these procedures in 1993 is estimated at 800,000. There were 3.4 million myocardial infarcts treated in the United States and Europe in 1993. In 1991, the prevalence of coronary heart disease in the United States was 6.3 million and coronary heart disease caused 478,530 deaths in the United States. The estimated prevalence in 1991 of atherosclerosis in Canada was 1,876,000. SAA or a molecule with a conformation like SAA may be useful to stimulate removal of cholesterol and cause regression of atherosclerotic lesions.

Commercialization Status

This invention is a further spin-off from the amyloid drug discovery work conducted at Queen's and has also been licensed to Neurochem. Royalties are charged ranging from 1.5% to

2.5% of gross sales. The license also requires an issue fee, maintenance fees, milestone payments and minimum royalties. Neurochem will support the prosecution and maintenance of patent protection with a view to eventually supporting the development of a SAA analogue.

A U.S. patent has been issued and U.S. and PCT applications have been filed.

Control of Bleeding

Description

Haemophilia is a blood disorder in which one or more coagulation factors, usually Factor VIII, is either absent or reduced. The common therapy is transfusion with Factor VIII in a concentrated form. However, approximately 10% to 15% of all treated haemophiliacs develop antibodies to the concentrated Factor VIII.

Research led by a group at Queen's found that a combination of Factor Xa and phospholipid vesicles ("Xa/PCPS"), delivered intravenously, bypasses the requirement for Factor VIII in the coagulation cascade and induces rapid haemostasis at a wound site with the cessation of bleeding within 15-30 seconds. The ability of Xa/PCPS to bypass Factor VIII offers a potential treatment to those haemophiliacs who have developed antibodies to the conventional Factor VIII replacement therapy. In addition, PARTEQ management believes that, Xa/PCPS therapy may have the potential to arrest bleeding in "normal" patients suffering from trauma, battlefield injuries and other hemostatic disorders such as von Willebrand's disease, an inherited haemorrhagic disorder. Xa/PCPS can be made synthetically and does not necessarily require the use of any blood products.

Commercialization Status

PARTEQ has licensed this technology on an exclusive, world-wide basis to IMMUNO AG ("IMMUNO"). IMMUNO, based in Austria, is a subsidiary of Immuno International AG ("Immuno AG") in Zurich, shares of which are, partially, publicly held. Immuno AG specializes in products for the treatment of blood-related disorders. IMMUNO has opted to pursue a long term license after completion of a two year collaborative research and development agreement with Queen's to further develop and test Xa/PCPS as a potential therapy. IMMUNO has an obligation to pay minimum annual royalties of U.S.\$50,000 until commercial sale occurs and then a royalty on sales in those countries in which the invention is under patent protection. The royalty rate is 4% if the final product is based only on PARTEQ's licensed technology; 2% if other technology has to be licensed from a third party.

Patents have been issued in the United States, Canada, and Australia and are pending in Europe and Japan.

DNA Indexing Linkers

Description

The technology consists of a method and sets of specially designed indexers that provide a means of mapping and manipulating whole genomic DNA. Using only basic, proven techniques of molecular biology and sets of different indexers, the information contained in the non-identical cohesive end sequences of cleaved sites may be exploited to map these sites within a genome. PARTEQ management believes that the methods are simple, may be amenable to automation and may be applied to virtually all existing genomic libraries, clones or sources of DNA (including complementary DNA). Management further believes that the use of limited sets of mass produced synthetic DNA indexers rather than unique polymerase chain reaction ("PCR") primers and probes may provide cost advantages. The detection and analysis procedures provide sequenceable templates without the need for subcloning.

Commercialization Status

The technology is a joint invention between Queen's and Atomic Energy of Canada Limited ("AECL"). PARTEQ has entered into an agreement with AECL to carry out a co-operative development program for scientific research and commercialization of subsequent intellectual property. The agreement provides that AECL is entitled to 67.5% of royalties from licensing and PARTEQ is entitled to 32.5% of royalties. PARTEQ and AECL have granted an exclusive (except for use by PARTEQ or AECL) world-wide license to ProtoGene Laboratories Inc. ("ProtoGene") of Palo Alto, California to commercialize this intellectual property in consideration for an issue fee, a royalty of 4% of net revenue received by ProtoGene from Canadian and United States sales and 0.6675% of net revenue received by ProtoGene elsewhere.

Patent applications are pending in Canada and the United States.

Impotence

Description

A research group at Queen's, in collaboration with Pentech Pharmaceuticals Inc. ("Pentech") of Chicago, has discovered and tested, in a human clinical setting, a drug that is effective, when taken orally, in treating psychogenic impotence. The Massachusetts Male Aging Study conducted in 1987 to 1989 found that the prevalence of all forms of impotence in the 1,290 noninstitutionalized men in the 40 to 70 age category responding to the survey was 52%. An estimated 10-25 million men in the United States suffer from some degree of impotence but perhaps fewer than 3% now receive treatment. In 1985 impotence accounted for in excess of 400,000 outpatient visits to physicians in the United States. The most effective treatments currently available includes drugs for penile injections, vacuum constriction devices and penile implants.

Commercialization Status

PARTEQ has granted an option to Pentech to obtain exclusive world-wide rights to the intellectual property. If the option is exercised, Pentech will pay an issue fee, milestone payments and a royalty of 4% of net sales. Pentech is sponsoring further development and covering all patent expenses. The inventors are entitled to 60% of PARTEQ's net proceeds. Pentech is currently conducting Phase II human clinical trials in both the United States and Canada with this drug.

A U.S. patent application was filed in 1994.

Iodine Therapy

Description

A combined research effort by Dr. William Ghent from Queen's and Dr. Bernard Eskin from the University of Pennsylvania School of Medicine led to a better understanding of the role of elemental iodine in fibrocystic breast disease ("FCBD"). Ghent and Eskin have theorized that the trace element, molecular iodine, is necessary for breast normality. FCBD refers to a wide variety of non-cancerous conditions of the breast that are usually characterized by the formation of breast cysts and scar tissue. It has been reported that the incidence of FCBD is between 50-80% of the adult female population.

A prospective, placebo controlled, double blind study with molecular iodine of 56 patients showed a 65% improvement in the treated group versus a placebo effect of 33% in the control group.

Commercialization Status

The iodine therapy technology is jointly owned by Eskin and by the Ghent Estate. This technology is protected by U.S. and Canadian patents. Patent applications have been filed in the United States, Norway, Japan, Denmark, Brazil, Bulgaria, Europe, Canada, Australia and with the PCT office. The technology was licensed on behalf of the inventors to Mimetics Inc. ("Mimetics") of San Mateo, California on an exclusive world-wide basis. PARTEQ is entitled to 20% of the share of the net royalties to be received by the Ghent Estate from the licensing arrangement with Mimetics. This equates to 0.25% of net sales by Mimetics of licensed products covered by a patent and 0.15% of its net sales of other licensed products. Mimetics is preparing an application to be made in 1995 to the FDA for approval to commence Phase II trials for the treatment of FCBD.

Multi Drug Resistance Associated Protein

Description

Many types of cancers regress initially in response to currently available drugs but the disease often recurs with resistance to all anti-cancer drugs. A research group at Queen's has identified a protein, called multidrug resistance associated protein ("MRP"), that is over-produced in a resistant human lung cancer cell line. The research group has also demonstrated a cause and

effect relationship between the over expression of MRP and multidrug resistance. It has been established that MRP alone is sufficient to cause multidrug resistance. Although MRP was originally detected in a lung cancer cell line, evidence of expression in other cell lines, including a breast cancer cell line, has been confirmed.

It is estimated that there were in excess of 116,000 new cases of cancer diagnosed in Canada in 1993, and almost 60,000 deaths resulting from cancer. It is estimated there were 19,100 new cases of lung cancer diagnosed in Canada in 1993. Lung cancer accounts for in excess of 25% of cancer deaths and remains the leading cause of cancer death. Small cell lung cancer accounts for approximately 20-25% of all lung cancers and although up to 90% of the tumours are responsive to chemotherapy, patients almost always relapse with multi-drug resistance disease.

Excluding skin cancer, breast cancer is the leading type of cancer in Canadian women. In Canada in 1993, it is estimated there were in excess of 16,000 new cases diagnosed and 5,400 deaths from female breast cancer. Currently one in nine Canadian women is expected to develop breast cancer during her lifetime and one in 23 women will die of the disease. Breast cancer incidence rates in Canada are among the highest in the world but are exceeded by those in the United States.

Commercialization Status

PARTEQ has identified a number of ways that MRP may be used for therapeutic and diagnostic purposes. A licensing strategy has been prepared for development of commercial product. PARTEQ has licensed this technology by the following fields of use. Royalties on the licenses described below range from 1/2% to 5% of net sales.

Oligonucleotide Therapeutics

Isis Pharmaceuticals Inc. ("Isis") of Carlsbad, California has been granted exclusive worldwide rights to develop and market oligonucleotide therapeutics targeting MRP. Isis plans to use its antisense technology to develop drugs to block the synthesis of MRP and its proprietary oligonucleotide combinatorial strategy to develop drugs that interfere with MRP function.

Isis is a public company that has a broad oligonucleotide research program and multiple compounds in pre-clinical and clinical development.

Gene Therapy

PARTEQ management believes that MRP may be used in a gene therapy setting by protecting healthy cells against the highly toxic effects of chemotherapeutic drugs. Introducing the gene for MRP into normal bone marrow cells may increase the chemotherapy tolerance of these cells that may permit the administration of higher doses of chemotherapeutic drugs and increase the likelihood of successful chemotherapy treatment and survival. To date, PARTEQ has granted the following licenses relating to various methods of gene delivery:

- (1) Avigen Inc. ("Avigen") of Alameda, California has been granted exclusive worldwide rights to develop products, based on the MRP gene, utilizing single stranded DNA viral vectors. Avigen is a biotechnology company that is developing therapies for selected diseases utilizing adeno-associated viral vectors to insert genes into patients' cells.
- (2) Ingenex Inc. ("Ingenex") of South San Francisco, California has been granted coexclusive world-wide rights to develop products, based on MRP, utilizing double stranded DNA and RNA viral vectors. Ingenex is a private company focused on developing products for the area of drug resistance.
- (3) Genetic Therapy Inc. of Gaithersburg, Maryland has been granted a co-exclusive license under the same terms as outlined above for Ingenex.

Small Molecule Therapeutics

To date, PARTEQ has licensed this field of use to three companies. The first is Eli Lilly and Company, a large public multinational pharmaceutical company, which has been granted a non-exclusive license. The second is BASF Bioresearch Corporation and its affiliates, BASF AG and Knoll AG which has also been granted a non-exclusive license. The third is Cadus Pharmaceuticals Corporation ("Cadus") which has been granted a nonexclusive small molecule license and an exclusive right to identify molecules through the screening in yeast. Cadus is a New York based company working to develop drugs that regulate cell-to-cell signal transfer. Cadus has developed proprietary, yeast-based technology that will be used to screen organic compounds for activity against MRP in a high throughput screening system.

PARTEQ has filed U.S. and PCT patent applications. PARTEQ is also in discussion with a number of companies for additional licenses for the MRP technology. The inventors are entitled to 50% of PARTEQ's net proceeds derived from this intellectual property.

Analytical Instrumentation

Differential Oxygen Analyzer

Description

Several physiological processes, such as photosynthesis, transpiration, respiration and nitrogen fixation, can be measured *in vivo* by monitoring the rates at which plant materials exchange gases with the environment. Plant physiologists have for a number of years used carbon dioxide analyzers to measure photosynthesis in plant life. A research group at Queen's has developed a technique and a device capable of reliably measuring the difference in oxygen concentration between two flowing gas streams at a greater sensitivity than is available through current methods.

Commercialization Status

PARTEQ has licensed this technology on an exclusive world-wide basis to P.K. Morgan Instruments Inc. ("Morgan") of Andover, Massachusetts. Morgan specializes in the design and manufacture of scientific and medical testing instrumentation for the medical, industrial, plant physiology and research markets. The license provides for an issue fee, maintenance payments, a royalty of 10% of net sales and minimum royalty payments. The inventors are entitled to 60% of PARTEQ's net proceeds. Prototypes have been completed and PARTEQ anticipates that product will be ready for commercial sale in the first quarter of 1995.

A U.S. patent application was filed in October 1994.

Nitrogen Fixation

Description

Nitrogen is an essential element for plant growth and a number of plants are able to access their nitrogen requirements from soil bacteria. The bacteria live within nodules in a plant's root structures where they reduce atmospheric nitrogen gas to a form of nitrogen that the plant can use in its growth. This field of biological nitrogen fixation is increasing in importance as producers look for ways to increase yields and limit the use of expensive and environmentally-hazardous nitrogenous fertilizers.

A research group at Queen's has developed a new method and instrument for estimating the rate of nitrogen fixation in plants. This invention is jointly owned with the United States Department of Agriculture ("USDA"). PARTEQ has licensed from the USDA rights to this invention in consideration for 20% of the net proceeds from the commercialization of the intellectual property.

Commercialization Status

PARTEQ has licensed this entire technology package on an exclusive basis to P.K. Morgan Instruments Inc. (see "Differential Oxygen Analyzer"). The license provides for royalty payments of 7% of net sales. The inventors are entitled to 60% of the net proceeds of this intellectual property. Prototypes have been completed and tested and the licensee anticipates market launch in 1995.

A U.S. patent has issued on this technology and an application is pending in Canada. A U.S. patent has also been issued on an electrolytic device for the generation of controlled concentrations of hydrogen. U.S. and Canadian applications are pending for a system for measuring concentrations of minor gaseous components in a flowing gas stream.

Rock Movement Instrumentation

Description

A vast array of instruments are available to monitor the behaviour of rock structures and engineering structures but these have only two-dimensional capability. A research group at Queen's has developed an instrument that is capable of detecting and measuring movement of rock in three dimensions. The instrument can be installed onto the rock surface and across any critical structure to be monitored.

PARTEQ management believes that the instrument potentially has a wide range of applications in underground and open pit mining, tunnelling and geotechnical industries. Management also believes that it may be used to monitor the short and long term stability of an excavation project to indicate the potential for ground failure in underground and surface working areas. The instrument permits the introduction of a multidirectional monitoring program and management believes that it may potentially play a role in improving production efficiency and safety.

Commercialization Status

PARTEQ has licensed this technology on an exclusive basis to Roctest Limited ("Roctest") based in Montreal. Roctest is a publicly traded company that specializes in the field of *in situ* testing and monitoring of soils, rocks and structures. A prototype has now been completed by Roctest for site testing. PARTEQ is entitled to a royalty ranging from 6% to 8% of net sales depending on sales volume.

Patent applications have been filed in Canada and the United States.

Chemical/Petrochemical

Extractive Fermentation for Ethanol Production

Description

Production of ethanol by fermentation is hampered by a phenomenon known as end-product inhibition, a condition where high ethanol concentrations in the fermentation broth actually decreases the ethanol production rate. A research group at Queen's has developed a process that allows ethanol to be continuously extracted from the fermentation vessel using an organic solvent with very high affinity for ethanol that is non-toxic to the microorganism being used. Because the ethanol concentration is never permitted to reach inhibitory levels, the rate of production remains high.

Ethanol is increasingly being used as an oxygenate in gasoline. Oxygenates are fuel additives that reportedly promote cleaner combustion by adding oxygen to the gasoline. The annual production of United States ethanol plants is in excess of 3.2 billion litres and ethanol/gasoline fuel

blends represent approximately 8% of the total sales of gasoline in the United States. Canadian production of fuel grade ethanol is currently approximately 30 million litres.

In June 1994, the Environmental Protection Agency in the United States ruled under the *Clean Air Act* that at least 30% of the oxygen content in reformulated gasoline must come from renewable sources such as corn and other crops. Environment Canada has designated ethanol blended gasoline as an "Environmental Choice" product.

Computer simulation was done in order to evaluate the economic advantages of this process relative to conventional fermentation technology. PARTEQ management believes that this simulation indicates that the process may allow for savings in excess of 4 cents per litre depending on how the technology is used. The process has been scaled up to accommodate a 150 litre fermenter and sophisticated computer control and monitoring systems.

Commercialization Status

PARTEQ entered into a two year exclusive option agreement with Simon-Carves Fenco Inc. ("Simon Carves") of Toronto, Ontario, effective April 30, 1993, for the rights to this extractive fermentation process for the production of ethanol. Simon-Carves is an engineering firm jointly owned by SNC Lavalin of Montreal and Simon-Carves Ltd. of Stockport, England. The agreement provides for issue and performance fees and a minimum issue fee if Simon-Carves exercises the option for a long-term license. PARTEQ is required to pay 10% of its revenues to the Department of Energy, Mines and Resources ("EMR") until it has paid an aggregate of \$786,000 to EMR following which EMR is entitled to receive 5% of PARTEQ's revenues with respect to the intellectual property. If PARTEQ defaults under its agreement with EMR and fails to cure the defect within 90 days of notice of the defect, EMR is entitled to terminate the agreement and to a non-exclusive world-wide licence to commercialize the intellectual property.

Patents have been issued in the U.S., Canada, U.K., Sweden, France and Germany and an application is pending in Japan.

Temperature Scanning Adiabatic Reactor

Description

A temperature scanning reactor ("TSR") is a bench scale chemical reactor combining the continuous ramping of feed temperatures with a mathematical treatment of the resultant performance data to increase kinetic data generation rates by orders of magnitude over those possible using conventional reactor systems. According to PARTEQ management, the most straightforward applications of the technology are to compare performance of (usually heterogeneous) catalysts that may have quite different optimum operating conditions and to discriminate between, and statistically fit, complex reaction rate models of the type typically encountered in heterogeneous catalysis.

PARTEQ management believes that the TSR technology may potentially be applied to many other areas by exploiting its combination of modern high precision, analytical capabilities and advanced software programs to support the rational design, selection, and operation of catalysts and catalytic processes.

The TSR consists of a feed section, an appropriate mini-reactor and a real time analytical device. The heart of the TSR, however, is software that resulted from research by a team in the field of catalysis at Queen's. Unlike conventional research reactors where efforts are expended to maintain catalysts in an isothermal state, a TSR exploits the non-steady state operation of the system in its mathematical treatment of the data.

Commercialization Status

PARTEQ is assisting the principal inventor in creating a new venture, SE Reactors Inc. ('SE Reactors"), to exploit this technology. PARTEQ has granted a world-wide exclusive license to SE Reactors in consideration for an issue fee, royalty payments of 5% of net sales in those countries in which patents exist, diligence payments and minimum royalties.

A U.S. patent has been issued and applications are pending in the U.S., Canada, Europe and Japan.

Advanced Materials

Nanocrystalline Materials

Description

The understanding and use of nanocrystalline materials is an important development in the field of advanced materials science. This class of materials exhibit properties that are different from those in the normal crystalline or amorphous forms with the same chemical composition. At grain sizes in the range of nanometers, a large percentage of all atoms are located at grain boundary sites. The atomic structure at grain boundary sites is different from that in the crystalline and amorphous states hence properties such as corrosion resistance, wear resistance, hardness, creep and magnetization are different.

A research group at Queen's has developed a process using a pulsed plating electrodeposition technique to produce 100% pore free, and 99.9% pure, nanocrystalline nickel with grain size ranging from less than 10 nm to 100 nm. This nanocrystalline nickel has been compared with conventional nickel and has shown significant improvement in wear and corrosion resistance, magnetic properties and hydrogen solubility and diffusion. A number of other nanocrystalline metal alloys have now also been made using this process.

PARTEQ management has identified numerous potential applications for the technology from various industries including use in magnetic recording heads for both tape and disk drives, use in heat exchanger tubes in the nuclear, petrochemical and chemical industries and coating high performance parts for the automobile, aerospace, nuclear and utilities industries where both improved wear and corrosion resistance is needed.

Commercialization Status

Research is continuing and a number of composites and nickel and iron alloys have been deposited in the nanocrystalline form. PARTEQ has founded a new company, Nanometals Corporation ("Nanometals"), to develop and exploit this technology and Nanometals is currently in discussion with potential corporate partners and joint venture firms.

Development agreements are being pursued with a number of different companies on different applications. The license with Nanometals provides for an issue fee, maintenance fees and royalties ranging from 3% to 5% on net sales, with minimum royalties. Nanometals is currently wholly owned by PARTEQ but 50% of its outstanding common shares are held in trust for the inventors and management of Nanometals. PARTEQ has an obligation to pay to Donwoodtech Ltd. ("DWT"), a consultant providing consulting services relating to the nanocrystalline technology, 10% of royalties received net of patent and commercialization costs, until DWT has received, in the aggregate, a sum of \$100,000 at which time the share of royalties to DWT will be reduced to 4% on the next \$5 million of royalties less such costs and 1% on the succeeding \$10 million of royalties after such costs.

A U.S. patent was issued in October 1994 with both process and product claims and a U.S. Continuation in Part application is pending. A PCT application designating Canada, Europe, Brazil, Korea, and Japan is pending.

Thick Sol Gel

Description

Sol-gel ceramic films and coatings are intended for use as protective layers in a large number of industrial applications. A research group at Queen's, with support from the Ontario Centre for Materials Research ("OCMR"), has developed a new sol-gel process that can produce high quality coatings of zirconia, titania alumina and lead zirconate titanate, in the $5\mu m - 100\mu m$ thickness range on stainless steel, carbon steel, inconel and silicon substrates. The films are adherent, pinhole and crack free and have excellent prospects as corrosion resistant and thermal barrier coatings and for use as electro-mechanical actuators.

According to PARTEQ management, specific industries that may benefit from this intellectual property include the chemical and petrochemical processing industry, the waste incineration and boiler industries, the high temperature engine industry, the microelectronics industry, the plastics and metal moulding industry and the biomedical device industry.

Commercial Status

Research is continuing and a number of applications in the area of corrosion and thermal resistance as well as dielectric coatings have been identified. PARTEQ is in the process of establishing a new development company, Datec Coating Corporation ("Datec"), to exploit the technology. Development agreements are being negotiated with a number of companies for

specific applications. PARTEQ Management anticipates that Datec will sublicense applications on a field of use basis.

This technology will be licensed to Datec for a royalty and PARTEQ expects to receive 25% of net proceeds from this royalty stream. PARTEQ also expects to hold an equity interest in Datec.

A U.S. patent application is under preparation.

Medical Devices

Elbow Implant

Description

Total joint arthroplasty is a well-established surgical procedure for the hip and the knee. With advances in implant design and surgical technique, arthroplasty of the peripheral joints is growing in usage. A multidisciplinary team of biomechanical engineers and surgeons at Queen's has been collaborating on the development of a total elbow prosthesis that capitalizes on this trend. The elbow designed at Queen's is based on anatomic principles. This should allow for restoration of joint biomechanics and a higher degree of restored joint function and range of motion.

Commercialization Status

To date, 27 devices have been implanted, with as much as five years of clinical history. Patents have issued in the United States and Canada. PARTEQ has licensed the exclusive, worldwide rights to the intellectual property to Wright Medical Technology Inc. based in Arlington, Tennessee. PARTEQ is entitled to an issue fee and a royalty of 5% of the net selling price of the intellectual property, with minimum royalties specified.

Performance Readiness Monitor

Description

This technology consists of a simple hand held vibratory stimulus response device to monitor sleep behaviour and performance readiness. The unit may be used for the home screening of patients suffering from insomnia or excessive daytime sleepiness prior to, or as an alternative to polysomnographic recordings in a sleep laboratory. The device may also serve as an adjunct to portable home polysomnography units. The device consists of an integrated unit that periodically emits a low amplitude vibration of a short duration. The device then records the patient's response, or lack thereof, to the stimulus. The patient responds by activating a small microswitch. Data is then stored for later retrieval and analysis by down-loading to a microcomputer through a standard interface.

Presently there are several working prototypes of the hand held units that are being used for experimental and research purposes. Studies have been carried out to determine the effectiveness of

the device to accurately identify the nature of the response in a cross section of good and poor sleepers. The extent of the correlation between the unit's measurement of behavioural aspects of sleep and widely accepted physiological definitions of sleep have also been evaluated. The results of these tests showed a high degree of correlation. Studies to qualify the unit's efficacy are ongoing.

Commercialization Status

A U.S. patent has been issued. PARTEQ has granted a world-wide exclusive license to EPM Systems Limited of Midlothian, Virginia. The license provides for an issue fee and royalties on net sales commencing at 6% and decreasing to 3% over time and minimum royalties.

Prevention of Decubitus Ulcers

Description

An invention to prevent and treat pressure ulcers (bed sores) was jointly developed by researchers at Queen's and DuPont Canada Inc. The technology is a dynamic support surface with a large number of small elements configured and driven so that tissue blood flow is maintained. Blood flow is essential to sustain tissue oxygen levels. Without oxygen, the tissues die and ulcers form. Healthy, mobile patients move enough to relieve pressure and thus prevent tissue death from occurring; pressure ulcers are usually seen in situations where mobility has been lost. The incidence of decubitus ulcers in 1985 was estimated to be between 1.5 and 3 million cases in the United States. PARTEQ management believes that, in addition to the inpatient and nursing home bed market, this intellectual property may have applications in wheelchair seating and other support surfaces where maintenance of tissue blood flow is important.

Commercialization Status

PARTEQ has exclusively licensed its rights in this technology to MICOS Medical Systems Inc. ("MICOS") of Ottawa, Ontario. MICOS is required to pay PARTEQ royalties on net sales of 2.5% to 3%. MICOS has minimum annual royalty obligations escalating to \$100,000 per year by 1996 and is responsible for all patent costs.

Patents have been issued and are in good standing in Taiwan and New Zealand. Patents have also been issued in the United States, Austria, Belgium, Switzerland, Germany, Spain, France, the United Kingdom, Greece, Liechtenstein, Luxembourg, the Netherlands, Sweden, Italy, Norway, Australia and Mexico. Maintenance fees have not been paid with respect to the latter patents but may be paid up to the applicable due dates. Patent applications are pending and are in good standing in Canada, Japan and South Korea. A patent application in Finland requires payment of maintenance fees but the maintenance fees may be paid until the applicable due date.

Q'Straint

Description

Q'StraintTM is a wheelchair and occupant restraint system developed by researchers at Queen's. The front of the wheelchair is secured to a transport vehicle via parallel straps attached to two front floor anchor points. The rear of the chair is similarly secured via parallel straps to two rear floor anchor points. The occupant is secured directly to the floor through a lap belt, the ends of which are connected to a respective rear chair strap so that impact forces imposed by the occupant and chair on the rear anchors are co-linear and no twisting forces are imposed on the chair.

Commercialization Status

This technology is exclusively licensed world-wide to A. Girardin Incorporated ("Girardin") of Cambridge, Ontario. An enhancement to the system, a positive floor pocket locking mechanism, is also protected by an issued U.S. patent and licensed by PARTEQ to Girardin Corporation on the same terms as the underlying technology is licensed to Girardin. PARTEQ receives a royalty of \$5 for each adapter unit sold and \$10 for each wheelchair system sold.

In a move to protect this intellectual property, PARTEQ and Girardin, in 1993, jointly initiated a patent infringement suit against Kinedyne Corporation, a company based in Kansas. Although no assurance can be given regarding the outcome of the lawsuit, PARTEQ believes it has a strong case for infringement.

Patents have been issued in the United States and Canada, and an application is pending in Canada. Trademarks have been registered in the United States and Canada.

Other Properties

PARTEQ also has a number of other intellectual properties that are at different stages in the commercialization process. Some of these properties are summarized in the following table.

Technology	Description	Patent Status	Commercial Status
Air Coupled Ultrasonic Transducer	Air coupled transducer exploiting integrated circuit design principles	United States patent issued. Application pending in Canada	Working prototypes developed and tested
Allatostatin Gene	Gene coding for the allatostatin family of insect neuropeptides	United States application filed	Awaiting expression in a baculovirus system before commencing commercial activity
Anti-Coagulants	Compounds with an anti- coagulant effect	Application pending in United States; PCT application filed	Seeking licensees
Anti-yellowing agents	Compounds to prevent or reduce yellowing in pulp and paper	United States application filed in 1994	Technology owned by Microwave Chemistry Corporation (shares are 40% owned by PARTEQ and 60% owned by, or held by PARTEQ on behalf of, the inventors. Development ongoing. Seeking licensees
APT Multimedia Data Integrator	System to synchronize one or more digital data acquisition systems	United States application filed	Beta Test prototypes nearly complete
Butyl Rubber	Process for the production of butyl rubber	United States application filed in 1994	Process being evaluated by potential licensee
Damping of Mechanical Vibration	Active damping of mechanical vibration by using superconductors in a magnetic field	United States application filed in 1994	Development ongoing. Seeking licensees
Heparin Assay	Two different assays based on enzymatic reactions	United States patent issued to, and PCT application filed by, Research Corporation Technologies	Assigned to Research Corporation Technologies
IBDG - E. Coli Test	A chromogenic assay for E. Coli	Patents have issued in Canada and United States	Exclusive licence with Diagnostic Chemicals Limited

Technology	Description	Patent Status	Commercial Status
Microwave Catalysis	Process using pulsed microwave energy to heat surface of catalysts to stimulate chemical reactions	Canadian patent issued. Applications pending in Canada and United States	Technology owned by Microwave Chemistry Corporation (shares are 40% owned by PARTEQ and 60% owned by, or held by PARTEQ on behalf of, the inventors). Development is ongoing. Seeking licensees
MTP Implant	An anatomically shaped resurfacing implant of the first joint of the great toe	Issued in Canada, United States, U.K., Switzerland, France and Germany	Implant being finalized for initial clinical trial
Neuroprotectants	Class of compounds aimed at enhancing neuroprotection	No applications yet filed	Exclusive license with Neurochem Inc
Neurotrophin Antagonists	Peptides capable of reducing undesirable neurotrophin mediated activity	Filed in the United States	Negotiations ongoing for exclusive license
Polymer Support Catalyst	Polymer-supported catalyst for ethylene polymerization and copolymerization	United States application allowed, pending Canadian application	Material being evaluated by polyethylene producers and catalyst suppliers
Polymers of Vinyl Ethers	Process for production of higher molecular weight poly vinyl ethers	United States application filed	Development ongoing
Porphyrin Derivatives	Ethanolamide derivatives which act as chemotherapeutic and/or photosensitizing agents	Issued United States patent. Applications in the United States, Canada, Europe, Mexico and New Zealand pending.	Development ongoing. Seeking licensees
Syndiotactic Polystyrene	Process for making syndiotactic polystyrene using a metallocene derivative system	United States and PCT applications filed	Seeking licensees

USE OF PROCEEDS

The net proceeds to be received by the Company from the sale of the Common Shares offered hereunder are estimated to be \$26,170,000, after deducting the aggregate Agents' fee of \$1,680,000 and the expenses of the Offering to be paid by the Company estimated to be \$150,000.

The Company will pay \$25,000,000 of such proceeds to Queen's on closing and issue the PARTEQ Options in consideration for its Royalty Interest and the right to participate in the development of the Portfolio as described herein. The balance of the net proceeds of this offering will be retained by the Company for working capital purposes.

PARTEQ DIRECTORS AND MANAGEMENT

The following table sets forth the names, municipality of residence and principal occupation of each of the directors and officers of PARTEQ:

Name and <u>Municipality of Residence</u>	Title	Principal Occupation
John P. Molloy Kingston, Ontario	President and CEO	Executive Director PARTEQ Research and Development Innovations
Dr. David Bacon Kingston, Ontario	Chairman of the Board	Professor, Chemical Engineering Queen's University
Dr. Carl Hamacher Kingston, Ontario	Director	Dean, Applied Science Queen's University
Dr. Duncan G. Sinclair Kingston, Ontario	Director	Vice Principal, Health Sciences Queen's University
Dr. Suzanne Fortier Kingston, Ontario	Director	Acting Vice Principal, Research
Dr. Alex Curran Oakville, Ontario	Director	President Alex Curran Consultant Inc.
Mr. Paul F. Campbell Halifax, N.S.	Director	Partner Ernst & Young
Mr. Richard R. Walker Lansdowne, Ontario	Director	President Meri Consulting Associates Inc.
Dr. Martin Walmsley Toronto, Ontario	Director	Director, Premier's Council Technology Fund, Ontario (retired)

Mr. John P. Molloy holds a B.Admin. from College Militaire Royal de Saint Jean and an MBA from Queen's. He joined PARTEQ (then an administrative centre within Queen's) from a position as Commercial Account Manager with the Bank of Montreal in 1986 to manage commercialization activities. He assumed the position of Executive Director of PARTEQ in January 1992. He has been responsible for all aspects of PARTEQ's commercialization activities

and has founded a number of companies based on University generated technology. He is currently on the Steering Committee of Bionet and is a director of the Genetic Diseases Network, and Neurochem Inc. He is a member of the Association of University Technology Managers, the Licensing Executive Society, the Commercial Development Association and the Canadian University Intellectual Property Group.

Mr. Richard J. Hicks holds a B.Sc. from the Imperial College of Science and Technology, University of London and is a Registered Patent Agent in Canada and the United States. Following many years in private practice, Mr. Hicks joined Queen's in 1984 as the Director of Patents and Licensing. He is now the Director of Intellectual Property at PARTEQ. He is a registered Professional Engineer of Ontario, a Fellow of the Patent and Trademark Institute of Canada, a Notary Public, and a member of both the Licensing Executive Society and the Association of University Technology Managers.

Mr. Bruce Ackman holds a B.Sc. in Biochemistry from McGill University and an MBA from Queen's. He joined PARTEQ in 1992 and is now Manager, Commercial Development. Prior to joining PARTEQ he was Senior Product Manager at Dow Corning Canada. He is a member of the Association of University Technology Managers and an adjunct lecturer at the Queen's School of Business.

COMPENSATION AND INCENTIVE PROGRAM

The Board of Directors of the Company has established a Stock Option Plan which permits the Board from time to time, in its discretion, to grant to any employee, director or senior officer of the Company, options to purchase Common Shares from the Company. The maximum number of Common Shares that may be issued under the Plan is 280,000. Options to acquire 140,000 Common Shares have been granted to the directors and officers of the Company. Each officer and director has been granted an equal number of Options. The Óptions issued to the directors and officers vest on the closing of this offering and have an exercise price equal to the offering price. The Options terminate on the occurrence of certain events stated in the Stock Option Plan and expire 5 years from the date of their issue. The remaining unissued Options shall be issued on such terms and conditions as the Board may impose.

Directors will receive an annual fee of \$4,000 per year and \$500 for each meeting attended.

DESCRIPTION OF SHARE CAPITAL

The authorized capital of the Company consist of an unlimited number of Common Shares. At the date hereof, 1 Common Share has been issued and is outstanding.

DIVIDEND POLICY

The Company does not anticipate paying cash dividends in the foreseeable future, but intends instead to retain future earnings to fund development of the Portfolio. Any future determination to pay cash dividends will be at the discretion of the board of directors of the Company and will depend upon the Company's financial condition, results of operations, capital requirements and such other factors as the board of directors of the Company deems relevant.

PLAN OF DISTRIBUTION

Pursuant to an agreement (the "Agency Agreement") to be dated prior to the closing of this offering, between Marleau, Lemire Securities Inc. and Richardson Greenshields of Canada Limited(collectively, the "Agents"), the Company, PARTEQ and Queen's, the Company has appointed the Agents to act as its exclusive agent to effect the private sale of the Common Shares at a price of \$10 per share. The Agents have agreed to use their reasonable best efforts to effect the sale of the Common Shares on behalf of the Company. The Agents shall have no obligation to purchase the Common Shares of the Company as principal. The Agency Agreement provides that the Company will pay to the Agents a fee of \$0.60 per Common Share payable in cash at the closing of this Offering.

The following events will occur contemporaneously with the closing of this offering:

- 1. the execution and delivery of the Participation Agreement;
- 2. the execution and delivery of the Royalty and Development Agreement;
- 3. the execution and delivery of the Administration Agreement;
- 4. the grant of the PARTEQ Options; and
- 5. the reorganization of PARTEQ's business as described under "PARTEQ Innovations Inc. - Reorganization of PARTEQ's Business".

This offering is being made pursuant to exemptions from the prospectus requirements of the securities laws of the provinces of Canada. The minimum subscription is \$150,000. Purchasers of Common Shares will be obliged to establish their qualifications to invest in accordance with the requirements of such securities laws.

A resale of the Common Shares will be subject to restrictions under applicable securities laws which will vary depending on the relevant jurisdiction. Prospective purchasers should consult their own professional advisors with respect to such restrictions.

The Common Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any United States state securities laws, and may not be offered or sold except in transactions exempt from or not subject to the registration requirements of the U.S. Securities Act and any applicable state securities laws. Accordingly, the Agency Agreement provides that the Common Shares may be offered and sold in the United States only to qualified institutional buyers (as such term is defined in Rule 144A under the U.S. Securities Act, "Qualified Institutional Buyers") in accordance with Rule 144A under the U.S. Securities Act ("Rule 144A"), and outside the United States only in accordance with Regulation S under the U.S. Securities Act. Prior to completion of any sale of Common Shares in the United States, each U.S. purchaser thereof will be required to represent, warrant and agree that: (1) it is a Qualified Institutional Buyer and is acquiring the Common Shares for its own account or for the account of a Qualified Institutional Buyer as to which it exercises sole investment discretion; (2) it understands that the Common Shares have not been and will not be registered under the U.S. Securities Act or any United States state securities laws and that the contemplated sale is being made in reliance on Rule 144A to Qualified Institutional Buyers; (3) if it decides to offer, sell or otherwise transfer any of the Common Shares, it will not offer, sell or otherwise transfer any of the common Shares, it will not offer, sell or otherwise transfer any of such securities, directly or indirectly, except as permitted by the legend set forth below; and (4) it understands and acknowledges that upon the original issuance thereof, and until such time as the same is no longer required under the U.S. Securities Act or applicable state securities laws, certificates representing Common Shares, and all certificates issued in exchange therefor or in substitution thereof, shall bear the following legend:

"THE COMMON SHARES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "U.S. SECURITIES ACT"), AND MAY BE OFFERED OR SOLD ONLY (A) TO THE COMPANY, (B) IN ACCORDANCE WITH RULE 144A UNDER THE U.S. SECURITIES ACT, (C) IN ACCORDANCE WITH RULE 904 OF REGULATION S UNDER THE U.S. SECURITIES ACT, OR (D) WITH THE PRIOR WRITTEN CONSENT OF THE COMPANY, PURSUANT TO ANOTHER EXEMPTION FROM REGISTRATION UNDER THE U.S. SECURITIES ACT."

RISK FACTORS

The development of a research-based discovery or innovation into a commercial product involves a high degree of risk. Frequently the same or similar discoveries are made by different researchers within a reasonably close period of time and not disclosed except in secrecy to a patent office. Development, at considerable expense, on discoveries may proceed only to find another inventor is able to establish priority. Substantial expense is often involved in commercial development and many problems may arise throughout the process which could result in failure. Further testing may fail to confirm initially favourable results or show side effects which may reduce or eliminate value. Regulatory hurdles may not be achieved but such information may only be available after considerable development has occurred. Even when a commercially marketable product emerges, market projections may not be attained. The descriptions in this Offering Memorandum of specific discoveries and innovations should be read with these considerations in mind. In addition, investors should have regard to the following additional risk factors with respect to the Company's participation in the development of the Portfolio:

Technology Risk

The Company's success from this project depends on university research generating discoveries with commercial potential. In addition, the properties included in the Portfolio

require significant development and there can be no assurance that any of the properties will be commercialized successfully.

Researchers' Rights to Discoveries

Inventors at Queen's are not required to offer discoveries with commercial potential to PARTEQ. Accordingly, PARTEQ will only obtain rights to new discoveries if researchers choose to offer the discoveries to PARTEQ rather than other private sector companies active in this business. In addition, PARTEQ will only obtain rights to improvements to intellectual property included in the Portfolio if such improvements are assigned to Queen's or PARTEQ. Also, PARTEQ may not obtain rights to an improvement to a property in the Portfolio which is developed by a researcher after moving from Queen's to another employer who advances a competing claim.

Government Funding

Research at Queen's is primarily financed through government funding. Government funding levels have been decreasing and there can be no assurance that current levels of research can be sustained as the level of funding decreases.

Patents

A number of the projects discussed in this offering are the subject of patent applications. There is no guarantee that such patent applications will issue and there is no guarantee that if patents do issue, that they will not be challenged by third parties. Patent searches are regularly undertaken before most applications are filed but rights to manufacture searches generally are not done before filing. There can be no guarantee that making, using or selling the invention claimed in an issued patent will not infringe patents of third parties.

Reliance on PARTEQ Management

The Company's success depends largely on PARTEQ's successful management of both its current intellectual property portfolio and the development of its future intellectual property opportunities. Although PARTEQ has been active in founding a number of technology oriented companies, it has not had resources to dedicate to the commercial development of its intellectual property portfolio and its experience in funding and managing such development projects is limited.

Market Considerations

The market in Canada for the development of technology resulting from university research is limited. Development of intellectual properties with parties in foreign countries may require significant effort and expense.

Lack of Technology Entrepreneurs/Managers

There are a limited number of experienced technology entrepreneurs/managers with experience in commercializing intellectual properties, especially in the biotechnology field. There can be no assurance that PARTEQ will be able to attract or retain qualified entrepreneurs or managers for its commercialization products.

Availability of Capital

PARTEQ and the Company will require additional financing to complete the commercialization of items in the Portfolio. There can be no assurance that such funding will be obtained.

INTEREST OF MANAGEMENT AND OTHERS IN MATERIAL TRANSACTIONS

The only material transactions in which the directors, officers or shareholders of the Company or their respective associates or affiliates have or have had an interest that is material to the Company are as follows:

- (a) the Agency Agreement described under "Plan of Distribution"; and
- (b) the Administration Agreement described under "The Company Operating Expenses and Administration".

MATERIAL CONTRACTS

The only material agreements or other contractual arrangements entered into by or on behalf of the Company are:

- (a) the Participation Agreement described under "The Company Investment Objective";
- (b) the Royalty and Development Agreement described under "Royalty and Development Agreement";
- (c) the Stock Option Plan described under "Compensation and Incentive Program";
- (d) the Administration Agreement described under "The Company Operating Expenses and Administration"; and
- (e) the Agency Agreement described under "Plan of Distribution".

Copies of each of the foregoing agreements, together with the Queen's License described under "PARTEQ Innovations Inc. - Reorganization of PARTEQ's Business" may be examined during normal business hours at the executive offices of the Company, Suite 200, 1250 Bay Street, Toronto, Ontario, at any time during the course of distribution of the Common Shares offered hereby.

LEGAL MATTERS

The matters referred to under "Eligibility for Investment" and certain other legal matters relating to the issue and sale of the Common Shares offered hereby will be passed upon on behalf of the Company and the Agents by Goodman and Carr, Toronto, Ontario and on behalf of Queen's and PARTEQ by Tory Tory DesLauriers & Binnington, Toronto, Ontario and Cunningham, Swan, Carty, Little & Bonham of Kingston, Ontario.

AUDITORS

The auditors of the Company are Peat Marwick Thorne, Chartered Accountants, located at Suite 400, 865 Princess Street, Kingston, Ontario.

PURCHASERS' CONTRACTUAL RIGHTS OF ACTION

Securities legislation in certain of the provinces of Canada provides purchasers or requires purchasers to be provided with a remedy for rescission or damages where an offering memorandum and any amendment to it contains a Misrepresentation. As used herein, "Misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement in the Offering Memorandum not misleading in light of the circumstances in which it was made. These remedies, or notice with respect thereto, must be exercised, or delivered, as the case may be, by the purchaser within the time limit prescribed by the applicable securities legislation.

Each purchaser should refer to provisions of the applicable securities legislation for the particulars of these rights or consult with a legal adviser.

Rights for Purchasers in Ontario, British Columbia and Newfoundland

In the event that this Offering Memorandum, together with any amendments hereto, delivered to a purchaser of Common Shares resident in Ontario, British Columbia or Newfoundland, contains a Misrepresentation and it was a Misrepresentation at the time of purchase of Common Shares by such purchaser, the purchaser will be deemed to have relied upon the Misrepresentation and will, as provided below, have a right of action against the Company for damages or, while still the owner of the Common Shares purchased by that purchaser, for rescission, in which case, if the purchaser elects to exercise the right of rescission. the purchaser will have no right of action for damages against the Company, provided that:

(a) the right of action for rescission or damages will be exercisable by a purchaser resident in Ontario, British Columbia or Newfoundland only if the purchaser gives notice to the Company, not later than 90 days after the date on which the payment is made for the Common Shares, that the purchaser is exercising this right;

- (b) the Company will not be liable if it proves that the purchaser purchased the Common Shares with knowledge of the Misrepresentation;
- (c) in the case of an action for damages, the Company will not be liable for all or any portion of the damages that it proves does not represent the depreciation in value of the Common Shares as a result of the Misrepresentation relied upon; and
- (d) in no case will the amount recoverable in any action exceed the price at which the Common Shares were sold to the purchaser or, in the case of a purchaser resident in Newfoundland, the price at which the Common Shares were offered to such purchaser.

Rights for Purchasers in Alberta

In Alberta, every purchaser of Common Shares pursuant to this Offering Memorandum shall have a right of action for damages and/or rescission against the Company if this Offering Memorandum or any amendment thereto contains a Misrepresentation.

In Alberta, no action shall be commenced to enforce a contractual right of action unless the right is exercised:

- (a) in the case of rescission, on notice given to the Company not later than 180 days; or
- (b) in the case of damages, on notice given to the Company not later than one year,

from the date of the transaction that gave rise to the cause of action.

Rights for Purchasers in Saskatchewan

In the event that this Offering Memorandum and any amendment hereto or advertising or sales literature used in connection therewith delivered to a purchaser of Common Shares resident in Saskatchewan contains a Misrepresentation and it was a Misrepresentation at the time of purchase of the Common Shares, the purchaser will be deemed to have relied upon that Misrepresentation and will have a right of action for damages against the Company or may elect to exercise a right of rescission against the Company, in which case he has no right of action for damages against the Company, provided that:

- no person or company is liable where the person or company proves that the purchaser purchased the Common Shares with knowledge of the Misrepresentation;
- (b) no person or company, other than the Company, is liable with respect to this Offering Memorandum, an amendment to this Offering Memorandum or advertising or sales literature used in connection with a distribution or trade of the Common Shares pursuant to an exemption contained in the Securities Act

(Saskatchewan) or a decision of the Saskatchewan Securities Commission unless that person or company: (i) failed to conduct a reasonable investigation sufficient to provide reasonable grounds for a belief that there had been no Misrepresentation; or (ii) believed there had been a Misrepresentation relied on; and

(c) in an action for damages, the defendant is not liable for all or any portion of the damages that it proves does not represent the depreciation in the value of the Common Shares as a result of the Misrepresentation;

but no action shall be commenced to enforce these rights more than:

- (a) in the case of an action for rescission, 180 days after the date of the transaction that gave rise to the cause of action; or
- (b) in the case of any action, other than an action for rescission, the earlier of 180 days after the purchaser first had knowledge of the facts giving rise to the cause of action or three years after the date of the transaction that gave rise to the cause of action.

Purchasers of the Common Shares resident in Saskatchewan will not be bound by a contract for the purchase of Common Shares if the Company or its agent receives notice in writing indicating the intention of the purchaser not be bound thereby at any time up to two business days after receipt by the purchaser of this Offering Memorandum and any amendments thereto.

Rights for Purchasers in Quebec, New Brunswick and Prince Edward Island

Notwithstanding that the Securities Act (Quebec), the Securities Act (New Brunswick) and the Securities Act (Prince Edward Island) neither provide nor require the Company to provide to purchasers resident in these jurisdictions any rights of action in circumstances where this Offering Memorandum or any amendment thereto contains a Misrepresentation, the Company hereby grants to such purchasers the equivalent contractual rights of action as are set forth above with respect to purchasers resident in Ontario.

General

The foregoing summaries are subject to the express provisions of the Securities Act (Ontario), the Securities Act (British Columbia), the Securities Act (Alberta), the Securities Act 1988 (Saskatchewan), and the Securities Act (Newfoundland), and the regulations and policy statements thereunder and reference is made thereto for the complete text of such provisions.

The rights of action described herein are in addition to and without derogation from any other right or remedy that the purchaser may have at law.

CERTIFICATE OF THE COMPANY

Dated: January 27, 1995

The foregoing contains no untrue statement of a material fact and does not omit to state a material fact that is required to be stated or that is necessary to prevent a statement that is made from being false or misleading in the circumstances in which it was made.

Gordon H. Fox Chief Executive Officer Marvin Kates Chief Financial Officer

TO 4530514142770709

Comordians tipfice

3101 BATEMAL STEERI, TOMONIC ON THEAT, IDA 11) SHE

A. IO:

PALL NOT

Res DL IIII

Alfana . Isra

ANES:

(TA COVER PAGE) - 1

TIBRANIST

HONY OUTFIEL,

The sect you fune 2nd at 4:00 P.M. at the Contact y Development

in the sole to strend your task which is a second sole of the sole

9 any change to my part I will proailld like to make a change please and the solith will be away in Israel to be there the my home, unless I happen to be there and the solution

Diamond, formerly of Queen's?
I Diamond, formerly of Queen's?
I a large C
I a large C
I a provide the second se

mernatively, you can let me know and I will co-grouped a set

no orward to seeing viu and


Coll 10-11

WUN /

Sint

Blool (Arc 4:30 H Jeannis —

P.Ø1



'amous chemist turns art collector

SCOTT TRACEY

ne sam

Alford Dodovic stor

Alfred Bader's story is a true "rags to riches

rn a Jew in pre-war Austria. • would go on to found one of • mld's largest chemical compaind become a world-renowned • tor and dealer in fine paint-

is in Guelph as the keynote or at the annual conference of hemical Institute of Canada. ...t the University of Guelph ind wife Isabel told them

der was born in Vienna in 1924 A is adopted by his aunt after father died. Bader was two Ks old at the time. His aunt, like father, was a Jew and Bader was sed in this faith. His natural iner, however, was a Catholic ittempted often to convince the

ing man to change his religion. Whenever I did see my natural ther she would talk to me about tholicism. When you also coner all the Jewish propaganda at it time I was a very mixed-up kid, e recalled

following anti-Jewish demonitions in 1938, the British goviment offered 10.000 entry visas Jewish children and Bader was of the first to arrive in England. 1940, however, the British govnment became concerned there iv be a spy among the refugees placed them in internment ups

Bader was eventually shipped to inada as a prisoner of war, beuse Canada was willing to accept DWs but not refugees. The plane hich brought Bader to Canada so contained some captured Nazis ind when we arrived there were eople shaking their fists at us houting. 'You damn Nazis'." Bader emembered.

He got a good education in the Caadian camp and was eventually acepted to Queen's University in (ingston, where his life changed.



FAMED CHEMIST: World renowned chemist and art collector Dr. Alfred Bader is making a brief appearance in Guelph this week. Accompanied by wife

"I was so wonderfully welltreated at Queen's," he smiles. "It was the first time in my life I was treated as a real human being."

This kindness bestowed upon him during his school years has been returned many times over, as the university has become the primary source of Bader's generosity

Last year he donated approximately \$14-million to Queen's for the purchase of a castle in England, and has also donated \$2-million for the enlargement of the university's art department so it will eventually be able to accept the couple's massive collection of fine paintings, including a number of Rembrandts

While attending Queen's Bader worked during the summer for the Murphy Paint Company in Montreal. On graduation he accepted a full-time job formulating paints there.

His research had taught him

some+little-known tricks of the trade, and Murphy's clients appreciated it

"Sales went straight up and the salesmen, being on commission, loved me," Bader said. "They were always arguing over who would take Bader the next day."

So he was obviously surprised when Murphy president Harry Thorpe asked him to leave the company to obtain a PhD at Harvard and then return. Thorpe paid \$1,600 for Bader's education.

By the time he finished Harvard, though, Murphy had been bought by Pittsburgh Plate Glass Company and Bader went to PPG's paint research facility in Milwaukee, where he has lived ever since,

He stayed with PPG for four years "and at one point they sold one of my patents for \$1-million so 1 felt my committment was repaid."


While still working for PPG.

Chemical Institute of Canada conference, held at the University of Guelph **SCOTT TRACEY** The Guelph Mercury on tricks of the Bader and an attorney friend

Bader and an attorney filend founded Aldrich Chemical for \$250 each in 1951. They flipped a coin to see who would name the new company and his friend won, naming it for his fiance, Betty Aldrich.

Bader spent 40 years building the company's reputation and saw it grow from \$1,700 in sales the first year to more than \$800-million this year. Despite having founded the company, Bader was thrown off the board of directors in 1991 amid "trumped-up charges" he undermined the integrity of the company by selling a call option on 10,000 shares in the company.

Although obviously furious at the attack on his credibility, Bader says now his expulsion had "a silver lining." Specifically, it enabled him to sell more shares in the company to fund various endowments to the arts. With more than three million shares. Bader is still the company's largest shareholder.



IN THE CITY

The Guelph Mercury

All talk, no action

Televised debate fizzles

<text><text><text><text><text><text><text><text><text><text><text><text><text><text><text> ty's record over the

few questions from the nel, beginning with voter the evening warmed up hospital redevelopment

one political pundit called can style" campaigning University of Guelph Professor Pred Vaughan, of the Political Stud ies department, was at the debate and said this was the first time he has seen anything like this bro chure in Guelph during 30 years of elections

BY RICHARD DOOLEY

Rick Ferraro more than wants his Id job back, he wants to know why

he lost it It's a question that has dogged him since losing his seat as Guelph's MPP in the 1990 election that swept Bob Rae and the NDP to

mai swept soo lae and the KUP ino "The set to know it it was former Liberal premierer David F. terson, Rick Ferraro, the hospital save or a combination of all those things that cost the election," For-main the set of the set of the set of the thing that cost the election," For-main the set of the set of the set of the thing that cost the election, "For-main the ferraro support table. It was a decision that was due to the set of the set of the set of the the set of the set of the set of the main the ferraro support table. It was a decision that was due to the set of the set of the set of the main the set of the set of the main the set of the set of the main the set of the set of the hospital the set of the set of the through that set and. It was an the set of the set of the hospital the set of the set of the hospital the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the the set of the set of the set of the set of the the set of the set of the set of the set of the the set of the the set of the set of the set of the set of the the set of the set of the set of the set of the the set of the set of the set of the set of the the set of the set of the set of the set of the the set of t

In this people a three sectivy notices 1 think people appreciated his outbook No stranger to elections or pro-vincial politics. Ferraro said he was lands to run araan because of a growing concern for the future "I'm worried about where this province is going and in particular about the future for our young people" he said

BY SCOTT TRACES Dr. Alfred Bader's story is a true de of rags to riches Born a Jew in pre-war Austria Bader would go on to found one o the world's largest chemical compa nes and become a world-renowne collector and dealer in fine paint

FERRARO FAMILY Former: Liberal MPP Rick For-raro is running for his old job with the support of his by their children Kewin and Krista

Ontario Election '95

Rick Ferraro: Running for answers

 FERRAGO FAMILY
 Former Libraria Importantia Importanti Importecha Importantia Importanti Importantia Importanti

FACTS

FACTS Rectors, 45 maned wile JoAnn works in the first of a local surgery in Gateloh, an Issue that input have costs the member of the first of a local of the Issue first the first of a local of the Issue His stand on the Issue first the date care is the number of the date of the date. If the date is the number of the date of the date. If the date is the number of the date.

FERRARO

sely by the deficit His take on the campaign: "It's been a dirty campaign and will likely get worse "

trust politicians in general "I think it is up to us to win that

essential element of global markets Famous chemist turns art collector But because of the country's reli

BY SCOTT TRACEY

nes and become a wordt-converted collector and dealer in fine panot panot and the annual conference is a statistical of the second second second based of the second secon

BY SCOTTRACEY The Groundwards Canada must place more em-phasis on research and device ment suse is our research and device ment suse is our research and device the subscription of the subscription Multie the coulting the university of the coult was a public the the ment of clemistry more. Martin Moskovits, chairman of the depart ment of clemistry more. Martin Moskovits, and place this west of the coult was a public the canadam Society for Chemistry of the subscription of the list of provides and out were subscription. The fact, the said the coult of the subscription of the list of provides th

Column clarification

Chemical research

Due to an error in the editing process, quotation mark - oppeared in a satu-reat column by T. Sher Singh on Saturday's Perspective p.ge. The fault junctuation made it appear as though some of the pass-se were direc-uotes from - orwinein PC leader Mike Harris when in fact, they were no fiberarrow as not the author's

Election candidates on radio phone-in show

Guelph's candidates for the MPP and take to the radio wives Wednes tay meth. The phone line will be thrown open to allow the public to pose ques-tions of the candidates.

All take to the crothese were written max meth The potterana will be broad in the motion of the cranidiates incumbent NDP MPP Derek incumbent

ard collector for Alfred Basker is making a break of the alfred Alfred Theorem March 1 (Secondard Alfred Al

comps Badler was eventually shipped to Canada as a prisoner of war, by Canada as a prisoner of war, by POWs but not refuses. The place which brought Badler to Canada also contained some captured Nar-mant when we arrived there were poorle shiaking their tists at us booting. "You drams Naras." Badler remembered U. . : comediate to man the 't.

FAMED CHEMIST World renowned chemist and Isabel, Bader was the keynote speaker at the annual ard collector for Alfred Bader is making a brief ap-Deparance in Guegh this weak A companed by with e University of Bueloh the second tracet in equivalence that the Chemistry of Bueloh the second tracet in equivalence that the second tracet is the second tracet in equivalence that the second tracet in equinatity is

MERCURY

Stephen Rhodes Publisher ny Managing Editor Roc C en Advertising Manager Accountant Marc Datien, Circulation Manager Composing Foreman Neicor Fuziti zian Press Room Foreman Published to Trimeon Newspaper, Company Ltd er 13 Maconnel Striket Box Gok Gok pr. Civitano NTH 6P3

EDITORIAL/The economy The power of

life and death

As the principal setter of interest rates and other strar anada's monetary policy puzzle, the Bank of Canada has an amount of heat over the years

Interpart INTP years. Furthermore, he suggests, any ement in overall living standards in a Ganada over the next ill be patry, and will be at least partially offset by higher hower gover memory transfers to popel. This sad reality, h lower gover memory is hong. It not only helped a 94? recession by overdaing it is hong, if not only helped as 94? recession by overdaing it is hong people of joins of the improving standard of living they should have enjoyed to of 2° Fire the loof them?

to say than the central bank's tight monetary policy was 1 sparcity of suggestive material may be okay, coming from . But it does mean that nothing much is likely to change very und without some constructive change, there will be nothing thing, to prevent Bank of Canada officials from making the source of t

such suggestions as to where we go from here to imply that the unelected governor of the

A clarification lescription of hired thugs made in Saturday's editorial wi repreted by some of our readers as derogatory. A sentence

OTTAWA DIGEST/

What really happens on Parliament Hill

OTTAWA (TNS) — Taxpayers uld be spending as much as \$2 some changes to a government bill

idy will likely tak

to the Senate in the fal

On Correspondence

The Mercury, 8-14 Macdonell St. Nill 61



Klein comes down with the health-cut blues BY JULIA NECHEFF

RALPH KLEIN

e centeu all no longer nt the Torres' power base of rural as a notion that perhaps agional health authorizio Think the wheels are falline of the torrest power base of rural time to the reasonable perceited segment time to the reasonable segment time

ared to actually do anything p the NDP-But he's ready to

poli that suggested most Alber ans were satisfied with the health are system Vivone said that must differ from that Klein's street sense and his

nomic and political association with Canada is the best option for Que

WHAT CANADA THINKS In a letter to the monthly An-glican Journal, K. Teddy Smits of Kitchener urges alternatives to perative education programs, ull end the NDP's failed Jobs Kitchener urges alternatives to ong jail terms Many people have been hurt or talled in a crime and some voices urge longer sentences to get the

vork Within 90 days of taking office, the

DON ROSS

a trustee on the We v Board of Education

LIBERAL

Breachastweet were valued to scatabolish studies and clear report carsing seventatives. Were valued to scatabolish control for international control for internat

Be wary of small pot holes

Ontario Election '95

Candidates comment on education

We asked: What are main platform planks on education issues?

ELAINE ROGALA

The NDP's platform on education

NDP

v greater financial burden r huiton We will also de new students assistance pro id will examine the feasabi-

ding an income-con-epayment program e program links be-and universities, and

ity education does not suffer beca we all benefit from higher edu tion Cost should not stop any ch

restructure and redire ct. We will ask students and educators to mak priorities and the NDP will wor hard to obtain a reasonable balance between budget cutbacks and qua

TED ARNOTT

CONSERVATIVE

Wellington's Member of Pr ial Parliament. I have alway

Parents in Wellington tell me they want more accountability, objective



 New Jobs & Training
 New Community Health Programs New partnerships

On June 8th re-elect DEREK FLETCHER 🗹 CALL 766-1971 NEW A

authorized by the C.F.O. 17 Macdonell Street




FARMER DON: Wellington Liberal MPP candidate Ross's campaign office. Ross is trying shares a laugh with Guelph MP Brenda Chamberfain at bent Tory MPP Teld Arnott shares a laugh with By VALERIE HILL

1990s The job gave the quiet-spoken Port a chance to flex his cost cut Noss a chance to flex his cost cut ting measures. Tax rates did not in-crease under his leadership and the board was able to reduce the num-ber of consultants from 22 to 12. The number of superintendents also took a dive, from 11 to seven ELORA - Don Ross is willing. DRA - Don we up the farm e Liberal candidate for Well-n says he has considered tem-uly turning his 550-acte dary, and cash crop operation over to some else if elected as MPP in ensemble includer lon It provincial election have to make some ns about what would farm," he says. At the is unwilling to get out logether. "I don't look career as financially team there (at the board) that I can take to the provuncial level ' Ross sports wire frame glasses, wears tidy tweeds and has a long lean. Preston Manning look about him. He seems more an accountant than a farmer. Yet his dedication to the land becomes obvious when he table about bus famility tong hatema

f alonge-read career as financease padmits a nind generation farmer arristo area. He is married the land becomes obvious when he is a volume with Wet aloout care and dismity for baout care and dismity for sor resides in the family home-deas resides in the family home-deas areas the reader areas the source from the son son resides in the family home-dead caress the read from the son son properties. inally ill uple has two daughters who attends Humber col Robin, 24, an English ma-University of Guelph vas a teacher during the 4 early 70s but gave it up to nore time to farming. He ved as trustee on the Well

The Guelph Mercury, Tuesday, May 29, 1995 A5





Offer ends May 31, 1995.

Possibly, the Best Car Dealers in the World.



Gil Hardy is a Queen's Park columnis to: Thomson News Service



Quebec Premier Jacques Pari zeau's switch in his political ap proach should fool no one, say, an editorial in the weekly Tri bune of Campbellton, N.B.:

ssociation. Can't be Yet reports indicate Parizeau Is

be No one is being fooled If Parizeau is now singing the praises of a confederal union, it's only because he cannot sell separat ism to the reasonable people of Que

PINION

MERCURY

Stepher Rhodes Publisher er svoy Managing Editor Flixot Accountant Vien Composing Foreman Nets - Flixot 2 an Press Room Forer P Hished N, Trinnson New papers C impacy util 8 14 Macocnel Streel Brix active Gue of Children and Nith

EDITORIAL/The economy The power of

life and death

As the principal setter of interest rates and other s mada's monetary policy puzzle, the Bank of Canad

A clarification

the description of hired thugs made in Saturday's editorial interpreted by some of our readers as derogatory. A senten it the editorial reforme to eangsters was not intended to

OTTAWA DIGEST/

What really happens on Parliament Hill OTTAWA (TNS) — Taxpayers rould be spending as much as \$2 some changes to a government bill

ading the computers axpayers as much as \$3 , we are moving to go

On Correspondence



Klein comes down with the health-cut blues BY JULIA NECHEER



the . RALPH KLEIN

urged them to stay the

mered the government over almost daily during the Several times they raised

Alberta are causing the government grief I think the wheels are falling off

Unions finally see Bill 40 threat

Queen's Park Gil Hardy

THINKS In a letter to the monthly An-thean Journal, K. Teddy Smits of Internatives to

WHAT CANADA

Quebec Premier Jacques Pari teau's switch in his political ap proach should fool no one, say

Gil Hardy is a Queen's Park columnist for Thomson News Service



Ontario Election '95

Candidates comment on education We asked: What are main platform planks on education issues?

a trustee on the v Board of Educal

LIBERAL

this . . . wi e, the Libe ELAINE ROGALA NDP

The NDP's platform

minimises for values and provide statistics of the statistical statistics of the statistic statistics and the statistic statistics and the statistic statistics and the statistic statistics of the statistic statistics and the statistic statisti

perative programs with school sands We know that colleges and univer thes must be accessible and allordar Ne will call that students are New will ensure that students are the substitution of the students are the students are students are the student are students are students are the student are students are students are student are students are student are

NEW DEMOCRATS

Be wary of small pot holes

Be wary of small holes on you property, warn the Guelph OPP. In the second seco



CALL 766-1971 authorized by the C F.O. 17 Macdonell Street

Election profile:Don Ross-Liberal



FARMER DON: Wellington Liberal MPP candidate Ross's campaign office. Ross is trya bares a laugh with Guelph MP Brenda Chamberlain at bent Tory MPP Ted Arnott shares a laugh with a By VALERIE HILL

sa laugh with Gueph Mr brenda Chamorana au cean to y wirr ver-ALERIE HILL 1996 reachtraine TRANSITION CONTRACT STATES Rest a chance to flex his cost cut reace under his leadership and the ber of consultants from 21 to 12 her of super intervents from 21 to FLORA - Don Ross is willing,

REGION

TED ARNOTT

CONSERVATIVE

s Wellington's Member of

students first. rents in Wellington tell me the more accountability, objective sticks to demonstrate school

wears tidy tweeds and has a long lean. Preston Manning look about hum. He seems more an accountant than a farmer Yet his dedication to the land becomes obvious when he talks about his family's long history al career as financially he," he admits oss is a third generation farme) he Harriston area. He is married an elementary school teacher is also a volunteer with Well

dospice, a group con-care and dignity for Iy ill le has two daughters ho attends Humber col bin, 24, an English ma-iversity of Guelph

NO PAIN. 5.8%* Financing JAIN. in Special Edition Options



1995 CIVIC SE SEDAN





NEWSLINE

Money motive for murder

<text><text><text><text><text>

No charges in scalding

TORONTO (CP) -- Charges won't be laid in the death of a disabled girl who was found badly scalded in her usburban home last December But police said a coroner's inquest will be held into the death of Audrey Cohen. 9 It was determined that Cohen drowned in thathub

determined that Cohen drowned i bathtub Her parents have complained police treated them as criminals during the investigation No date has been set for the

Firm shocked by WCB bill

PETERBOROUGH (CP) — A mix-up at the Workers' Compensation Board may foice a local company out of business, its owner says Canac Kitchen Design Studios was recently billed \$26,511 for compensation premiums — \$16,500 more than owner Gord Fishel expected

more than owner Gord Fishei expected The WCB discovered Canac employees had been wrongfully classified for two years through no fault of the company. Fisher's premiums have been increased about 53 000 a year and the WCB has billed him retroactively to Jan 1 bas

Judge rapped for deadline

for each of the second second

Inmates beat towing owner

LONDON (CP) The owner of a towing company was beaten by mattes at a local detention centry while evra in cal detention centry while evra inca five-day in matters a biological backware of the holorement Link sufficient a backen biorement link sufficient a backen

Son jailed in dad's death



PROTEST: Metro councillor Jack Layton joins in a protest with shipper at Queens Park Monday. The shippers want Ontario to ban lap dancing i bars, a practise they say is putting their health and lives at risk

Dumps harm health

TORONTO (CP) — A new study say, children future neor a neuroit persone landfill site have a neuroit neuroit andfill site have a neuroit severe the study of the study of the study of the terror top have a neuroit site of the study of the terror top have a neuroit site of the study who helped expose the datagers concealed beautions in the Low Cana caractersor groups in the Low Cana caractersor groups in the study of the study who helped expose the datagers concealed beautions in the Low Cana caractersor groups and the study of the study who helped expose the datagers concealed beaution in the Low Cana caracter a study and the study of the study who helped expose the datagers in the study of the study

The Liberal and Conservative camps are singing back and forth years are singing back and forth years and the singing back and forth in a news release Monday, the Lib-erals sand Harris told a high school student who asked him about the toos: "You'll have to end up setting wat, "nocolate bars to pay for some of these thin >, on your own."

Tories under attack ONTARIO ELECTION '95

White Conservative Leader Mit Marris tries to build up this standards the standards the build up this standard to build up the stan tarres trains to hulk up has standing in Laberal and NDP opponents are in the Ontario of the foundations DVP Permiter Box Reg and Liberal SWF Permiter Box Reg and Liberal in the Ontario of the Insert of the Insert of the Insert of these spending that has resteribulies. The International Constraints, the insert polising sector in the Insert of Insert of the Insert of the Insert of the Insert of Insert of the Insert of the Insert of the Insert of Insert of the Insert of the Insert of the Insert of Insert of Insert of the Insert of the Insert of Insert of Insert of Insert of Insert of Insert of Insert Insert of Insert of Insert of Insert of Insert of Insert of Insert Insert of Insert of Insert of Insert of Insert of Insert of Insert Insert of Insert of Insert of Insert of Insert of Insert of Insert Insert of Insert Insert of Inse

PROVINCE

Chocolate bar battle breaks out

LORONTO (CP) It's a sign of hon ting in the run up to the June 8 Ontario election — they're lighting over choco-Jate bars

Local Conservative candidate Manuaret Mariand fired back atternet entitled AFB/Too En-To fi, she said Harris was ap Wohum Collegate. who exponing the was selling chocolate bars as part

Advance polls open Thursday



It's A Tough Feeling To Beat.

Elantra (TA) ----For those who know they're special. We've created the 1995 Elantra Special Edition. With a host of features including + electronically controlled multi-point fuel injection + front and rear tabilizer bars + power brakes + remote fuel filler door release + variable intermutent windsheld wipers + tinted glass with shade band + full wheel covers + front and rear mud guards + child safety rear door locks • height adjustable front seat belts • dual cup holders and more. This sporty. Special Edition family sedan starts at a very special price. But hurry, this spacious car is ED of nist one-ol-a-kind, it's one of a thousand and time is limited Look out for the Accent Sport and Sonata Special Edition too HYUNDAI

> **Guelph Hyundai** 785 Woodlawn Road West, Guelph 836-7669



ALFRED BADER FINE ARTS

DR. ALFRED BADER

Ø.

ESTABLISHED 1961

June 2, 1995

Mr. Scott Tracey The Guelph Mercury P.O. Box 3604 8-14 Macdonell Street Guelph, Ontario N1H 6P7 Canada

Dear Mr. Tracey:

Isabel and I enjoyed our time together last Sunday and now want to thank you for your interesting article in your Tuesday paper.

The photograph which you took is excellent, and we wonder whether you could possibly send us a couple of prints of that photo.

With many thanks for your help and best regards, I remain,

Yours sincerely,

AB/cw

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 Tri 11/277 0730 Fix 11/277 0700



National Gallery I Canada

Musée des beaux-arts du Canada 380 Sussex Drive P.O. Box 427, Station A Ottawa, Ontario K1N 9N4

29 June 1995

Dr. Alfred Bader c/o Aldrich Chemical Co. P.O. Box 2060 Milwaukee, Wisconsin 53201 U.S.A.

Dear Dr. Bader:

The National Gallery of Canada has invited Mr. Andrea Rothe, Chief Conservator at the J. Paul Getty Museum to visit our collections and present a lecture on his recent restoration of Titian's <u>Venus and Adonis</u>, now considered a fully autograph version of the celebrated <u>poesia</u> in the Prado. Mr. Rothe will lecture at the Gallery on Thursday 27 July at 10:00 am and we would be very pleased if you could join us. The lecture will be held in the small lecture hall, and guests are invited to meet in the Tour Group Lobby at 9:30 a.m. for refreshments.

I do hope that you will be able to attend and I very much look forward to meeting you at this event.

Yours sincerely,

Dr. Colin B. Bailey Chief Curator

RSVP: 998-6929



tional Gallery Mus e dis beaut-irt du Canada 500 < ... 9507 R. 45×25 111 POSSAL Par avio Not 160 POSTAB WOD Milwaukee, Wisconsin 53201 U.S.A. . c/o Aldrich Chemical Co. P.O. Box 2060 Dr. Alfred Bader





FAX FROM

ALFRED BADER FINE ARTS

Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin 53202 Telephone: 414/277-0730 Fax: 414/277-0709

July 24, 1995

To:DR. COLIN B. BAILEY
Chief Curator, National Gallery of CanadaFax:613/993-4385

Dear Dr. Bailey:

Thank you for your letter of June 29th to Dr. Bader and the invitation contained therein. However, Dr. and Mrs. Bader are in England through the end of the month and will be unable to attend.

Also, may I ask you to update Dr. Bader's address? He has not been with Aldrich Chemical for over two years now. He now has his own gallery, and mail addressed to the gallery at the address above is not delayed in forwarding. Thank you.

Best wishes,

Hery Weiss

Cheryl Weiss Office Manager



July 13, 1995

Dr. Jean Cooley Research Associate Syncrude Canada Ltd. Edmonton Research Center 10120 - 17th Street Edmonton, Alberta Canada T6P 1V8

Dear Dr. Cooley:

Thank you for your letter dated June 26th to Dr. Bader and the lovely photos.

Dr. and Mrs. Bader are in England through the end of the month. He will respond personally upon his return to Milwaukee.

Best wishes,

Cherry Weiss

Cheryl Weiss Office Manager





ALFRED BADER FINE ARTS

DR. ALFRED BADER

ESTABLISHED 1961

August 1, 1995

Ms. Donna MacKinnon Bolster Art Educator, Adult Programs Winnipeg Art Gallery 300 Memorial Blvd. Winnipeg, Manitoba R3C 1V1 Canada

Dear Ms. Bolster:

I am sorry that a long trip to Europe has delayed my responding to your letter of June 22nd.

I realized the financial difficulties in which the Winnipeg Art Gallery finds itself, when you had to pass on showing the Queen's traveling exhibit of Old Masters some years ago.

If matters should ever change, please find enclosed the "menu" of my talks. Of course, I would be happy to give more than just one talk. In Edmonton in April, for instance, I gave five talks in two days, some on art and some on chemistry.

Unfortunately, travel expenses for a couple are quite high, but our living expenses in Winnipeg would be practically nil because we would stay with Isabel's family.

With all good wishes, I remain,

Yours sincerely,

AB/cw

Enclosure

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUI MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709



· ·

- 4 .

June 22, 1995

Dr. Alfred Bader Astor Hotel Suite 622 924 East Juneau Avenue Milwaukee, Wiscons U.S.A. 53202

Dear Dr. Bader

Mr. Mark Bernstein has been in touch with re with re the possibility of your giving a set of a set of gallery about your art collection. The start of Mr. Bernstein that the Gallery would be interested in a talk, but regretably our current restrained fiscal circumstances prevent us from taking on any more protects. With continual cutbacks in public funding, we are struggling to fund existing programs

I promised Mr. Bernstein that I would contact you to 1 out the costs as you see them for you to give a taik Winnipeg. While I regret deeply that the Gallery cannot contibute in any way other than a tree lecture hail, Mr. Bernstein might wish to pursue funding from othe such as the Queen's Alumni Associa

As a Queen's graduate myself (Arts '71), I am well as your fine art collection. I do regret that today's climate prevents the Winnipeg Art Gallery from extending a fully sponsored invitation.

I can be reached at Tel. (204) 786-6641. ext.260 or F

Bunch Coly,

Donna MacKinnon Bolstei Art Educator, Adult Programs





00. 21 07 100 14 20 FAL 204 788 4998

WPG. ART GALLERY



JULIE

MOUERN NA "Paulo

, s*

DR	ALTRED	CAREK	-			
					-	÷.
		4 4 17,		2. 1	w	

FAXE HIM 277 CTLC.

- WINDIF AKI JONEST

MESSAGE

*0

refer Plantal et al.

. "

W MIN WITHING

MY IM RATIN. IN WAS

Section of Automatica

HIGTORIA I

01,11

IN LOW P

For further information about any of these programs, call the Program Line if 775-7297

L' 0001





FAX FROM

DR. ALFRED R. BADER

Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin 53202 Telephone 414-277-0730 Fax No. 414-277-0709

June 22, 1995

To:	Ms. Donna MacKinnon Bolster
	Art Educator, Adult Programs
Fax:	204/788-4998

From: Cheryl Weiss Office Manager

Dear Ms. Bolster:


Thank you for your fax of today. Dr. Bader is presently traveling in England and the Continent and will not be returning to Milwaukee until the end of July.

Your letter does not include any time frame for the talk. If your anticipated calendar requires an answer prior to Dr. Bader's return, I can forward your letter to his home in England. Otherwise, he has requested that less urgent matters await his return. Please advise if you would like me to forward this invitation to him. If I do not hear from you, Dr. Bader will reply after he returns to Milwaukee. Thank you.


Best wishes,

hery Meiza

Cheryl Weiss Office Manager



The state of the s and the second states and the states of the second second states of the second se THING WILL TUR WE AND -----一日一 "第一一一一一里的那个不能够不了,不过这一一面,不可能的有些不能不能不能。" · · · · 141 1411 77 141 141 - E - H - E -



• • •

WELL AND HALFEY

: Jin 22. 1995

10: Ms Cnery! Weiss

From: Donna Markinnon Boirte


V.

I do appreciate receiving voit 1 to a plast. As in possible date for a talk of it will a start of structure discussed. I would suggest that if a start of property to him to respond to my Fax them. Fix for all the End of the T will look forward to heatles from 7 and that time.

Troop with

Donna MacKinner Bolster Art Educator, Adult Prog





00 22 95 197 PT IS LSV 201 TVS 1 VS

FAX WINNIPEGARTGAN Impling People In The View of Stra KOMEMCRIAL BOX. - - -

FAX #

RE DET ALL ALLEMANNESS

MESSAGE

NUMBER OF STREET, STRE

d () + [** + 1.][].



W001

For further information about any of these programs, call the Program Lit

1001



A Chemist Helping Chemists

August 2, 1995

Dr. Jean Cooley Research Associate Syncrude Canada Ltd. Edmonton Research Center 10120 - 17th Street Edmonton, Alberta T6P 1V8 Canada

Dear Dr. Cooley:

Please don't mind that a long trip to Europe has delayed my thanking you for your gracious letter of June 26th and those fun photographs.


I must have told you before, but Isabel and I cannot remember our ever being treated with greater care than we were in Edmonton. And of course, much of that care came from you.

Perhaps three or four years from now, you might like to ask us to Edmonton again to give another series of lectures.

With all good wishes, I remain,

Yours sincerely,

AB/cw



75th CSC Conference Lecture Series

June 26, 1995

Dear Dr. and Mrs. Bader

On behalf of the 75th CSC Conference Lectures I want to again thank you again for coming to Edmonton as our 75th CSC Conference speaker. You managed to bring together the chemical, art and religious communities in Edmonton through your series of talks. I personally enjoyed meeting both of you. It was a pleasure to put together the schedule for your visit. While it might have appeared as if I did all the work I must acknowledge that I had lots of assistance from many others.

I now have the prints from the photos which my colleague, Bob Hall, took. I've enclosed a set for you. I hope they will bring back happy memories of your visit. We often discuss parts of your talks. In particular it was almost as if we are in the lecture room when we read the article in Chemistry in Britain on Josef Loschmidt.

I am sorry that you had some difficulties when returning to the US. That week I tried to go to my home in Halifax flying with a Canadian air line. Unfortunately it took a day and a half because there was too much fog in Halifax to land on the first day (although we were within a few feet of the runway). However, we must accept some delays to ensure our safety.

Last week I received a copy of your book which Anne Alper arranged for both of you to sign. I am looking forward to many hours of enjoyable reading.

I hope you will again come to Edmonton. Your visit was certainly a high point for the local CIC section.

With best wishes to both of you for an enjoyable summer.

Sincerely,

Jean covery





ALFRED BADER FINE ARTS

DR. ALFRED BADER

ESTABLISHED 1961

August 8, 1995

Ms. Moira Minke Vice-Chair, Seat Endowment Committee The Guelph Centre 147 Wyndham Street North, Suite 404 Guelph, Ontario N1H 4E9 Canada

Dear Ms. Minke:

Just a note to thank you for your letter of August 2nd telling me about your exciting project to build a Guelph Civic Centre. It is good to know that both governments are helping so substantially, and I have little doubt that you will be successful.

As you will be able to imagine, we are asked many times, sometimes several times a day, to contribute to all sorts of worthy causes, and we want to concentrate our help where it can really make a difference.

I do hope that you will understand.


With all good wishes, I remain,

Yours sincerely,


AB/cw

bc: Florence Campbell

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAL AVENUL MILWAUKEE WISCONSIN USA 53201 TEL 414 277-0780 Fax 414 277-07



THE GUELPH CENTRE



147 WYNDHAM STREET N., SUITE 404 GUELPH, ONTARIO NIH 4E9 (519) 763-3232

Honorary Patron The Honourable H.N.R. Jackman Lieutenant Governor of Ontario

Advisory Board Hon. Lincoln Alexander Louis Applebaum Peter Appleyard John E. Birnbaum Doug Bridge Brenda Chamberlain MP John Counsell Ken Danby Arnold Edinborough Derek Fletcher MPP Maureen Forrester Celia Franca Bill Glassco Nicholas Goldschmidt

Margaret MacKinnon Chair. Citizens' Committee Vice-chair

Campaign Team John Akin Dr. Bob Aldis Betsy Allen Ida Baggio Cliff Barker Sharon Bayne Ross Beatty Doug Bennett Jane Caspers Dick Chaloner Nancy Coates Mary Cocivera Terry Crowley Ross Davidson-Pilon Ralph Dent Phillip Desjardins Bob Dewhirst Carol Ann Douglas Terry Doyle Don Drone Dale Ellis Eleanor Ewing Ken Fisher Jeanne Forsythe Doug Gamsby Dennis Grimm Marilyn Gifford Peter Gifford Anne Godfrey Wayne Hepburn Monte Hewson Paul Holland John Hurst Kelly Janzen Ginty Jocius Lorie Jocius Dr. Lawrie Jones Nick Kaethler Joanna Kendall **Ric Knowles** Carol Koenig Frances Marciniak Clara Marett

Ken Hammill Edith Kidd Joseph Macerollo Hon. Pauline McGibbon Frederick T. Metcalf Fred Mills Paul D. Mitchell Walter Pitman Imelda Gazzola-Porcellato Dr. Mordechai Rozanski Dr. Brian Segal Ion Vickers Hon, William Winegard

Anne Godfrey

Anne MacKav Murdo MacKinnon Earl MacNaughton Pat McCraw Mike McDonald **Bill McKie** Kay McKie Gillian McPherson **Bill McTaggart** Moira Minke Gary Nadalin Judith Nasby Robin-Lee Norris Paul Ord David Pady Sandra Pady Ross Pauli Jim Pleva Vladimir Rasper Sharon Rice Grant Robinson Joyce Robinson Pat St. John Susan St. John Jim Schroder Lourene Scott Dr. Ranjit Singh Brian Skerrett **Rosemary Smith** Sam Sorbara Sally Stelter Jim Stevens Blair Stewart Geoffrey Sumner-Smith George Todd Paul Truex Fred Vaughan Dr. Peter Vaughan Frank Vigor Bob Watt Charlie Whittaker Beatrice Youngman

Douglas Bridge, Campaign Chair Sally Wismer, Office Manager Markham Wismer, Office Assistant Dr. Alfred Bader Alfred Bader fine Arts Gallery Suite 622, Astor Hotel 924 East Juneau Avenue

> Milwaukee, Wisconsin USA 53202

Dear Dr. Bader:

It was interesting to read about your philanthropic support to Canada - to Queen's University where you once studied. Your gesture is exemplary and one which will benefit Canada and our students. Further, the donation of personal art will indeed enrich not only Queen's, but also the Canadian art world.

I would like to familiarise you with a project that will build a new civic cultural and conference centre in Guelph.

The Guelph Civic Centre will be a community facility for meetings, conference, concerts and public ceremonies. Located in the heart of downtown Guelph, the centre will house an 800-seat concert hall, a 250-seat theatre, a 350-seat conference and reception hall in addition to meeting spaces for local groups.

Moriyama & Teshima Architects of Toronto have designed a building that is sensitive its riverside environment. ARTEC acoustical consultants of New York have ensured that the concert hall "sings".

The City of Guelph is contributing \$4.67 million of the \$13.67 million cost of construction. The Provincial and Federal Governments have each confirmed \$2 million of the cost. To date companies, foundations and corporations have committed \$3.7 million of the remaining \$5 million public fundraising campaign.

One focus of our campaign involves the endowment of seats in the Guelph Civic Centre. A contribution of \$1,000 (payable over three years) allows you to have an inscribed plaque placed on a seat in either the concert hall or the theatre. The naming of seats is an excellent way to recognize a family member or loved one in perpetuity.

August 2, 1995



Guelph City Council has given final approval to proceed with construction immediately. Building should commence in mid-August with the doors opening by Spring 1997.

I look forward to speaking with you further about this exciting community project.


Sincerely,

· · · · ·

AL. Thile

Moira Minke Vice-chair Seat Endowment Committee

MM/m letters#3/bader.let



A Chemist Helping Chemists

August 28, 1995

Dr. Maurice Yeates 717 Bay Street, Suite PH-07 Toronto, Ontario M5G 2J9 Canada

Dear Maurice:

Thank you so much for sending me Sandra Martin's article in *The Globe and Mail* about my book. She is the writer who stated in her Saturday night article that David Smith inquired whether he couldn't have the money instead of the castle!

Of course, I am not a writer, and I was very aware of the fact that the book has many, many details that will bore the majority of readers. But I wanted it to be both a chronicle of the fine chemicals business between 1950 and 1990 and of the major paintings that I hope will come to Queen's.

At least she did spell my name correctly! But she might at least have commented on how wonderfully well-written David Smith's introduction is.

And your quotation from Byron is wonderful, as well.

With all good wishes from house to house, I remain,

Yours sincerely,

AB/cw

bc: Professor David Smith Mr. Jeffrey Simmons



A Chemist Helping Chemists September 26, 1995

Dr. Leo Klag 5781 McAlear Avenue Montreal, Quebec H4W 2H3 Canada

Dear Leo:


Thank you for your New Year's wishes, which Isabel and I reciprocate.

Unfortunately, there is not much chance that we will come to Montreal in the near future. But do keep in mind that the distance from Milwaukee to Montreal is the same as that from Montreal to Milwaukee, and we would love to see you in Milwaukee.

With all good wishes, I remain,


Yours sincerely,


AB/cw




00 to be then the by code one Heard a rough brace last 1/2 + his wife 'i veril to vis, I the Nussbaume never resident about you. It was walled family are all in lood health Just Tweeks age one of love Ile auxNoix confrares am ruives hard on son)hope that you a with you? S. p. 1. 20/9, it Karuat, Gash Israel farmer pert Leing . tovis, twith us. He asked 1)ear Hilbedi-

and your loved ones in the coming year. and happiness Wishing you peace, health





-111



Dr. Alfred Bader 2961 North Shepard Avenue Milwaukee, Wisconsin 53211

A Chemist Helping Chemists

September 28, 1995

wo gregill

Dr. Jesse Ng Department of Chemistry McGill University 801 Sherbrooke Street West Montreal, PQ H3A 2K6 Canada

Dear Dr. Ng:


Queen's University has told me that you might like to be in touch with me.

With all good wishes, I remain,

Yours sincerely,

AB/cw

Ofc.Ph.: 414/277-0730 Ofc.Fax: 414/277-0709



Jesse Ng, 02:45 PM 9/8/95 , Bader's address

Date: Fri, 08 Sep 1995 14:45:22 EDT From: Jesse Ng <CHJN@MUSICA.MCGILL.CA> To: <records@post.QueensU.CA> Subject: Bader's address

Hi,

I would like to write to Dr. Alfred Bader and wonder if you could send me his home address.

Thank you.

Jesse Ng (#2147119) Department of Chemistry McGill University

September 20/95


Dr. Bader,

The above is for your information. We have informed Ms. Ng that it is not our policy to disclose addresses, but that we would pass her request along to you.

Sharon Steiler)

Department of Development

1



P.O. Box 519, Merrichville, Ort., KOGE INO Octover Site, 1995

Dr. Alfred Boder, Suite 622, Astar Hotel, 924 East Juneau Ave., Milwaukee, Wis, 33202 Dear Fleped: of your letter. dated May 31st. at least to get fact I that, being retired Dide not wrsit the otto of Maass chemistry Building on a daily basis. The information, which you provided willem W. Van & Veiet, is much ap-preciated. Without your help Spiculty. With revewed thanks and best urshes,) remain

Sincerely yours, Robert V. V. Micholles





Dr. Alfred Bader 924 East Juneau, Suite 622 Milwaukee, Wisconsin 53202 Phone: 414/277-0730 Fax: 414/277-0709

A Chemist Helping Chemists

October 11, 1995

Major I.C.J. Boxer 194 Lawrence Avenue East Toronto, Ont. M4N 1T1 Canada

Dear Major Boxer:

One fall-out - quite unexpected - of writing a book is that the writer receives delightful letters, such as yours of September 14th.

I am thankful that you bought two copies of the book before that damning review in the *Toronto* Globe & Mail appeared. If you had seen that first, you might not have bought even one!

It would be delightful if we could meet personally, and I could learn more about your fascinating life. We come to Toronto once or twice a year, and Isabel is loyal graduate of Victoria University, which just bestowed upon her an honorary Doctor of Sacred Letters. You might be interested in her convocation address, and so I enclose a copy.

We plan to be in Toronto for a couple of days from the 18th to the 20th of this month, staying at the Chelsea Inn. We are arriving on the Wednesday morning and I plan to spend some of Wednesday afternoon visiting old friends in the Chemistry Department at the University of Toronto. Then we have two meetings, on Thursday afternoon and Friday morning, one with an Ontario Minister and the other with a Federal Government Minister to try and persuade them to help Queen's with funding of an art museum. But if you should be free, it would be great if we could meet for a little while. If not next week, then perhaps on one of our next visits.

With all good wishes, I remain,

Yours sincerely,

AB/cw Enclosure



ar fetried, int I myed then that Ruffell was missie a Wohel Lawrede. He andmored "The fact That I can defacate twice daily? It may he hisaunly abode and no bui ban prove the wing! iswere of the above mendined blessing/statement. flexe is withing you and you's a such that I'l yer will observe that the English text - deel not contain any words in brailets. The omission is "NOT EVEN ONE HOUR". Fin preyer board wind " The Prime B. Bigh he and Si Vicher departed to their . W & share you suchnessed independent *) hy muttales are semewhat well - Winnipes to obtain a copy of Dimbhy " tild on occapion they get body." if I and pullic libraries had to go to how thing by They year and all the viry help. " rechance lightle lone graves ago when he was shell receive and a latter coltan of him thy is but outer according the state in the merican and how The reason for wang this sheer is your quate tan que him the great sat faction of his life. hos lien receased now achie sewice, eight years. I risilie in the hay, furtherength Hents. He was influermented of it all on one page in he beginning of the back , an the time , in a liggestry, Ryfell was asked when ister and I former the coyal Engineers wine on Trado so did lightin brow thay and here or are JOHN BOXER AVE EAST 194 LAWRENCE AVE EAST TORM 10 - NT MIAN 111 b) I gave it to a Relyticity minister , in Circu when in to the QMC tie I had on new you autoacces may College, Kondon Minisfily (you referred to Have and I impred your ledwinkers . your graphed to Pres for to mod lack Synahron Reaction a word about Rincipia mathematica or hing is therein wide, in second capit's low your in contacting your his Whistlew also one for ef. good self here treen and my alma maked was Sep 14 195 hair il saile

trus de emistil

MY DEAR TIMOTHY

An Autobiographical Letter to his Grandson

by

VICTOR GOLLANCZ

But in the Authorised Daily Prayer Book of the United Hebrew Congregations of the British Empire you will find something very interesting on page four, almost immediately after the beginning of the carly morning service. A magnificat has been recited; the spirit and body have been commended to God at the dawning of the day; and thanks have been given for the commandment that we should sanctify ourselves by washing our hands. Then comes the following: "Blessed art thou, O Lord our God, King of the universe, who hast formed man in wisdom, and created in him many orifices and vessels. It is revealed and known before the throne of thy glory, that if one of these be opened, or one of those be closed, it would be impossible to exist and to stand before thee. Blessed art thou, O Lord, who healest all flesh and doest wondrously." The reference is to the processes of urination and evacuation. A religion that regards these processes as to be religiously rejoiced in is an integral religion. תפלת שחרית **ורד אַתָּה יְהוֹה אֶלהִינוּ מֵלֶך הָעוֹלָם אֲשֶׁר יְצֵׁר אֶת הָאָרָם** בּחְכַמָּה וּבְרָא בו נְקָבִים נָקָבִים הַתּוּלִים הַתּוּלִים גָּלִי וְיְדְיּעַ כְּפְגִי בְפָא בְבוֹרֶך שָׁאָם יְפְּתְחַ אֶזִי מְהָי וְיִייִים אָחָר מַהֶם או יְפָתִם אָחָרוּ צַּרְוּך אַתְה יְהוֶה רוֹפָא בְכֹ בָּשָׁר וֹמַהְכִּיא כַּעֲשוֹת 11 **14 HENRIETTA STREET COVENT GARDEN** 1952 V. WINNIPE

This Librer i May and Riveron President & Forguier time tox his to Australia he was 3 h, yah. the has been S times about the world. Pople Line was brow in Drouts 1957. Tust (his father Civil). His home mellower. This Father 7 times. *) this mithen 10 times We used to get the hew apold surfaces country stage. We were married 1956 (Sovaprik) In these days Flora and I still in inverse the der the resserved program. Robert Brownang hes it poen "CARD 16% EZRA " The trens letter of the predented in 120 Seconds" The criters showing to be genes that! still do prese forday in the Parih's *1 2. 5 MADANI I'M & JAN AGLE WAS I EIRE Schurday Globe and mail. 1 5AW 5-34 Clear rot det. hay one weeks

Major I.C.J. Boxer, 5 Parkwood Avenue, Toronto, Ontario, Canada.

May 24th 1955

Queries Editor, New York Times Book Section, Times Building, 229 West 43rd Street, New York City 36, N.Y., U. S. A.

> Re:- W.B.'s Request for Palindromes, New York Times Book Section, Sunday May 22nd 1955.

Dear Sir,

Your reader W.B. is interested in Palindromes. Will one in Hebrew dating back some eight centuries be a useful addition to his collection? The following, which is attributed to Ibn Ezra (1092-1167), was written in a form of a letter to his family after a prolonged absence from his home:

דעו מאביכם פילא בוש אבוש שוב אשוב אליכם כי בא מועד.

This may be translated, somewhat crudely, as follows:

"From your father be advised -I will no longer tarry, I will return in all hurry, Comes the appointed day, No longer will I stay away."

In reading the above palindrome backwards the uninitiated should note that letter 20 (equal 'M') takes the form of \square when occuring at the end of a word.

Ibn Ezra used palindromes and numerous similar odd codes and devices in his voluminous research works in the fields of philosophy, mathematics, astronomy, travels, biblical commentaries and interpretations, etc. He also employed them while in low spirits resulted from his contemplations of the behaviour of his fellow creatures, which, in turn, led to his pessimistic views about the outlook of the future of mankind.

Very truly yours,

3494 Jeanne Mance St., apt. 606 Montreal, Quebec H2X 2K1

October 11, 1995

Dr. Alfred Bader 2961 North Shepard Avenue Milwaukee, Wisconsin USA 53211

Dear Dr. Bader:

After 3 years of job searching in the area of Montreal and Ontario, I am writing this letter to solicit your help in finding employment. It seems to me that a good way to access the hidden job market (80% of jobs are not advertised) is to contact people like you who might have job leads. From your numerous contacts in North America, perhaps you know of companies who may be looking for someone with my background. It is difficult for you to help someone you do not know; so, I have included a list of my referees should you wish to contact them. You may also contact Profs. John Stone (613-545-2624), Bob Gordon (613-545-2651) and Gary Van Loon (613-545-2633) (Chemistry) at Queen's. Originally from Mauritius, I came to Canada in 1981 on a student's visa, and became a Canadian citizen on Sept. 28. I can now travel in North America easier than before, so that relocation would not be a problem.

I have enclosed my curriculum vitae with this letter. Although an inorganic chemist by training, I have a solid experience in organic synthesis, and I have worked on projects in wide-ranging fields. For example, I have synthesised polysilanes (titanium catalysts), studied the hydrogenation of arenes (cobalt catalysts), synthesised antihypertension drugs and designed antidiabetic agents (vanadium compounds). However, my strength lies in my multidisciplinary background which I have exploited to provide assistance to researchers in other disciplines for 3 years (Medicine and Pharmacology) through bimonthly reports and group meetings. I also have experience in reviewing technical documentation (English and French) from proofreading other students' theses.

I have excellent organisational skills and I am a good leader who knows how to motivate people. With my background, I feel I can contribute effectively in the following areas: fine chemicals, petrochemicals, pharmaceuticals (e.g., metal ions in medicine), metal extraction and as a technical writer.

Thank you for your help.


Looking forward to your reply,

Yours sincerely,

Jesse Ng

Encl.

P.S. Please note that I am no longer at McGill as my contract ended on September 30th.



Jesse Ng


3494 Jeanne Mance Street, Apt. 606 Montreal, Quebec Canada H2X 2K1 Tel: (514) 284-4450

PERSONAL DATA

Multidisciplinary background (Inorganic, Organic and Physical Chemistry). Perfectly bilingual (French and English). Coordinated the operation of a research laboratory at McGill University for 4 years, as resident troubleshooter and as resource person to graduate stiudents. Member of the ORDRE DES CHIMISTES DU QUÉBEC.

EMPLOYMENT HISTORY

January 1995 to	Post-doctoral fellow, MCGILL UNIVERSITY, Montreal, Quebec
present	 Synthesis of polysilanes using titanocene catalysts (with Prof. John Harrod). Assessment of their properties as liquid crystals. Directed the research projects of graduate students.
July 1991 to December 1994	 Collaborated with Prof. Alan Shaver (Chemistry) and Dr. Barry Posner (Medicine) in the design and synthesis of peroxovanadium compounds for use as antidiabetic agents. Worked with Dr. Dusica Maysinger (Pharmacology) towards encapsulating the compounds for oral administration. Coordinated and directed the research programmes of graduate and honours students. Organized weekly seminars for Drs. Shaver's and Harrod's groups.
September 1993 to present	 Instructor, DAWSON COLLEGE, Montreal, Quebec Taught: (i) Organic Chemistry to students in Chemical Technology, and (ii) General Chemistry. Taught a Chemical Technology laboratory where students worked on various projects such as: analyses of vegetable oils and gasoline by GC, perfumes by GC-mass spectroscopy, heavy metals in water by atomic absorption spectroscopy and rate of esterification by titration. Also taught students the identification of organic compounds by qualitative analysis and by spectroscopic techniques.
September 1990 to December 1990	 Research Scientist, CIBA-GEIGY, Basel, Switzerland Worked in the Pharmaceutical Research Division (with Dr. Jürgen Maibaum) as member of a team involved in the synthesis of anti-hypertension agents. Synthesised indole, pyrrole, quinazoline and succinimide derivatives.




September 1986 to April 1990	Teaching Assistant, UNIVERSITY OF BRITISH COLUMBIA, Vancouver, B. C.							
	Supervised laboratory experiments in Organic Chemistry.							
September 1985 to	Teaching Assistant, QUEEN'S UNIVERSITY, Kingston, Ontario							
April 1986	• Supervised laboratory experiments in General Chemistry; conducted regular tutorials.							
EDUCATIONAL BACK	GROUND							
September 1986 to	Ph.D. (Inorganic Chemistry), UNIVERSITY OF BRITISH COLUMBIA							
August 1990	 Mono- and binuclear cobalt hydrides (with Prof. Michael Fryzuk): studied the homogeneous hydrogenation of arenes using cobalt phosphine complexes as catalyst precursors. Synthesis of phosphines and aromatic substrates. Directed the work of summer students in 1987, 1988 and 1990. 							
May 1985 to May 1986	M.Sc. (Physical Chemistry), QUEEN'S UNIVERSITY							
	• Raman spectroscopy of aqueous acetic acid solutions (with Prof. Herbert Shurvell): Spectral deconvolution of band envelope. Calculation of equilibrium constants.							
September 1981 to April 1985	B.Sc. (Honours, Chemistry), First Class, QUEEN'S UNIVERSITY							
AWARDS								

1985 to 1986	Tuition Bursary, Queen's University
1985 to 1986	Queen's University Graduate Fellowship

EXTRACURRICULAR ACTIVITIES

- Avid tennis player; active participant in the Chemistry Tennis Ladder at McGill.
- Organized and participated in softball games with the Chemistry department at McGill.
- Enjoy volleyball (starter on high school's team for four years).
- Safety Officer of my research laboratory at McGill. Ensured that proper safety guidelines are adhered to by members of my laboratory.
- Proofread 17 Ph. D. and M. Sc. theses (and counting) while at McGill and at UBC.
- Student representative on the Safety Committee in the Chemistry department at UBC for 3 years; duties included regular inspections of other research laboratories, submitting written reports as well as voicing students' concerns to the Committee.
- Volunteered at the University Hospital (UBC); helped in coordinating the activities of elderly patients in the Acute and Extended Care units.
- Volunteered at the Information & Counselling Centre and at the Language Bank of the International House at UBC.

References Available Upon Request



PUBLICATIONS

- 9. *Mol. Cell Biochem*, **1995**; with A. Shaver, D. A. Hall and B. I. Posner (in press). "The chemistry of vanadium compounds relevant to insulin mimesis."
- 8. Inorg. Chim. Acta 1995, 229, 253-260; (special issue in honour of F. A. Cotton's 65th birthday); with A. Shaver, D. A. Hall, A. -M. Lebuis, R. C. Hynes and B. I. Posner. "Bisperoxovanadium compounds: synthesis and reactivity of some insulin-mimetic complexes."
- Acta Cryst. Commun. 1994, C50, 1044-1046; with A. Shaver, R. C. Hynes and B. I. Posner. "Potassium (N¹, N¹⁰-5-nitro-1,10-phenanthroline)oxodiperoxovanadate(V) dihydrate, an insulin-mimetic peroxovanadate."
- J. Biol. Chem. 1994, 269, 4596-4604; with B. I. Posner, J. W. Burgess, R. Faure, A. P. Bevan, D. Lachance, G. Zhang-Sun, I. G. Fantus, A. Shaver, D. A. Hall and B. Soo Lum (see also: Borman, S. Chem. Eng. News 1994, 72(8), 35). "Peroxovanadium compounds: a new class of potent phosphotyrosine phosphatase inhibitors which are insulin mimetics."
- 5. Inorg. Chem. 1993, 32, 3109-3113; with A. Shaver, D. A. Hall, B. Soo Lum and B. I. Posner. "Insulinmimetic peroxovanadium complexes: preparation and structure of potassium oxodiperoxo(pyridine-2carboxylato)vanadate(V), K2[VO(O2)2(C5H4NCOO)]•2H2O, and potassium oxodiperoxo(3hydroxypyridine-2-carboxylato)vanadate(V), K3[VO(O2)2(OHC5H3NCOO)]•3H2O and their reaction with cysteine."
- 4. Inorg. Chem. 1991, 30, 2437-2441; with M. D. Fryzuk, S. J. Rettig, J. C. Huffman and K. Jonas. "Nature of the catalytically inactive cobalt hydride formed upon hydrogenation of aromatic substrates. Structure and characterization of the binuclear cobalt hydride [{Prⁱ₂P(CH₂)₃PPr^{i₂}}Co]₂(H)(μ-H)₃."
- Can. J. Chem. 1988, 66, 1912-1918; (special issue in honour of C. A. McDowell's 70th birthday); with B. U. Petelenz and H. F. Shurvell. "The complementary use of factor analysis and spectral deconvolution in a study of the CD₃COOD-D₂O system."
- 2. J. Phys. Chem. 1987, 91, 496-500; with H. F. Shurvell. "The application of factor analysis and band resolution techniques to the Raman spectra of acetic acid in aqueous solution."
- 1. Can. J. Spectrosc. 1985, 30, 149-152; with H. F. Shurvell. "A study of the self-association of acetic acid in aqueous solution using Raman spectroscopy."



REFERENCES

Prof. Alan G. Shaver, Dean of Science

Department of Chemistry McGill University 801 Sherbrooke Street West Montreal, Quebec Canada H3A 2K6 Tel: (514) 398-6237 or 398-4211 (Dean's office) Fax: (514) 398-3797 shaver@omc.lan.mcgill.ca

Prof. Michael D. Fryzuk

Department of Chemistry University of British Columbia 2036 Main Mall Vancouver, B. C. Canada V6T 1Z1 Tel: (604) 822-2897 Fax: (604) 822-2847 fryzuk@unixg.ubc.ca

Prof. John F. Harrod

Department of Chemistry McGill University 801 Sherbrooke Street West Montreal, Quebec Canada H3A 2K6 Tel: (514) 398-6911 Fax: (514) 398-3797 harrod@omc.lan.mcgill.ca

Prof. Herbert F. Shurvell

Department of Chemistry Queen's University Kingston, Ontario Canada K7L 3N6 Tel: (613) 545-2646 Fax: (613) 545-6669 shurvell@queensu.ca



· j · k ,

in all

· ICF-CHANGELLOR

MICO DAUCI III MORE AN AN III F.351 JUDCALAN

N 1. . . .

Enclosed is the most recent draft of your schedule retriction of the science of a forwarding to you a letter from Mac. 6 beauter of the science of Appreciation from the contract of the former of the

There also has been a change in the time of your in during with in patrick and letober 19. It is now scheduled for 9:00 a m. Octor at 19. Unit admiterestand this was necessary to accommodate other in the unone this down it pose a problem for you and Isal in the patrick. In an interest we have be rescheduled. Perhaps you would domitere the unit be rescheduled. Perhaps you would domitere the unit before. Both Florence at 1000 and the interest has suggested that is only one would domitere the units of the suggested that is only one would be the units.

Both Mellssa Kluger and Jenniter Baranda and the second se



QUEENS PRINCIPAL

→→→ BADER

You had asked about your bool sales here 2.5 and a subject of the second sales and book signific.

Included with the schedule are biographical notes on William Saunders withur Eggleton for your meetings or October 19 and 30 respectivel

Finally, bruce Buchan informs me that the book "Strategic Management is e case on Sigma-Aldrich is not vet in print. Bruce had hoped to have a copy for a sigwhen you arrive but he expects now that copies won't be available until November

At this particle to the terms of the transmission of the hange at your methods but von mever know in will be in touch in the enables. Please contain memory ou rave any directions or wish any scheduling adjustments.

 Cathy has been trying unsuccessfully to reach Marion Dick to see if we can to the help to her on the day of Marion's arrival at Summerhill. She will control.



Revised: October 12, 1¹¹

	2.00
	-
··· / ···	
_*	
CHEDH CHEDH	-
-	
er	
	11 12 13
	1

(S1111)		M.Tavish váll contact Bader	Will include David McTavis Prime A report			Will include David McTavish and Margo Burdha		4 Alumia we exerted tragilights routy. See detail ou Alumin						1 Resultand that is in "	ing a scrathered ing ing ing ing ing ing ing ing ing ing
W 64	a second second	t Tarlsea Inn	ath Phr 000 Bay Street	v. ju Jaconter	· · · · · · · · · · · · · · · · · · ·	95 Wellington Street West Suite L/02	- In	R. d Em Room reserved by Joinne Office)	Roliday Inc.	H. I uas Ibo	to at the second se	the second s	Wallace Hall, It a	de nord of Cleder	
10000		1	bill Samaletsion. Menotical and an analogo increasion of a solution of a	Interview with Prinche Michael and Solar Solar Solar	- David McTavish with meet Boders prior to meet Evidence on	Arr Eggs to market the state of the state	Violandos Lumousure Service Corck, p. P. der	Arrive Holistev Ita	Classed 45 Registration and 1	Ser 45 Reception and Class Dimon. 6 Just 1: 44 diment	Puricipal's Cerieth	I that game Off. s	The particular and the second s	10 H (
11/11					, ter ,				16 d (0) f - co	and graphics	× 10,2 ×		1	1 1 1 1 1	· ·
11/11	1	,	1					Urbish wes	-						

100 g

→→→ BVDEK

Contraction and the contraction of the contraction



	INCE VAR NOSTATE WILL AND		 i to and it Street, Cathy to artistig 	Bouis Castel will escort Baders	 contact Parce Parce of the phone: 531-4399 Mericoa Morger a Lourte di Bartin en haize baer trivot di Note. Melissa is on the Hillel freecutive and met Dr. Bade in fast year's Hillel meetung auth frim. Taxi return 	Principal will escort Baders to	Contact. Bradie Bode	there is a straight the second				0 - 121-01-12 	10.0	Rener v. 18 v. 18 neurosary
		E.F. A.	MeTawih h	Levil .	Eddish Flous	Personal	North	incretall	Will West		Lisan Kul			
BADER VEST			former with Bayed & Anodals	interview with Biggs Association and the	Meet work 11 Fed ment	Rill Legert fidhwed by Terrie 181 to a		Legents to first root to	received a state the second and second and with Mive	Branch Marthard Aler David and Aler	nth Mateutry Veat	Line has the		
		1 Y I I I I I I I I I I I I I I I I I I	- 1 - I		-			н () () () () () () () () () () () () ()	1. 11. 12. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	1.1				:
			t inger 1	No to			((- AM				1		Len



•		4. 	and first	Dr. Brown will mort bhaers		· · ·		and the Marine of		1. • • • 1 • • • • • •	1	Please	rle	could you you in al	· is Ore	Land Part
,	-	9) - 101 - 101	K ir at. Tarkgan fet	1.6.4 4.6.6. 1. 1	1	Truch to			· · · · · ·	· · · · · · · · · · · · · · · · · · ·	· · ·	name De Ellis	Notel ung reheaule	e yoir un	huil ac 5	. hoperna
			Provide the second seco	d have supported as the set of the set				-		Press of a second se		J cou	with the Notel W	Could z	Jumme	and no
reluin				4 A.			-		4 E 72							
+ lease	-		We (11 %)							V			- HI			



10/12/95 THU 15:38 FAX 613 545 6838

QUEENS PRINCIPAL

121006

N WOR

CALUDEL TO IT

d Mrs. Alfred Bader reactines of Richardson Hall reaction Universit Kingston Ontario K7L3N

Fair Dr and Miss Bader


On behalf of Kingston City Council and the citizens of the second and an upcoming City Council Meeting to receive a reliably invite you to attend an upcoming City Council Meeting to receive a relificate of Appreciation for your generous donations to Queen's University.

He presentation is planned for October 24, 1995 at 7:30 F.M. in the council chambers, that Half. If this date is inappropriate for you, could you kindly advise this office as soon as possible.

> · ID-92D-1 20 · mm ·

1. 18. 1.

look forward to seeing you on October 24, 199:



10 12/95 THU 15:39 FAX 613 545 6838

QUEENS PRINCIPAL

→→→ BADER





The Honourable Williem Sauodenson

Minister of Economio Development. Tads and Townson

WILL SIT DRUMMARSON WER SUDDING Minister of Faagamic Develop Hent, irade and iourism br June 26 1995 The appointment was 19 members introduced by Premier Mike 1 One of Canada's leading money manage B shut to noticele election of June 8.

Equation, we tour over a ministry with a i ball provincial and federal electrons, we proadened mandate, incorporating the lists served as financial comptrolies to tourism division of the former Ministry of an interview we Conservative Inabonic Culture, Tourism and Recreation. The Clevestion campaigns in 1984 and 1986 new Ministry of Economic Development. Trade and Tourism has a key role to play (Mr. Saunderson served as a member in improving the business climate, creat- i the Unterio Pension Commission and no jobs, stimulating tourism and raising Ontario's economic confidence

said: "I'd like to restore Ontario as the major fundraising can paigns to the province of economic opportunity and University of Ottawa Tommo's the engine of economic growth and Canada He added that he wanted to him to Janada in 1994 the University toster a positive business climate that 1 of Ottawa awarded Mr. Saunderson 😁 would lead to job creation help balance in their successes in vertoprime a the budget, make government less introsive, and out the principles of sound tinancial management into practice in 13 3002 14 the day-to-day affairs of government


Gordon (now Ernst & Young). Keeping . Hameia a child thereo wi

roministik lieht businest eens an evelonitigures helped him bevelop en athic of fiscal prudence that has become one of his defining traits.

1971, he co-founded Scat made as part of a streamlined cabinet or in ovestment Counsel Ltd., which recard marris, whose Procressive Conservative | ment firms. He lett his final position as party formed the government effer win- | vice-president to enter active politins en E a provincial calludate. Mr. Saunderso: : has been involved in politics since 1961 Wir saunderson is the memoe for Eraising funds for candidates in munici-

SIL TO STATE HE HAS BUR BESING THE : work in pusiness politics hurch char-Ettes and amateur sports Amond Upon his appointment, Mr. Saunderson 1 many volunteer contributions handline in Li zabeth mospital Scouts Canad III. engthy career as remarkable for its . anthropy as for its protessional ac

Mr. Saurderson and rus wite. Me. Mr. Saunderson graduated from the ; have three prown children wanted and university of Toronto with a history pediatric an entitling and the begree. He became a chartered account - ident and member of the 1988 - ----tent and worked for the firm Clarkson & Clanacian Ulympic rowing and the



10 12 97 THU 15:39 FAX 613 545 6838

QUEENS PRINCIPAL

→ -- BADER


Blographical Notes on the Honourable Arthur C. Eggleton, P.C., M.P.



Un Eggleton is in his second political career, having been elected to the Pariau enlanada on October 25, 1993, as the member for York Centre in the City of Longer rk (Mercopolitan Toronto). Shortly after that election, Prime Minister seated block sinted him President of the Treasury Board and Minister responsible

arred on the Metropolitan Toronto Police Commission and the Boa arren National Exhibition, as well as numerous commutees and task forces de arren many community issues. Mr. Eggleton has been a member of the Board Ic Federation of Canadian Municipalities, Chairman of its International Progmonittee and Co-Chairman of the National Action Committee on Race Relate

\$1008





A Chemist Helping Chemists

October 30, 1995

Mr. Ron McMillan Manager/Inspector Kingston Humane Society Box 734 Kingston, Ontario K7L 4X6 Canada

Dear Mr. McMillan:

Thank you for your letter of October 19th regarding a contribution to help a larger facility to house your animal shelter.

Yours is, of course, a most worthy cause, but surely one that should be helped mainly by Kingston residents.

As you will be able to imagine, we receive several requests for financial help every day and try very hard to give priority to help people, particularly through Queen's University, which has helped me so much. I do hope that you will understand.

With all good wishes, I remain,

Yours sincerely,



KINGSTON HUMANE SOCIETY Box 734, Kingston, Ontario K7L 4X6 (613) 546-1291

October 19,1995

Mr. and Mrs. Alfred Bader:

t

I have asked Councillor Garry McColman of Kingston Township Council to pass this letter along to you by hand. I sincerely hope that you are not offended with our boldness, but I have been touched over the past few years at the wonderful generosity that both have you have shown toward Queen's University and the City of Kingston.

In 1995, the Board of Directors of The Kingston Humane Society had to make the most difficult decision of our lives, we had to purchase a much larger facility to house our animal shelter. The cost to purchase and renovate the facility is approximately \$500,000. We have our current building for sale and will realize about \$150,000 from the sale of this building.


Given the financial climate of our area these days this task is monumental and we need your help. I have enclosed the names of the key Members of our Board who can be contacted regarding the new shelter.

Thank you again Mr. and Mrs. Bader, you are a blessing to our community.

Yours truly,

Manager/Inspector Kingston Humane Society

P.S. Again, please forgive my boldness, but I am doing this to secure a safe, clean and larger shelter for all of the animals that we must tend to each day!



KINGSTON HUMANE SOCIETY Box 734, Kingston, Ontario K7L 4X6 (613) 546-1291

Manager/Inspector

1

Ron McMillan 231 Dalton Ave. Box 734 Kingston, Ont K7L 4X6 546-1291

Building Director/Past President

Barb Donaldson Joyceville, Ont KOH 1Y0 542-8205


President Kingston Humane Society

Sue Nelson 1046 Redwood Cres. Kingston, Ont K7P 1Y9 389-8091

Treasurer

Paul Mason 9 Wagner St. Glenburnie, Ont KOH 1S0 546-1347

Legal Advisor Black Lloyd Carron & Minnema Mr. D. Carron 247 Brock St. Kingston, Ont K7L 4V8 549-3262





A Chemist Helping Chemists

October 30, 1995

Mrs. Phyllis Mineis 315 Eunice Drive Kingston, Ontario K7M 3M7 Canada

Dear Mrs. Mineis:


In response to your letter, I wish that Isabel and I could help. However, I am 71 and a loan to you and your husband - obviously good people, but people whom we do not know - does not really make good sense. I am likely to die within the next ten years, and surely you will understand how such a loan would complicate my estate.

I am relieved to know that you and your husband are well-employed and have intelligent and well-educated children.

Isabel and I just wish that we could have been in Kingston a little longer and have had a chance to talk to you personally, but unfortunately we couldn't do that.

With all good wishes, I remain,

Yours sincerely,



315 Eunice De, Kingston, Ont., KTIT3M7

Dear Dr. + Mis Bader. I have started letters to you several times in the last year, but I have never sent them to you. I am writing to you today because I know Fou are in Kingston at the agrees Etherington at centre I an writing to you to ask you if you would I consider helping me financially I am a Queen's graduate and my son is in second you Phys. Ed and Science. He plays for the Colden Carls Football tean. My daughter is in 4th year at Trent and will do her education degree next year at Queens. My husband and I have always been well employed and have supported queens in the past. about six years ago we made didn't succeed. We are fighting to keep our head above water, but it tertifies me to be on the retriement side of age fifty and facing enormous debb, If we would borrow two hundred thousand dollars without interest, we



could be out of debt in ten years, I realize this is publicly a most outrageous request and a few years ago I never thought I'd ever be acking for the kind of help. of help. We are not stupid people and we do not waste our money, but we did make a dreadful mistake. If you would lead us the meney at alow interest rate or interest free 1 ful we could pay it all back in ten years. Right now I could pay \$1500 per mente and once the children are onto of selent, I would increase the payment. We could provide you with character references and I have already had a potre check because I work will children. You probably think I am erapy to be asking for your help, but it you would consider it . I would be so grateful.

Yours sencerely, Phyllis Mineis 544 - 4655

Queens No.

068 558-4





A Chemist Helping Chemists

October 31, 1995

Ms. Carol K. Barrett 61 Drennan Street Kingston, Ontario K7K 2S2 Canada

Dear Carol:

Thank you for visiting me twice last week and for giving me your collection of 30 vignettes entitled "Meditations on Blacks, Whites and Other Mysteries" and for allowing me to share this collection with others.

You wrote that you are asking me to help you help yourself, and I can do this only by sort of thinking out aloud.

I have read your collection carefully twice, and I must tell you right off that I am handicapped because I practically never look at television, I have never watched a talk show, and I just don't know who some of the people - for instance, Spike Lee - are.

But I found your vignettes very thought-provoking, and they reminded me very much about how Jews thought in Austria after Hitler marched in in 1938.

Black humor certainly has its place, and only sometime - as perhaps in your vignette #3 - does it go to an extreme that might be hurtful.

I felt the same way about the publication of the Queen's Engineering Society, "The Golden Words", published last week. I found the essay about Jews quite juvenile and silly and some of the jokes about the Pope quite funny. I think that even the Pope would laugh about the possibility of getting a special rate from AT&T to speak to God. But the joke about Pope-style condoms went, I think, beyond the line and must have been quite offensive to believing Catholics.

But back to your vignettes. I must tell you that I share some of your prejudices. I don't think that I ever dated a blond girl: I always identified blond with the Aryan Germanic type. And I was scared of girls with massive cleavages and I want to assure you that there are many men who really much prefer flat-chested girls. When you find the right partner, you will also find that you are cared for for what you are and not your cleavage or your hair. Ms. Carol K. Barrett October 31, 1995 Page 2

You will have realized from your answering machine that I tried to telephone you but then only heard that interesting music on your answering machine.

We were talking past each other when you wrote about being turned down for a loan. I thought that you had been turned down by Queen's University, when in fact, you were turned down by a bank. This doesn't surprise me at all, as banks are not likely to give loans to students who cannot put up ample security.

I understand that you are on an OSAP award for 1995-96 and that you may be receiving an automatic refund on your balance just about now.

May I suggest that you talk to two people at Queen's? One is Ms. Dietlind Fletcher in Financial Services. I understand that you had applied for a Work Bursary, which was declined because the University didn't realize your financial needs. Please do explain this to Dietlind Fletcher.

The other person who might help you is Mrs. Judith Brown, who works at Summerhill West. Mrs. Brown used to teach French and is, I believe, a very caring and helpful person. Mrs. Brown does not work in Financial Services, but I believe that she will want to help you as clearly I would like to help you.

I am sharing your vignettes with Dr. Boris Castel, the editor of the Queen's Quarterly. He will certainly not be in a position to publish the entire collection, but he might be able to advise you and might be able to use a few of the pieces in the Quarterly.

Also, I will share your vignettes with my very able literary agent in London and see what he advises.

Frankly, I don't think that you will find a publisher for your collection who would do so good a job in promoting the work that you would actually get some financial rewards. On the other hand, if some or all of your pieces are published, even without financial reward, you will find that your next works would be accepted more readily.

I don't have to tell you that I believe that you are a very able and challenging writer, and Isabel and I very much hope that we will stay in touch.

With all good wishes, I remain,

Yours sincerely,

Carol Barrett 61 Drennan ST. Kingston, Ontario K7K 2S2

Dear Mr. Bader

1

In my first year, here at Queen's I attended your speech on the importance of an Arts Education. I enjoyed your speech very much and was especially touched by your story about how you came to attend Queen's. You talked about how McGill had turned you down because you were Jewish and how you had been so kind to Queen's because they chose not to discriminate against you. As a person of Colour these issues of racism are especially close to my heart. I have always kept an eye on you since then, from your donation of the Castle to over \$600,000 in aid to Bosnia. I know that you are very kind and this is why I thought of you now that I am needing assistance with a certain matter. I want to warn you before you continue reading that I am not asking for a handout but instead I am asking you to help me to help myself.

I have had a very difficult time this year. There weren't many good summer jobs available this summer and I barely managed to scrape by with a few odd jobs and part time jobs. For this reason I have not been able to save any money towards school. I have a small student loan and I will be starting a Job at CANTEL Canada in a week or so. I have also applied for another loan to tide me over until my paycheques start to come in. Well, you are probably wondering how I need your help.

I am a french major but my real passion is writing. I have written a book of humorous reflections entitled, "Meditations on Blacks, Whites and Other Mysteries". It has gotten excellent reviews from the few people that I have shown it to. I've been told, "You must publish this". I know that the publication of this book will also help me to become financially independent but it is very difficult for a new author to get looked at in the ever competitive world of publishing. There is a subsidy publishing company that would publish my book but that also will cost money which I do not have. If there is any way that you could help me to publish this book I would really appreciated it. I know that you have recently published a book yourself and so you may be able to relate to my situation.

I have enclosed a copy for you. I hope that you will give it a read. I will warn you that it helps if you have a deep dark sense of humour. While you are reading along, you may be wondering why I haven't said anything about Anti-Semitism. That's because I saved that part for the end. It really made a better finish to put my feelings about that at the end but you will see why when you read this book.

I hope to speak with you soon





A Chemist Helping Chemists

November 1, 1995

Mrs. Cathy Perkins Box 165 Wolfe Island, ON K0H 2Y0 Canada

My dear Cathy:

I have just learned about your mother. What can one say, other than to quote Job: The Lord has given, and the Lord has taken away.

Isabel and I loved seeing you at Summerhill even though it was for such a very short time.

Could we perhaps persuade you to spend a long weekend with us here in Milwaukee next winter? We'll be returning from England on December 24th, and there is now a very convenient non-stop Midwest Express flight from Toronto to Milwaukee.

I am afraid that the enclosed photograph will sadden you also, just as it saddened us. But perhaps Monique would like to have it.

With all our love, I remain,

Yours sincerely,



ł



OFFICE OF THE PLINE TAL

FAX IRANAMISSION

lasti to the second 10: I saled and Alfred wars. LAA. DEL S Principal William Leggett : ROM: Bob Burnside Cathy Perkins Lauren Sharpe ··· Jovce Zakos a the third of the p. I survey yesterday. The p. 1. H. Apple of U kaner 2 . the dist & delease the so mare. the expects to be home ... i · · · · · · Number of pages including this cover page

Ø001



A REAL PRINCIPAL OF THE 6838 QUEENS PRINCIPAL

→→→ BADER



Or O DI DIE DETSU 10 A.C.

FAX TRANSMISS

DATE

It and October and I have

2351 North Shepard Avenue With and the vi


in sa Z 414-902 8332

H-HOM: Dianne Smile: Mexili II AND AND PROVINCE STATISTICS

Catholic Press

it with the

In Alter to Pages Set Andres .





A Chemist Helping Chemists

November 2, 1995

Dr. Jesse Ng 3494 Jeanne Mance Montreal, Quebec H2X 2K1 Canada

Dear Dr. Ng:

A long trip to Canada has delayed my thanking you for your letter of October 11th.

As you may know from chapter 13 of my autobiography, *Adventures of a Chemist Collector*, I was ejected from Sigma-Aldrich, but except for the two top men in St. Louis, all the Aldrich people have remained my good friends.

Hence, I have written to Dr. Stephen Branca, who is Vice President in charge of new product development and a very fine chemist. My letter to him will be self-explanatory.

With all good wishes, I remain,

Yours sincerely,





ALFRED BADER FINE ARTS

DR. ALFRED BADER

ESTABLISHED 1961

November 2, 1995

Delta Chelsea Inn 33 Gerrard Street West Toronto, Ontario M5G 1Z4 Canada

Gentlemen:

Our stay at your hotel last Sunday night was really just horrible, as described in the enclosed report.

My wife could not fall asleep until 4:00 am because of that frightening experience just before midnight. She discussed this with your safety people both that night and the next morning.


It seems to me that a refund is in order.

Yours sincerely,

AB/cw

By Appointment Only ASTOR HOTEL SUITE 622 924 EAST JUNEAU AVENUE MILWAUKEE WISCONSIN USA 53202 TEL 414 277-0730 FAX 414 277-0709





		-
	MEMIS VIS VISSANT HLEPED BADER	· City D Nex Pron state by is c
		HY C C about of // letsed
	Iddress Mr N. Shepma	Phone (14 11 - 130 - 11 - 14 14) another
1. Overall, how did our hotel meet your	EXCLEDED MET DO MOT MEET EXPECTATIONS EXPECTATIONS	EXCERDID MET DO NOT MET BACTERIDAS REPETATIONS FABRICIATIONS
Expectations: Expected expectations	7. Room Service	
Wet expectations	od C C	-
X Did not meet expectations	Promptness () () () Anotics () () () () ()	Bell service
2. How did you make your reservation?		S _s) _s)
. > Through 1-800 Central Reservations X Called hole! directly	ounge -	Friendly Nowledgeable
EXCEEDED MET DID NOT MEET		b) If any of our employees were especially
EXPECIATIONS EXPECTATIONS	Direction Lunch O Dinner O Ouality of food	
3. Reservations	Cleanliness of facility	can show them our appreciation.
Friendly	Quality of service	1
Helpful 🔍 🔿 🔿	Value of your meal	14. What is the primary purpose of your stav?
4 Reception	Appresi of decore	X ^p leasure O Business
	9 Restanced (Rev.) amaa	○ Group Meeting/Banquet (
ice of front	- Mondally Dally Louise -	15. How did you come to select this hotel?
	Breakfast Dinnon	C: Attending a conference/convention/banquet O Fam a Dotta Drivitaco mambon
rvice		C 1 and a Detta FIMICge includer C Good location
	Cleanliness of facility O	O I am a member of Delta's Corporate program
3. Guest Koom -	Quality of service	○ Defta s reasonable rates ○ Lam a member of Canadian Dire
Finel immacción	Value of your meal O O O	O Through my travel agency
Cleanliness upon	Abpeal of decor	O Hotel was recommended
arrival	10. Sport/Filness Facilities	
Housekeeping during	Cleantiness C C C C C	S .
Maintenance during vour stay		10 1
Value for the rate	aintenance O	b) If no. why not? Due becow
6. Telephone Service	11. Hotel Facilities Valet/Laundry	c) If no, where would you prefer to stay? A 5AFE HOTEL
Accuracy/bromptness	Parking City Show	18. Arc you a Delta Prívilege Member?
of messages	Business Centre	Della Privilege #
of wake-up calls	0ther 0 0 0 0	on the reverse side.)
「「「「「「」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」」		



A Chemist Helping Chemists

November 8, 1995

The Honorable Gary H. Bennett Mayor, The City of Kingston City Hall Kingston, Ontario K7L 2Z3 Canada

Dear Mayor Bennett:

Please accept Isabel's and my sincere thanks for your and the Council's thoughtfulness in presenting us with the Certificate of Appreciation and the Key of the City of Kingston. We will treasure these.

With all good wishes, I remain,

Yours sincerely,

AB/cw

bc: Florence Campbell





Dr. Alfred Bader 924 East Juneau, Suite 622 Milwaukee, Wisconsin 53202 Phone: 414/277-0730 Fax: 414/277-0709

A Chemist Helping Chemists

November 10, 1995

The Honourable Dr. William Saunderson Minister of Economic Development, Trade & Tourism The Province of Ontario 8th Floor 900 Bay Street Toronto, Ontario M7A 2E1

Dear Dr. Saunderson:

Please accept Isabel's and my sincere thanks for the time which you and Ms. Kelso spent with us on October 19th.

Isabel and I think back to that meeting with such very mixed feelings. Good, one the one hand, because we met you and Ms. Kelso, clearly two thoughtful and caring people, and you, an eminent businessman; sad, because you had to tell us that the Province of Ontario has to renege on its promise to give Queen's University Can.\$3 million to help with the enlargement of the Agnes Etherington Art Centre.

It cannot have been easy for you, and perhaps even more difficult for you to tell us than it was for us to receive the sad news.


May I just impose on you to read a letter which was published by the *Kingston Whig-Standard* last March 18th? That gives, in a few paragraphs, why Isabel and I feel strongly that Ontario has made a mistake to renege on its promise.

Queen's is the most caring university I know, and my feelings about it will not change. I will just be saddened if it will not be able to receive our collection.

With all good wishes to you and Ms. Kelso, I remain,

Yours sincerely,

y. a Roa AB/cw





Dr. Alfred Bader 924 East Juneau, Suite 622 Milwaukee, Wisconsin 53202 Phone: 414/277-0730 Fax: 414/277-0709

A Chemist Helping Chemists

November 10, 1995

The Honourable Herbert Gray Solicitor General of Canada House of Parliament Ottawa, Ontario K1A 0P8 Canada

Dear Herb:

Our dinner with you and Peter Milliken on October 26th was truly one of the highlights of our trip to Canada. Please accept our sincere thanks.


Of course, you must have asked yourself why we would want to urge Ottawa to help Queen's with \$3 million to expand its Agnes Etherington Art Centre, and I hope that we answered your question.

That question has, of course, been asked by others, and I would like to impose on you to read a letter which was published by the *Kingston Whig-Standard* last March 18th. In that, I tried to give the answer.

I sensed both in this meeting and in our previous meeting that you really understand what we are trying to do.

Isabel's and my wills leave everything to the Isabel and Alfred Bader Foundation, which will be run by our youngest son, Daniel. He already runs the Helen Bader Foundation, employing a staff of ten competent people to give away about \$7.5 million (U.S.) annually. Daniel doesn't take a penny's salary and will, we are confident, be able to run the Isabel and Alfred Bader Foundation alongside the Helen Bader Foundation. Of course, he knows how very much we want to help Queen's University.

The latest annual report of the Helen Bader Foundation has just come out, and I enclose a copy.



The Honourable Herbert Gray November 10, 1995 Page 2

On October 30th, Dr. Shirley Thomson, the Director of the National Gallery, and Dr. Michael Pantazzi, the Gallery's Curator of Old Master paintings, visited our collection, together with Professor Volker Manuth, an eminent art historian from Queen's. I am sure that Dr. Thomson's and Dr. Pantazzi's report about our collection will reach you before long.

Herbert, please don't hesitate to let me know if I can answer any further questions.


With all good wishes from Isabel and me, I remain,

Yours sincerely,

ind

AB/cw

Enclosures





Dr. Alfred Bader 924 East Juneau, Suite 622 Milwaukee, Wisconsin 53202 Phone: 414/277-0730 Fax: 414/277-0709

A Chemist Helping Chemists

November 10, 1995

The Honourable Arthur C. Eggleton
President of the Treasury Board and Minister Responsible for Infrastructure
Suite 1702
95 Wellington Street West
Toronto, Ontario M5J 2N7

Dear Mr. Eggleton:

Isabel and I still remember with great pleasure our meeting with you on Friday, October 20th and want to thank you most sincerely for the time you took with us.

Of course, you must have asked yourself, "Why should Ottawa provide Can.\$ 3 million to help Queen's expand its Agnes Etherington Art Centre?" Please allow me to answer that question on two levels.

Last week, on that fateful day in Canadian history, October 30th, Dr. Shirley Thomson, the Director of the National Gallery of Canada, and Dr. Michael Pantazzi, its Curator of Old Master Paintings, visited our collection, with Professor Volker Manuth from Queen's. I expect that Dr. Thomson and Dr. Pantazzi will supply you with a report of their visit.

Beyond that, may I ask you to read my letter, which was published by the *Kingston Whig-Standard* last March 18th? This is in response to that very question, why Ottawa should help the Agnes Etherington Art Centre expansion.

I don't think that Isabel and I can really add anything to that, except to assure you that Queen's is the most caring university we know, and with your and our help, it could become one of the great centers of art and art history, not just in Canada, but in North America.

With all good wishes, I remain,

Yours sincerely,

My. a Baan AB/cw



FROM ! ConnAd Inc. Toronto

ConnAd

FAX NO.: 4167851236

To Cherge

11-13-95 10:43 P.01 276 Melrose Avenue Toronto, Ontario Canada M5M 173

> Vorce: 416.785.9250 Fax. 416.785.1236 E-mail: connad@magic.ca

The gluetos house been pert to Mitwankee & Please peud are

Thank

of the duplication to De. Ted Berefey.

To: Dr. Alfred Bader 924 East Juneau, Suite 622 Milwaukee, Wisconsin 53202 Voice: 414.277.0730 Fax: 414.277.0709 From: Grad Conn Conn Advertising Date: November 13, 1995 Number of pages (including cover): 1

Message:

XX 1 par Jm N. at the Carle It: elevine - he parte has plueter were part

Dear Dr. Bader,

Don Macnamara of the Queen's University International Study Centre passed along your letter of November 1, 1995 regarding the photograph of yourself and Isabel in the cloisters at Herstmonceux.

1 74 95.

My agency is responsible for the production of the latest round of materials for the ISC. The photograph was taken by our photographer. Alex Meyboom. If you could have publications credit him with "© Copyright 1995 Alex Meyboom Photography" he would be greatly appreciative.

Separately, I have made six 4X5 versions of the photograph (as you requested), and some duplicate trannies (for use by <u>publications</u>), which I will pass along to the ISC. If you would like additional photographs, please feel free to contact me directly at fax 416.785.1236 or e-mail *connad@mail.magic ca*)

NOTICE: The messages in this fax transmission are privileged and confidential information intended solely for the use of the individual or entity to whom they are addressed. If the reader of this notice is not the intended addressee, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If this facsimile is received in error, immediately notify us by telephone and destroy the facsimile in whole. Thank you



ConnAd

Contrast Rainer OLTast Line of Suntent? Milwonking Wasself N.220202 Convertific 200000 Convertific 20000 Convertific 20000

of the second se

which Wilson-I

Lood Maximum of the Consult, University himerations, see at Carterplane france and bits of minimum Children Children (and the planes, ashi'd bench at the back of an the Anoma of the Internet

(a) the property of the first first statement of the based points of provide the base of the first statement of the provident points of the provident points of the provident of the provident points of the provident poin

FAX FROM



DR. ALFRED R. BADER

Suite 622 924 East Juneau Avenue Milwaukee, Wisconsin 53202 Telephone: 414/277-0730 Fax: 414/277-0709

August 29, 1995

Page 1 of 3

To: Ms. Florence M. Campbell
Vice Principal, Advancement
Queen's University
Fax: 613/545-2593

Dear Florence:

You will have seen Sandra Martin's long review of my autobiography in *The Globe and Mail*. Ms. Martin was the writer who invented the quote in the Saturday Night article that David Smith asked me whether Queen's couldn't have the money instead of the castle!

Do you have any idea what she means by the first statement of her review, that the odd title is "part oxymoron, part downer"? By now, thousands of people have looked at the book, and many of these are very good friends who would surely have shared this thought if it were correct.

Maurice Yeates' quotation of Byron seems very applicable, and I hope that this will not get you down.

Fond regards, as always,

lud

AB/cw

Enclosure

